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Abstract 
The parasitic protozoa Trypanosoma and Leishmania are the cause of several highly 
disabling and often fatal diseases that affect millions of people in tropical and sub-
tropical regions. Glycolysis and especially the glycolytic enzymes within these 
parasites have been identified as potential targets for anti-trypanosomatid drugs. 
Recent research had identified N-aryl- 1 -amino-2,5 -anhydro- 1 -deoxy- 1 -D-mannitol 
derivatives as inhibitors of the enzyme phosphfructokinase (PFK), with IC 50 values 
in the low millimolar range. Following the synthesis of two compound libraries of 
2,5-anhydro-1-deoxy-D-mannitol derivatives, 37 was identified as a new inhibitor of 
PFK, with an 10 5 0 = 0.41 mM. Due to the structural similarities between these 
inhibitors and the effector for pyruvate kinase (PyK), fructose-2,6-bisphosphate, the 
libraries were also screened against PyK; 70 was identified as a new inhibitor and 
lead compound, with an 10 5 0 = 58 tiM. Competition experiments and molecular 
modelling suggested that 70 does indeed compete for the effector binding site. 
Lead and synthetic development led to the synthesis of a third library of ä-furanoid 
sugar amino amides. Approximately, a 10-fold increase in inhibition was observed 
for this library against PFK, the most potent inhibitor being 110 with an IC 50 = 23 
jiM. Competition experiments and molecular modelling suggested that 110 competes 
for the fructose-6-phosphate binding site. This library also gave good inhibition 
against PyK. Other areas of lead modification were also investigated that could lead 
to further library synthesis. 
In vivo testing of inhibitor 37 against trypanosomatid cells showed promising 
inhibitory activity, with an ED 5 0 = 0.15 mM. Such a result is promising for the future 
development of these inhibitors as, at an early stage of development, they already 
exhibit anti-parasitic properties. 
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ACD Available chemical directory 
ADME Absorption, distribution, metabolism, excretion 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ATP Adenosine triphosphate 
BOC tert-Butoxycarbonyl 
BOC20 Di-tert-butyl dicarbonate 
1 ,3-BPGA 1 ,3-Bisphosphoglycerate 




DHAP Dihydroxyacetone phosphate 
DIPEA NN-Diisopropylethylamine 
ED50 Dose required for 50 % response in a biological system 
EDCJ 1 -Ethyl-3 -(3 '-dimethylaminopropyl)carbodiimide 
ESI Electrospray ionisation mass spectrometry 
FAB Fast atom bombardment 
F6P Fructose-6-phosphate 
FTIR Fourier transform infrared 
GAPDH Glyceraldehyde-3 -phosphate dehydrogenase 
Gly-3 -P L-Glycerol-3 -phosphate 
xi 
G-3 -P Glyceraldehyde-3 -phosphate 
GTP Guanidine triphosphate 
HBA Hydrogen bond acceptors 
HBD Hydrogen bond donors 
HC1 Hydrochloric acid 
HK Hexokinase 
HOBt 1 -Hydroxybenzotriazole 
FIRMS High resolution mass spectrometry 
1050 Concentration required for 50 % inhibition 
Kd Dissociation constant 
K1 Inhibition constant 
KM Michaelis constant 
Lm Leishmania mexicana 
Lys Lysine 
m Multiplet 
[M + H]+ Protonated molecular ion 
[M + Na] Sodium adduct of molecular ion 
mCPBA meta-Chloroperbenzoic acid 
MeCN Acetonitrile 
MeOH Methanol 
NaBH3CN Sodium cyanoborohydride 
NAD Nicotinamide adenine dinucleotide (oxidised form) 
NADH Nicotinamide adenine dinucleotide (reduced form) 






PGAM Phosphoglycerate mutase 
ppm Parts per million 
PyK Pyruvate kinase 
q Quartet 
s Singlet 
SAR Structure-activity relationship 
SHAM Salicyihydroxamic acid 
t Triplet 
Tb Trypanosoma brucei 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
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1 	Introduction. 
1.1 	Overview. 
This thesis is concerned with the development and synthesis of inhibitors of 
glycolysis in parasites, in particular small molecules targeted against 
trypanosomatidae. By way of an introduction to this topic, some aspects and general 
methods of drug discovery, design and development are discussed. There then 
follows a more detailed review about trypanosomatidae, the glycolytic pathway and 
the rationale for selecting the glycolytic pathway as a target for trypanocidal drugs. 
1.2 	Drug discovery, design and development. 
1.2.1 Introduction. 
Traditionally, natural products have been the main and most important source for 
new drugs. Compounds have been isolated from many organisms including plants, 
animals (toxins) and micro-organisms.' One of the most famous was the 
serendipitous discovery of the anti-bacterial drug, penicillin 12  (general structure 
shown), and more recently the discovery of the anti-cancer compound, Taxol® 2, 
isolated from the western yew Taxus brevfolia 3 (Figure 1.1). 
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Figure 1.1 General structure of penicillin 1 and structure of Taxol® 2. 
2 
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Using standard medicinal chemistry procedures, these natural compounds were 
modified to produce drugs with improved activity, selectivity, bio-availability and 
ADME properties; reduced toxicity; and an altered spectrum of activity. 47 The 
greatest constraint in this process is the synthesis and evaluation of candidate 
compounds sequentially. This is particularly true for the fl-lactam penicillin 
derivatives, where, over a 30 year period, thousands of compounds were synthesised 
and screened for anti-bacterial activity. 7 However, advances in the wide field of 
medicinal chemistry, in particular utilising combinatorial chemistry" 8 and high 
through-put screening (HTS), 9 have radically changed the drug discovery process. 
1.2.2 Target identification and lead discovery. 
It is generally regarded that one of the initial steps in drug discovery is the 
identification of lead compounds that bind to a receptor or enzyme of interest. 
However, in order to do this, a therapeutic target must first be identified and 
validated, whether the disease concerned is infectious or non-infectious. 
Identification aims to find targets (normally proteins or DNA/RNA) whose 
regulation may lead to the inhibition or reversal of disease progression.' ° This has 
not always been the case; in the example of the discovery of penicillin, its anti-
bacterial properties were discovered well before the target enzyme, peptidoglycan 
transpeptidase, was known.' The sequencing of the human genome and other 
organism genomes has led to an increase in the number of potential therapeutic 
targets.' ° Complementary to this advance has been the development of technologies 
and tools to aid in target identification and validation.' 0 





step is to identify a lead compound. This can be accomplished in at least two ways; 
firstly, by random screening of primary compound libraries, where no specific 
structure or substructure is needed; secondly, by screening biased or focused 
compound libraries, where the individual members may bare a structural similarity to 
either substrates (or substrate intermediates) of the target, or of already identified 
lead compounds from random screening. 7 Advances in combinatorial and parallel 
synthetic chemistry, as well as screening techniques, has meant that compound 
libraries can be prepared and screened quickly and efficiently, with the goal being 
the discovery new lead compounds or even of new drugs." 
1.2.3 Library synthesis. 
Combinatorial chemistry is a very powerful tool in drug discovery as it facilitates the 
synthesis of large, small molecule compound libraries' 2 that are then screened for 
biological activity against a known target. It has been particularly important, not only 
for lead discovery, but also for lead modification. Combinatorial chemistry is defined 
as "the systematic and repetitive, covalent connection of a set of different 'building 
blocks' of varying structure to each other to yield a large array of diverse molecular 
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Figure 1.2 General example of the synthesis of a combinatorial compound library, 
based on a linear motif. 
It is evident from Figure 1.2 that the route to make large number of diverse 
compounds is greatly facilitated by combinatorial chemistry. For example, using 10 x 
A and 10 x B building blocks, Reaction 1 would synthesise 100 compounds (10 x 10) 
of the type A-B. Introduction of 10 x C building blocks for Reaction 2 would 
generate 1000 compounds (100 x 10) of the type A-B-C. Methods such as split 
synthesis on solid phase are used for this type of combinatorial library.' 3 Although 
this is a very basic example, it illustrates how large compound libraries can be 
generated based around simple, well known reactions such as peptide synthesis 
reactions, 11  whether on solid phase or in solution. Thousands of compounds have 
been synthesised and screened using combinatorial chemistry, and this increase in 
compound synthesis was expected to reduce the required time from finding an initial 
lead, to turning it in to a pre-clinical drug candidate. 14  Although some lead 
compounds have been identified by this approach,' 5,16  it was realised that the 
dramatic increase in the number of compounds available for screening would not 
necessarily lead to good, new lead compounds. In fact, it was observed that the hit 
5 
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rates were actually higher using tradition medicinal chemistry methods. 
14  It is now 
more common to find lead discovery and lead optimisation geared towards more 
rational structure-based design, often marrying the fields of combinatorial and 
parallel synthetic chemistry, computational chemistry and X-ray crystallography. 
14 
1.2.4 Lead modification. 
In situations where information about the structure and residues of the drug target are 
known (either by NMR or X-ray crystallography), structure-based library design 
becomes another very useful tool in the early phases of lead modification. 
14  Once an 
initial inhibitor has been identified, libraries can be designed based on its structure, 
creating a "focused library"; a diverse library of structurally similar compounds. A 
classical example of this is the synthesis of benzodiazepines' 2 as shown in Figure 
1.3. Using 3 simple building blocks, libraries of benzodiazepines were easily 
accessible introducing 4 elements of diversity. 12 
R4 0 
R2 	NHFmoc 	 R2 	
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Building block I 	Building block 2 	Building block 3 	 Benzodiazepine derivatives 
Figure 1.3 Access to benzodiazepine library from 3 simple building blocks. 
12 
High throughput screening is the method usually employed to screen large libraries  
and allows the simultaneous biological screening of each compound and relates it to 
a measure of inhibition of the chosen target. Therefore, this method permits a rapid 
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evaluation of each compound synthesised and can also result in the identification of 
structure-activity relationships (SARs).' 
Most drugs tend to be structurally specific' and act at specific receptor sites (such as 
the active site of an enzyme); hence, potency and activity are very susceptible to 
small changes in chemical structure. Recognition of certain ligand-receptor 
interactions may become apparent at this stage, such as hydrogen bonding and 
hydrophobic interactions. 17  However, identifying specific ligand-receptor 
interactions and confirming structure-activity relationships is greatly enhanced using 
computational power, incorporating docking methods. 18  If structural information 
about the target is known (X-ray crystal structure), compounds of interest can be 
docked into the receptor site using programmes such as DOCK, 18 taking into account 
steric and electronic parameters to find the most probable mode of binding. Although 
specific ligand-receptor interactions can only be formally identified by NIMR or an 
X-ray crystal structure of the inhibitor-target complex, docking still allows 
comparison between ligands and may identify reasons for trends in biological 
activity, allowing for the rationalisation of structure-activity relationships. In the 
initial stages of lead modification, this can be very useful not only for identifying 
potential ligand-receptor interactions and rationalising SARs, but also for further lead 
development. 
In recent years, a major concern in the drug discovery process has been the relevance 
of library or inhibitor design towards obtaining good drug-like molecules. Due to the 
advances in combinatorial chemistry, high-throughput screening and molecular 
genetics, the goal in lead modification was to find more potent inhibitors without 
necessarily taking in to account solubility, absorption and permeability properties 
7 
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that are essential for bio availability. 19 High-throughput screening methods are such 
that general solvents like dimethyl sulfoxide (DMSO) are used regularly in assays. 
Therefore, highly insoluble compounds can be screened and activity determined, the 
net result being in vitro activity is reliably identified for compounds with very poor 
thermodynamic solubility properties. 19 Medicinal chemistry often relies on 
incorporation of lipophilic moieties during lead modification to improve in vitro 
activity. 17,19  Conversely, it has been found difficult to improve on in vitro potency by 
incorporating polar groups. Both these observations only emphasise the trend 
towards design of inhibitors with poor solubility in an aqueous medium. Work in this 
area by Lipinski et al., 19 led to the discovery of set of rules, now more commonly 
referred to as the Lipinski Rule of 5: 
"The 'rule of 5' predicts that poor absorption or permeation is more 
likely when there are more than 5 H-bond donors, 10 H-bond 
acceptors, the molecular weight is greater than 500 and the calculated 
Log P (CLogP) is greater than •19 
At each round of lead modification, it is generally accepted that these parameters are 
likely to change, so it has been suggested that this rule is taken in to account early on 
in lead discovery programmes. However, the rule has been violated by a number of 
compounds including antibiotics, antifungals, vitamins and cardiac glycosides, which 
is thought to be due to the presence of functional groups which may act as substrates 
for 920 Further work in this area suggest modifications are needed as 
compounds that are compliant with the Lipinski Rule of 5 may still exhibit poor 
solubility and permeability. 2123 Such suggestions have been made by Hann and 
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Oprea22 who formulated the following criteria for lead like compounds: molecular 
weight < 460; 4 LogP < 4.2; number of rotatable bonds < 10; number of rings 4; 
number of hydrogen bond donors 5; number of hydrogen bond acceptors < 9. 
1.2.5 Recent methodologies in drug discovery and drug design. 
Although advances in combinatorial chemistry and high throughput screening have 
made it possible both to synthesise and biologically evaluate large numbers of 
compounds, this is still a small number in comparison to the total number of 
compounds that could be synthesised and evaluated . 24 In section 1.2.4, the idea of 
computationally docking potential ligands into receptor sites was introduced. 
Leading on from both of these notions is the application of virtual screening. 24  This 
method seeks to explore the binding mode and affinity of potential ligands from 
commercial databases such as the Available Chemicals Database (ACD), or smaller 
in-house databases such as more focused virtual libraries. 25  As well as acting as a 
screening method to identify potential ligands, virtual screening also acts as a filter to 
cut down on the vast number of compounds that could be potentially synthesised at 
the start of a drug discovery programme, hence, streamlining the whole process that 
chemists and computational chemists already use. 24 
X-Ray crystallography is a useful technique that has been used to identify not only 
protein structures, but also ligand receptor interactions, and has been widely used for 
lead optimisation in drug discovery. 26  Due to the importance that X-ray 
crystallography has on the acquisition of three-dimensional information (including 
binding interactions and structure-activity relationships), its function has, recently, 
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been broadened into a new approach for lead discovery and modification .26  High-
throughput X-ray crystallography has recently been developed and is used to screen 
molecular fragments and precisely define their binding sites to the target proteins. In 
turn, this method can be utilised as a guide for lead development and optimisation. A 
particular advantage is the identification of low affinity binding sites caused by small 
molecule fragments. Although their binding affinity may be in the millimolar range, 
concentrations used are much higher than conventional high-throughput methods, 2628 
and therefore, weaker binding sites and low affinity compounds can be identified that 
may have been missed by other screening methods. 26-28  The interactions that these 
fragments identify could prove to be crucial for lead identification and development, 
as the binding mode is specific, and the key interactions are well defined. 26 
In the method described above, the idea of screening molecular fragments was 
introduced and leads on to another recently developed method; fragment-based drug 
discovery. 29  In fragment-based approaches, low molecular weight chemical 
fragments (or very small molecules) are screened against a target of interest by 
means of an assay such as high concentration binding assays 30  or crystallography-
based methods. 31 Fragments which show inhibition, or the ability to bind to the 
target, can be considered as building blocks of a more complex lead compound 
series. 
There are two main methods in which fragments are converted into lead compounds. 
The first of these is fragment optimisation, whereby hits with micromolar (or better) 
affinities undergo conventional optimisation strategies (using methods such as 





benzimidazole 3 was identified as a weak inhibitor of gelatinase B, and, following 
library design and synthesis based on this structure (and mechanistic considerations), 
inhibitor 4 was discovered, which showed over a 100-fold improvement in potency. 32 
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4, IC = 13 iM 
Figure 1.4 Fragment optimisation of Gelatinase B inhibitor. 32 
The second method is fragment merging and linking.  29 The specific binding modes 
of fragments are preserved by linking or merging them together, usually leading to 
an increased affinity for the target. An illustration of this can be seen in Figure 1.5 
where the linking together of fragments 5 and 6 - which were already found to be 
moderate inhibitors of FK506 binding protein (FKBP) - produced inhibitor 7; a 100- 
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These examples are just a few of the total number of emerging strategies. They are 
developed by chemists and biologists worldwide, all attempting to identify potential 
drug targets and their inhibitors, with the goal not only of finding new drugs, but also 
of understanding, more fully, the biological processes and systems by which disease 
occurs and its progression inhibited. 
1.3 	Trypanosomatids. 
1.3.1 Trypanosomatid disease. 
African sleeping sickness, Chagas' disease and leishmaniasis are highly disabling 
and sometimes fatal diseases associated with the continents of Africa and South 
America. The parasitic protozoa Trypanosoma and Leishmania are the cause of these 
diseases and belong to the order Kinetoplastida. 34 ' 35 
Sleeping sickness in humans (African trypanosomiasis) is caused by two subspecies 
of Trypanosoma brucei (Tb). The usually chronic form of the disease, found in West 
Africa, is caused by Tb gambiense, and takes several years to progress to the 
meningoencephalitic stage; the more acute form that predominates in East Africa is 
caused by Tb rhodesiense, which only takes a few weeks to progress to this second 
stage. 14,16  Whilst in the blood and lymphatic system of the host, the trypanosomes 
proliferate before invading the central nervous system. This disease threatens over 60 
million people in 36 countries of sub-Saharan Africa each day. It is estimated that 
between 300,000 and 500,000 people have the disease, and if left untreated, both 
forms of the disease are fatal at the second stage. Unfortunately the current available 
treatment seems to be far from satisfactory. 37  Suramin 8 and pentamidine 9, (first 





disease. 36  Drugs used to treat the second stage (with central nervous involvement) are 
melarsoprol 10, (1949) and, the only drug to become available in the recent past, 
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Figure 1.6 Structures of suramin 8, pentamidine 9, melarsoprol 10 and 
eflornithine 11. 
These drugs, however, are far from adequate. Resistance against pentamidine by Tb 
gambiense has been observed, and eflornithine is ineffective against Tb rhodesiense. 
Recently, problems in treating this disease have emerged due to the resistance of 
trypanosomes to melarsoprol 10. As well as these problems, suramin 8, pentamidine 
9, and in particular melarsoprol 10, have serious side effects on the human host. 
Eflornithine 11 itself is impractical as it needs a hospital setting for administration of 
the drug, which is often unaffordable due to its high cost. 36 
Chagas' disease is caused by Trypanosoma cruzi and has a wide distribution in 
Central and South America. Many wild and domestic mammals can act as host for 





different ways: either the deposition of faeces on the skin (by a blood sucking 
reduviid bug) at the time of biting, or more directly by transfusion of infected blood 
or congenital transmission. Chagas' disease affects around 16 - 18 million people, 
and of these, about 5 - 6 million have developed incurable complications. These can 
appear between 10 - 20 years after the initial acute phase of the disease and include; 
cardiac lesions, digestive disorders and peripheral neurological disorders. Although 
there has been a significant improvement in the control of Chagas' disease by 
targeting the insect vectors, treatment is only available for the acute stages of the 
disease. Development of drugs is therefore needed to overcome the chronic form. 
34 
The disease leishmaniasis is caused by the different species of the genus Leishmania. 
Over 20 different species are known to be pathogenic to humans and they are 
transmitted by the bite of the phlebotomine sandfly. Depending on the form of the 
disease, the leishmaniases are divided into three general clinical patterns: cutaneous, 
visceral and mucocutaneous. It is thought that over 367 million people are at risk 
from this disease in 88 countries, and that there are at least two million new cases of 
leishmaniasis each year. The standard treatment courses that are currently available 
can only be given parenterally. They are long, expensive and may cause severe 
adverse reactions. 34 
Although chemotherapy is not, at present, satisfactory, it still remains the major 
method for the control of these diseases. Vaccine development has been attempted 
but has proved unsuccessful, due to the fact that many of the aforementioned 
parasites have developed intricate mechanisms for evading their host's immune 
system. 38  The reason why there is a limited amount of available treatment, is simply 
due to the market economy; most people that are at risk from these tropical and sub- 
14 
Chapter] 	 Introduction 
tropical diseases are among the poorest in the world so there has been little financial 
incentive for pharmaceutical companies to invest in the development of new 
drugs. 34,38 
1.3.2 Targets for anti-trypanosomatid drugs. 
In the last two decades, molecular approaches have been introduced to define 
potential new targets in trypanosomatidae, and to design new drugs, as the 
mechanisms for the currently available drugs remain largely unknown. 38,39  It appears 
that in trypanosomatidae, glycolysis is essential for survival in the human host: 38  the 
only supply of ATP for African trypanosomatidae living in the mammalian 
bloodstream, is the glycolytic breakdown of glucose to pyruvate. They have no 
Krebs cycle or mitochondrial respiratory chain that is coupled to ATP production 4° 
and, therefore, inhibition of glycolysis will lead to rapid death of these parasites. 413 
Due to the fact that trypanosomatidae have a long evolutionary distance between 
themselves and their mammalian hosts, 44 and also because of the unusual 
organisation of the glycolytic pathway in these parasites ,40'45 the parasitic enzymes 
are endowed with distinct properties (see section 3.5). Therefore, these properties 
may be exploited in structure or mechanism-based design of inhibitors, so that the 
glycolytic pathway of the host would remain unaffected .46 
1.3.3 The glycolytic pathway in trypanosomatidae. 
In contrast to other organisms, the seven glycolytic enzymes that convert glucose to 
3-phosphoglycerate, are located in peroxime-like organelles called glycosomes (see 
Figure 1. 7) 40 
 














MITOCHONDRION 	 fructose 1,6-P2 
o 	OHAP s 	DH AP 	 0-3-P 
13 	 2) 	 6 	
Pi- 
GIy-3.P I 	 CIy-3-P 	13-BPGA 
2 	 AD4 	 ADP 









Figure 1.7 ° The stoichiometric scheme of glycolysis in blood from T. brucei. 1, 
Hexokinase; 2, glucose-6-phosphate isomerase; 3, phosphofructokinase; 4, 
aldolase; 5, triose-phosphate isomerase; 6, glyceraldehyde-3 -phosphate 
dehydrogenase; 7, phosphoglycerate kinase; 8, glycerol-3 -phosphate 
dehydrogenase; 9, glycerol kinase; 10, phosphoglycerate mutase; 11, enolase; 12, 
pyruvate kinase; 13, glycerol-3-phosphate oxidase. Abbreviations: 1 ,3-BPGA, 
1,3 -bisphosphoglycerate: DHAP, dihydroxyacetone phosphate; G-3-P, 
glyceraldehyde-3 -phosphate; Gly-3 -P, glycerol-3 -phosphate; PEP, 
phosphoenolpyruvate; 2-PGA, 2-phosphoglycerate; 3-PGA, 3 -phosphoglycerate. 
Net ATP synthesis occurs in the cytosol under the reaction catalysed by pyruvate 
kinase (PyK). This is due to the fact that the glycosomal milieu is in redox and ATP 
balance because of a glycosomal glycerol-3-phosphate dehydrogenase and glycerol-
3-phosphate : dihydroxyacetone phosphate shuttle. This shuttle transfers electrons, 
eventually to allow the re-oxidation (by molecular oxygen) of NADH, produced by 
16 
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glyceraldehyde-3 -phosphate dehydrogenase. However, under anaerobic conditions 
glycerol-3-phosphate is converted to glycerol by the action of glycerol kinase, with 
production of ATP. Hence, the ATP and NAD balance are still maintained under 
anaerobic conditions, but one molecule of both pyruvate and glycerol is produced, as 
opposed to two molecules of pyruvate. The net production of ATP is also reduced 
from two molecules to one. 
Inhibition of any step of glycolysis in bloodstream form T. brucei should, in 
principle, stop ATP production and, therefore, cause death to the parasite. In fact, it 
has been shown that bloodstream form T brucei dies within minutes when starved of 
glucose, or incubated with the plasma-membrane glucose transporter inhibitor 
phloretin. 47 Trypanosomatid death is also caused by inhibitors of glyceraldehyde-3-
phosphate dehydrogenase, such as pentenolactone 48 or bromopyruvate, 49 and also by 
inhibitors of pyruvate efflux such as a-cyanocinnamic acid . 50 These inhibitors, 
however, cannot be used as potential drugs as they are not selective between the 
parasitic enzymes and the human equivalents. 
A well-known method of selectively inhibiting trypanosomatid glycolysis in vitro is 
the inhibition of glycerol-3-phosphate oxidase by salicylhydroxamic acid (SHAM), 
whilst adding glycerol to prevent the reversal of glycerol kinase. 5 ' This has been 
found to have a trypanocidal effect in rats , 52 but the concentrations of SHAM 
required (1 mM) are too high. The concentration of glycerol needed (5 nM) is also 
toxic towards the host. Recently, however, an alternative, highly specific non-
competitive inhibitor of glycerol-3-phosphate oxidase has been identified; the 
antibiotic ascofuranone, 53 but, as yet, no information is available about its in vivo 
efficacy. 
17 
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1.4 	Mechanisms of enzyme inhibition. 
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Figure 1.8 A scheme showing the mechanism of enzyme inhibition. 
The scheme shown in Figure 1.8 is an illustration of the general strategy for enzyme 
inhibition, where E is the target enzyme, S is the substrate for the enzyme, I is the 
inhibitor, and P is the product formed. The scheme shows both irreversible and three 
types of reversible inhibition. The inhibitor, I, is a reversible competitive inhibitor if 
it binds to E only, and prevents S from binding. I is a reversible non-competitive 
inhibitor if it binds to E and ES still forms. Finally, I is an uncompetitive inhibitor if 
it binds to ES only. Blocking the flux of the glycolytic pathway in trypanosomatidae, 
through inhibition as shown in Figure 1.8, needs two requirements. Firstly, that the 
target enzyme has sufficient influence on the pathway to cause eventual death to the 
parasite if it were to be inhibited, and secondly, that the inhibitor has a high affinity 
for the enzyme. 36 
Figure 1.8 also shows irreversible inhibition, where the inhibitor covalently binds to 
18 
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the enzyme (B-I). For example, this could be caused by the inhibitor possessing an 
electron acceptor site (such as a carbonyl or cyano-grou5), which reacts with a 
residue in or near the targeted binding site of the enzyme (such as the amino group 
on lysine). 
If the inhibitor bears a structural resemblance to the transition state of an enzymatic 
reaction, the formation of an isomerised complex (EI*)  may occur. These transition-
state inhibitors are usually found to exhibit a slow-binding process, corresponding to 
the conformational change induced in the enzyme by the inhibitor. 1 
Inhibitor design should also try to achieve selectivity between targeted and non-
targeted enzymes, thereby producing the desired effect in the parasite by targeting 
the parasitic enzymes, without harming the host, or interacting with the enzymes of 
the host. One method to achieve this would be by exploiting the differences in 
enzyme structure and mechanism between the target and host enzymes. Comparisons 
between the 3-dimensional structure of the parasite and host enzymes can reveal 
subtle or major differences that can be used to selectively target the parasitic 
enzymes by the design of specific inhibitors. 39 This has already allowed for the 
development of a relatively highly specific inhibitor for the trypanosomatid 
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Figure 1.9 Selective inhibitor of trypanosomatid glyceraldehyde-3 -phosphate 
dehydrogenase. 54 
1.5 	Enzymes in the trypanosomatid glycolytic pathway. 
1.5.1 Hexokinase (HK). 
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Figure 1.10 The role of hexokinase (HK). 
The role of hexokinase is to catalyse the transfer of a phospho group from ATP to 
glucose (Figure 1.7, enzyme 1). In humans, there are four isoenzymes of hexokinase 
(I - TV),55  and the trypanosomatid enzyme only has a low percentage identity with 
the human forms.  56  Hexokinase has a low substrate specificity, and therefore will 
accept a range of sugar molecules, which is also true for other hexokinases. 57 The 
trypanosomatid hexokinase is not regulated by its product, glucose-6-phosphate, and 
unlike the human isoenzymes, and it has a low specificity for ATP; indeed, it is also 
pill 
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able to utilise UTP and GTP. 34 Although there is no crystal structure available for the 
trypanosomatid hexokinase, the low sequence identity and the difference in kinetic 
properties from the human isoenzymes 55  potentially allows the possibility for 
development of selective inhibitors. In fact, this has been explored to some extent, 
and some N-acetylglucosamine derivatives were found to inhibit the enzyme. 
Notably, the inhibitor N-(m-bromobenzoyl)-D-glucosamine 13 (Figure 1.11) with a 
K1 of 3 tM (the KM of glucose is 110 .tM) has been reported . 34 ' 58 The inhibitory 
activity of this compound on yeast hexokinase is 50 times poorer 
59  and there are no 
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Figure 1.11 N-(m-Bromobenzoyl)-D-glucosamine 13, inhibitor of trypanosomatid 
HK. 
1.5.2 Glucose-6-phosphate isomerase (PGI). 
The second glycosomal enzyme (Figure 1.7, enzyme 2) catalyses the isomerisation of 
glucose-6-phosphate (Glc-6-P) to fructose-6-phosphate (1 76P, Figure 1.12). 
0 







-O 	 \(_oH 
OH HO  
Glucose-6-phosphate 
	 Fructose-6-phosphate 




The percentage identity of trypanosomatid PGI with the mammalian enzyme has 
been shown to be 58 %•34  No crystal structure is available for this enzyme, so its 
feasibility as a potential target for selective inhibitors is not yet known. It is also 
considered that this enzyme does not confer significant control over the glycolytic 
flux. 56 
1.5.3 Phosphofructokinase (PFK). 
Phosphofructokinase (Figure 1.7, enzyme 3) catalyses the phosphorylation of 
fructose-6-phosphate (1 76P) to afford fructose- i ,6-bisphosphate (F 1 ,6BP, Figure 
1.13). 
0 	 0 
11 0 	OH 	ADP 	 0 	OH 
'- 
S.. 	 - 
ATP 11 
HO 	OH 
Fructose-6-phosphate 	 Fructose-i ,6-bisphosphate 
Figure 1.13 Reaction catalysed by phosphofructokinase (PFK). 
The enzyme exists as a tetramer and, under physiological conditions, the reaction is 
irreversible. Its human counterpart consists of similar sub-units of about 85 kDa, and 
the regulation of this enzyme is controlled by a large number of metabolites and 
allosteric effectors. 34 However, the trypanosomatid enzyme has smaller sub-units of 
about 53 kDa,6°  and is activated only by its substrate fructose-6-phosphate, AMP and 
ADP . 57  It was also found that whilst the percentage identity between the 
phosphofructokinase of T brucei and L. donovani is high (70 %), between these 






Preliminary attempts to design inhibitors of trypanosomatid PFK have had promising 
results. Analogues of 2,5-anhydro-D-mannitol, bearing various arylamino groups at 
position 1 (see Figure 1.14), have shown inhibitory activity by reversibly binding at 
the ATP and F6P binding site. 6163 These inhibitors and further inhibitor development 
are discussed further in the following chapters. 
Ar 
OH 
Figure 1.14 General structure of N-aryl-1-amino-2,5-anhydro-1-deoxy-D-
mannitol that shows inhibitory activity against trypanosomatid PFK. 62 
1.5.4 Aldolase. 
Aldolase (Figure 1.7, enzyme 4) catalyses the conversion of F1,6BP to 
dihydroxyecetone phosphate (DHAP) and D-glyceraldehyde-3 -phosphate (G-3-P, 
Figure 1.15). 
0 	 0 	 0 II OH 	 II II 
Aldolase + 
Hd 	OH 	 OH 
Fructose- 1, 6-bisphosphate 	 Dihydroxyacetone phosphate 	Glyceraldehyde-3-phosphate 
Figure 1.15 Reaction catalysed by aldolase. 
The crystal structure of aldolase has been determined for both T brucei and L. 
mexicana and shows a large number of charged residues. 




have been synthesised that form a stabilised ammonium ion at the active site. They 
have shown significant inhibition against T. brucei aldolase, with virtually no effect 
on the mammalian forms of the enzyme. 56 
1.5.5 Triose-phosphate isomerase (TIM). 
The fifth enzyme in trypanosomatid glycolysis (Figure 1.7, enzyme 5) catalyses the 
reversible conversion of the triose-phosphates, DHAP and G-3-P (Figure 1.16). The 
human form of the enzyme has been shown to have about 52 % sequence identity 
between the trypanosomatid forms of T. brucei, T. cruzi and L. mexicana. 34 The 
crystal structures of these enzymes show that the active site residues are reasonably 












Figure 1.16 Conversion catalysed by triose-phosphate isomerase (TIM). 
1.5.6 Glyceraldeyde-3-phosphate dehydrogenase (GAPDH). 
Glyceraldehyde-3-phosphate dehydrogenase (Figure 1.7, enzyme 6) catalyses the 
phosphorylation of G-3-P to 1 ,3-bisphosphoglycerate (1 ,3-BPGA), in the presence of 
the cofactor, NAD (Figure 1.17). 
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II 	 11 
+ NA 	+ Pi 	
GAPDH 	
- O . + NADH -o 
OH 	
OH 
Glyceraldehyde-3-phosphate 	 1 ,3-Bisphosphoglycerate 
Figure 1.17 Phosphorylation catalysed by glyceraldehyde-3-phosphate 
dehydrogenase GAPDH in the presence of NAD and inorganic phosphate (P1). 
The trypanosomatid enzymes have a 45 - 48 % identity with the human enzyme. 
34 
However, a comparison of the crystal structures shows that the active site of the 
enzyme appears well conserved . 65 This is not the case for the NAD binding site, as 
it appears to have a hydrophobic cleft in the adenosine binding portion of the 
trypanosomatid enzyme, which is not present in the human enzyme. 39  Probing of this 
site with adenosine derivatives has found compounds that inhibit the trypanosomatid 
enzyme at micromolar and sub-micromolar concemtrations, but do not affect the 
human enzyme. 54  Figure 1.18 shows one of these compounds (N6-( 1-
naphthylmethy)-2'-deoxy-2'-(3 -methoxybenzamido)-adenosine) binding at the NAD 
binding site. It utilises the hydrophobic groove using the 1V 6-substituent of the purine 
to gain affinity, whilst gaining selectivity over the human enzyme by interactions of 














Figure 1.18 A model of L. mexicana GAPDH complexed with 1V6-(1-
naphthylmethyl)-2 '-deoxy-2 '-(3-methoxybenzamido)-adenosine in the NAD 
binding pocket. 54 
1.5.7 Glycerol-3-phosphate dehydrogenase (G3PDH). 
Glycerol-3-phosphate dehydrogenase (Figure 1.7, enzyme 8) catalyses the reversible 
conversion of DHAP and L-glycerol-3-phosphate (Gly-3-P, Figure 1.19). It has been 
shown that the human form of the enzyme possesses only a 28 - 30 % sequence 
identity with the enzymes from T. brucei and L. mexicana. 56 Coupled with the fact 
that the enzyme exerts significant control over glycolytic flux, this makes G3PDH a 
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+ NAD 
Figure 1.19 Reaction catalysed by glycerol-3 -phosphate dehydrogenase 
(G3PDH). 
1.5.8 Glycerol kinase (GK). 
Glycerol kinase (Figure 1.7, enzyme 9) catalyses the ATP-dependent 
phosphorylation of glycerol when sugar levels are low, but catalyses the production 
of glycerol and ATP in anaerobic conditions 40 '66 (Figure 1.20). The human form of 
the enzyme is only involved in glycerol phosphorylation. As it is unlikely that GK, 
under physiological conditions, plays an essential role in metabolism, it is also 
unlikely that, by itself, the enzyme is a suitable drug target. 
34 
0 
II 	 GK 
HO OO + ADP - 
	 HO(OH 	+ ATP '  
- 	 OH 
OH 
L-Glycerol-3-p hosph ate 	 Glycerol 
Figure 1.20 Reaction catalysed by glycerol kinase (GK). 
1.5.9 Phosphoglycerate kinase (PGK). 
Phosphoglycerate kinase (Figure 1.7, enzyme 7) catalyses the conversion of 1,3-
BPGA to 3-phosphoglycerate (3-PGA), producing ATP (Figure 1.21). 
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Figure 1.21 Reaction catalysed by phosphoglycerate kinase (PGK). 
The percentage identity between the trypanosomatid and human enzymes is 46 
%34 
Although the active sites of the parasitic and mammalian enzymes are well 
conserved, there is a difference in the ADP binding pocket, which makes this enzyme 
an interesting target for drug development. 
1.5.10 Phosphoglycerate mutase (PGAM). 
Phosphoglycerate mutase (Figure 1.7, enzyme 10) catalyses the conversion of 3-PGA 
to 2-PGA (Figure 1.22). Two classes of enzyme have been discovered; 2,3-
bisphosphoglycerate (2,3-BPGA) dependent and independent. 
67  The structure and 
mechanisms of these enzymes are also different. Humans possess the cofactor 
dependent mutase, whereas trypanosomatid PGAM is cofactor independent. The 
trypanosomatid enzyme is completely different from the human enzyme, and 
modelling of its 3-dimensional structure reveals that it is more related to the family 
of alkaline phosphatases. 56  This difference offers an excellent opportunity for the 
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Figure 1.22 Conversion catalysed by phosphoglycerate mutase (PGAM). 
1.5.11 Enolase. 
Enolase (Figure 1.7, enzyme 11) catalyses the dehydration of 2-PGA to 











Figure 1.23 Dehydration catalysed by enolase. 
Although the percentage identity between the parasitic (T. brucei) and the human 
enzyme is about 59 - 62 %, no crystal structures of either enzyme are available. 
Some atypical residues near the active site of the parasitic enzyme (Lys and Cys) 
could be exploited for the development of irreversible selective inhibitors. 34 
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1.5.12 Pyruvate kinase (PyK). 
Pyruvate kinase (Figure 1.7, enzyme 12) catalyses the conversion of PEP to pyruvate 











Figure 1.24 Reaction catalysed by pyruvate kinase (PyK). 
Trypanosomatid PyK is allosterically regulated by fructose-2,6-bisphosphate 
(although fructose- i ,6-bisphosphate does have a weak affinity for the effector site). 
This effector promotes the active R-state of the enzyme from the inactive T-state. 68 
In contrast, mammals possess four isoenzymes of PyK, one of which (MI) has no 
allosteric regulation and the other three (M2, L and R) are regulated by fructose-1,6-
bisphosphate. 67  Combined with the fact that the percentage identity between the 
trypanosomatid and human enzymes is 47 - 51 %, this makes PyK an excellent target 
for the development of selective inhibitors. Inhibitor design and synthesis for PyK is 
discussed in more depth in the following chapters. 
1.5.13 Glycerol-3-phosphate oxidase. 
Glycerol-3-phosphate oxidase (Figure 1.6, enzyme 13) is a mitochondrial enzyme. 
The T brucei form is a complex enzyme, but as yet no sequence or structure 
information is available. 34 
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2 	Library 1: Design, Synthesis and Evaluation. 
2.1 	Research aims. 
2.1.1 Phosphofructokinase (PFK). 
The overall aim of this research was to use parallel (or combinatorial) synthetic 
methods in order to create potential inhibitors of trypanosomal glycolysis, in 
particular inhibitors of the enzymes phosphofructokinase (PFK) and pyruvate kinase 
(PyK). The initial synthetic targets were based on work carried out by Samantha 
Claustre at at 1'Universit6 Paul Sabatier de Toulouse. 
61-63 Inhibitors were designed as 
derivatives of 2,5-anhydromannitol, 62  itself being structurally analogous to fructose-
6-phosphate (HP, Figure 2.1), a substrate of the enzyme PFK. It was shown that 
these compounds (N-arylamino-2,5-anyhdro- 1 -deoxy-D-mannitol derivatives, Figure 
2.1) inhibit Tb PFK by binding reversibly at both the F6P and ATP binding sites. 
62 
0 







Figure 2.1 Fructose-6-phosphate (F6P) and N-arylamino-2,5 -anhydro- 1 -deoxy-D-
mannitol. 
In addition, it was reported that when these derivatives were phosphorylated at the 6 
position, exclusive binding at the ATP binding site was observed. 62 The IC 50 and Kd 
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Table 2.1 Selected IC50 and K,j values of Narylamino-2,5-anydrO-1-deOXY-D 
mannitol derivatives against Tb PFK. Each determination was done in triplicate 
with SD ± 4 %6263 
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The presence of the phosphate group at the 6 position also led to a twofold increase 
in the inhibitory activity of these compounds, whilst the dissociation constants (K,js) 
appeared to remain comparable. In the absence of any crystal structure of 
trypanosomal PFK, the specific interactions of these inhibitors with the protein are 
not clear. However, for the best inhibitors (3-nitrophenyl derivatives) it was thought 
that the nitro group formed an ionic interaction with Lys226, situated in the ATP 
binding site, 62  which had been determined as hydrophobic by multiple sequence 
alignments between E. coli PFK and T. brucei PFK, where the residues Arg8 1 and 
Argi 11 in E. coli PFK have been replaced by proline and valine in Tb PFK. 60 ' 62 
The inhibition shown by these compounds, to date the only known inhibitors of 
trypanosomal PFK, is relatively poor (10 5 0 values are only in the millimolar range). 
However, when comparing the dissociation constants (Kd) of these compounds to 
those of the natural substrates for T brucei PFK, it was found that the values are 
similar (see Table 2.2). 




Table 2.2 Dissociation constants for natural substrates of Tb PFK. 
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Therefore, the decision was made to synthesise new inhibitors based around the 
existing 2,5-anhydro-D-mannitol scaffold. Primarily, this would further explore 
substitution at the 1-position, using already known chemistry and adapting it for 
parallel synthesis. The idea would be to produce compounds with drug-like 
properties (obey Lipinski's Rule of 519)  of greater inhibitory activity than the 
previously synthesised compounds, that could lend themselves to further synthesis 
and development. Knowledge of the environment of the binding site of these 
compounds would also be attained through structure-activity relationships (SARs). 
It is also interesting to note that compounds with a similar scaffold (2,5-anhydro-D-
maimitol) are known to be inhibitory towards glycosidase enzymes involved in a 
wide range of biological processes 69,10  Inhibitors of this type are also known to be 
active against mycobacteria, the causative of tuberculosis (Mycobacterium 
tuberculosis); 7 1,72 one or more arabinosyl transferase enzymes are inhibited by these 
compounds, leading to increased cell wall permeability. 71 
2.1.2 Pyruvate kinase (PyK). 
In contrast to PFK, no inhibitors were known for trypanosomatid PyK. However, this 
allosterically regulated enzyme is thought of as a good target for trypanocidal drugs 
due to the low sequence identity between the trypanosomal and mammalian forms of 
the enzyme, and due to the fact that trypanosomal PyK is regulated by fructose-2,6-
bisphosphate (F2,6BP, see Figure 2 . 2) . 68  Trypanosomatid PyK differs from 
mammalian PyK which is regulated by fructose-1,6-bisphosphate (F1,6BP, see 
Figure 2.2, discussed in introduction) 67  making the effector site an ideal target for 
inhibitors and inhibitor development. Although a crystal structure of L. mexicana 
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PyK has been determined, this is of the apo-enzyme and therefore is in the inactive 
T-state (no effector bound). Hence, the geometry of the effector site was not well 
known. 
Advances in computational power have led to the development of programs that use 
structure-based or target-based approaches to screen compounds (from the Available 
Chemical Database or other databases) for potential ligands and inhibitors of 
proteins. However, with no active R-state structure of trypanosomal PyK (with 
effector bound), notions about the effector site have been largely based on the T-state 
structure and the corresponding site in the yeast enzyme in order to carry out 
database mining and in silico screening with programs such as DOCK. 18  With the 
outcome of this approach uncertain, an alternative strategy was produced. Due to the 
structural similarity between F2,6BP, F 1 ,6BP and F6P (Fl ,6BP also being a substrate 
for PFK), the compounds synthesised for testing against PFK, would also be tested 
for activity against PyK. Again, with little known about the effector site for PyK, the 
results would hopefully provide an insight about the effector sight environment and 
structure, whilst also producing the first inhibitors of trypanosomal PyK. Any 
differences between the best inhibitors for PFK and for PyK could be exploited in 
further development in the hope of gaining specificity between both enzymes, as well 
as specificity between the trypanosomal enzymes and their mammalian counterparts. 
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Figure 2.2 Fructose- i ,6-bisphosphate (F 1 ,6BP) and fructose-2,6-bisphosphate 
(F2,6BP). 
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2.2 	Adaptation of N-arylamino-2,5-anhydro-1-deoxy-D-mannitol synthesis. 
2.2.1 Preparative scale reactions. 
As stated previously, the initial objective was to use an already known synthetic 
procedure and adapt it for use with parallel synthesis equipment in order to make a 
small library of compounds. The first step in the synthesis of these compounds is the 
formation of 2,5-anhydro-D-mannose 22 which forms the locked furanose scaffold. 
This is achieved by treatment of D-glucosamine hydrochloride with nitrous acid '61 as 
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Figure 2.3 Synthesis of 2,5-anhydro-D-mannose 22. 
This stereospecific reaction can be explained by the proposed mechanism shown in 
Figure 2 .4 .6373 Following the formation of the diazonium ion 23, the pyranose 
oxygen facilitates an intramolecular substitution reaction by rearside attack of the 
diazonium carbon. This results in the formation of a 3-membered cyclic intermediate 
24 and the evolution of nitrogen. The 3-membered ring then breaks down in order to 
form 2,5-anhydro-D-mannitol 22 and it's hydrated equivalent 22 .63,73  This reaction 
occurred cleanly, in high yield (88 %) and could be scaled up in order to produce 
sufficient starting material for the next step of the synthesis. However, the 
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thought that this would provide difficulty in the practical aspects of library synthesis, 
so it was decided that aldehyde 22 would be handled as a methanolic solution, thus 
avoiding any unnecessary difficulties and errors in the weighing out of this 
compound, and allowing it to be dispensed automatically using the Bohdan Neptune 
liquid handler (see Chapter 6). 
OH 	 r 	OH 
___ I 
H O$ OH -N
2 	 H HJ 
23 	 24 
+OH 
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HO 	OH 	 HO 	OH 
22 	 22' 
Figure 2.4 Proposed mechanism for the formation of 2,5-anhydro-D-mannitol 
22. 63,73 
The next step in the synthesis of mannitol derivatives is the reductive amination of 
compound 22 with an arylamine (as shown in Figure 2.5). 
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Figure 2.5 Reductive amination of aldehyde 22 with arylamines. 
These reactions again followed the same procedure as set out by Claustre et a!61 
however purification was achieved by mass directed methods using the Waters ZMD 
(see Chapter 6). Therefore, this method gives the advantage of not being restricted to 
the use of aryl amines for future synthesis; it would be possible to use amines that are 
poorly detected using a diode ray as used in HPLC. With the reductive amination 
being the reaction that would afford the target compounds, the yields were 
acceptable. The structures of these compounds were confirmed by comparison of 'H 
and ' 3 C NMR spectra to those previously reported. 61 ' 63 
2.2.2 Test library synthesis. 
It is important to note that the reductive amination reactions were carried out on a 
preparative scale. In order to test this reaction further, it was decided to synthesise a 
small 4-membered library on a combinatorial scale. Before embarking on the 
synthesis of larger libraries, the test library would serve to check that the methods 
used would be suitable and robust enough for smaller, combinatorial scale reactions. 
The compounds that were synthesised in this test library had been previously 
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Figure 2.6 Structures and yields of test library. 
Although the yields from the test library were lower than expected, enough material 
was produced to enable characterisation and screening against both PFK and PyK, 
deeming the methods suitable for synthesis of larger libraries. A possible reason for 
the low yields could be due to the fact that none of the reactions was monitored. 
Performing reactions in parallel subjects all reactions to the same general conditions. 
Another reason for low yield could also be loss of material during mass directed 
purification as again, the method used was a general method for all compounds. 
However, even with these problems, the overall aim of the library synthesis was 
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2.3 	Library 1. 
2.3.1 Library 1 design. 
As mentioned previously (at the time of this library synthesis), little was actually 
known about the structure of substrate binding sites of trypanosomal PFK, other than 
that the ATP binding site may be hydrophobic in nature when comparing to other 
PFKs60 ' 62 . Therefore, the design of this library was based around current inhibitors 
and reaction yields as discussed in section 2.2. Table 2.1 shows screening results of 
current inhibitors and the effects of substitution on the aromatic ring. It is interesting 
to note that there is no difference in the IC 50 values obtained for the un-substituted 
phenyl, 17, and the benzyl, 15, derivatives. Although the Kd value for 14 had not 
been determined, it is also interesting that the Kd value for compound 15 was 
comparable to those of the natural substrates for PFK. This, coupled with the fact 
that some inhibitors with a substituted phenyl group had already been synthesised 
and the effects on Tb PFK analysed, 61 ' 62 led to the decision that the inhibitors 
synthesised in library 1 would be based around 2,5-anhydro-1-deoxy-1-
(benzylamino)-D-mannitol 15, with diversity being introduced by means of 
substitution of the phenyl ring. Hence, substituted benzylamine derivatives were used 




























Figure 2.7 Benzylamine building blocks used in the synthesis of library 1. 
The amines shown in Figure 2.7 were chosen primarily to examine the effect of 
mono- and di-substitutions on the phenyl ring. As well as identifying new inhibitors 
of Tb PFK, the hope would be to try to determine a pattern that relates to inhibition 
(based on the aromatic substitution patterns), and hence to the environment in the 
ligand binding site. Other benzylamine derivatives were also used in this library 
synthesis to increase diversity in the hope that they may show some interesting 
results. The library size was restricted to 19 members simply on grounds of ease of 
compound handling. 
2.3.2 Library 1 synthesis. 
Library 1 was synthesised using the schemes and methods described in section 2.2. 
Figure 2.8 shows the structures and yields of all compounds successfully synthesised. 
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Figure 2.8 Library 1; structures and yields. 
The yields for the successfully synthesised compounds ranged from 6 % to 92 %. 
The library was designed so that a quantitative yield would produce around 200 mg 
for each compound. Therefore the compounds shown in Figure 2.8 were produced in 
sufficient quantity for biological screening. As has already been observed in section 
2.2.2 (the synthesis of the test library), some of the yields are quite low. Again, this 
can be attributed to the employment of a general method for all reactions. For 
example, those reactions with low yields may have benefited from longer reaction 
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times to go to completion. As well as this reason, the mass directed purification 
equipment (Waters ZMD) may have been a cause for the loss of yield. The reasons 
for this will be discussed later in Chapter 4. There were, however, two reactions in 
this library synthesis that were unsuccessful. These were the reactions with (4-
aminomethyl)-benzoic acid and 3-amino-3-phenylpropanoic acid. On inspection of 
the reaction vessels, this is thought to be because neither of these compounds 
dissolved (or failed to dissolve fully) in the solvent, methanol. Even though the 
library size is quite small, 17 out of 19 compounds were synthesised, characterised 
and submitted for biological screening against Tb PFK and Leishmania mexicana 
(Lm) PyK. The structures of these compounds were established by comparison of 1 H 
and ' 3 C NMR spectra to those of previously reported compounds. 61,63  In particular, in 
the 'H NMR spectra, characteristic doublet of doublet signals can be seen for the 
diasterotopic protons on Cl with a geminal coupling constant of around 12.5 Hz. In 
the ' 3C NMR spectra, characteristic signals can be seen between 8 = 76 and 86 ppm 
for the 4-carbon furanose scaffold (C2 - C5, see experimental). All compounds were 
established to have high purity by ' 3C NMR with the baseline showing no impurities. 
2.4 	Biological Screening and Evaluation. 
2.4.1 Initial screening method against Tb PFK. 
The screening method for library 1 (and indeed any subsequent library) was 
standardised so that the procedure would be relatively rapid, adaptable to high 
throughput screening and could also quickly identify any potential lead compounds 
or good inhibitors of PFK. It was for this reason that a 5 mM screening procedure 
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mM triethanolamine, pH 8.0), which was then tested against PFK where the final 
inhibitor concentration was 5 mM (0.25 p.g/ml PFK, 2 MM M902, 2 mM F6P, 1 mM 
ATP, 0.3 mM NADH, 1.7 units G3PDH, 0.9 units aldolase, 1 unit TIM). The activity 
of the enzyme before and after incubation was measured so that the percentage 
remaining activity of PFK could be calculated, giving an indication of the inhibitory 
effect of the inhibitors. Activity was calculated by measuring the absorbance 
decrease caused at 340 nm by the oxidation of NADH to NAD as shown by the 
enzyme couple in Figure 2.9. Hence, a decrease in absorbance would be proportional 





Mg-ADP + F1,6BP 
Aldolase 







Figure 2.9 Enzyme couple used in 5 mM screen to measure the effect of 
compound libraries on Tb PFK. TIM = triose phosphate isomerase. 
Any compounds that were identified as hits (showing at least 75 % inhibition at 5 
mM) were then further evaluated to obtain IC 5 0 values, Kd values or both. 
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2.4.2 Library 1 screening results against Th PFK. 
The results74 of the 5 mM screen of library 1 against Th PFK are shown in Table 2.3, 




25 58.1 ± 3.4 
26 85.3± 13.3 
27 65.4± 12.2 
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29 72.6 ± 13.9 
30 61.1±11.6 
31 67.6 ± 4.3 





34 62.5± 11.7 
35 58.6 ± 22.0 
36 56.9±8.7 
37 4.7± 0.0 
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Figure 2.10 A graph showing the screening results of library I against Th PFK. 74 
The results shown in Table 2.3 and Figure 2.10 show that all compounds tested in 
library I inhibit Th PFK to some extent at 5 mM. However, it can be seen clearly 
from the chart in Figure 2.10 that inhibitor 37 (2,5-anhydro-1-deoxy-(3,4- 
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dichlorobenzylamino)-D-mannitol) has a much greater effect on the activity of PFK 
than any other compound, as the enzyme activity was reduced to 4.7 % of its original 
activity. The structure of 37 is shown in Figure 2.11 (along with the structure of the 















Figure 2.11 Structures of the best inhibitors from the library 1 screen, 32 and 37. 
Evidently, the screening results identified 37 as the best inhibitor of PFK from 
library 1 and hence, a potential new lead compound. Therefore, to follow on from 
these results, 37 was re-synthesised on a larger scale to provide a sufficient amount 
of the inhibitor for further testing. 
Although the initial results above seem promising, they do not take into account the 
pKa of the secondary amine. Throughout the series of compounds, the substitution of 
the aromatic ring is likely to alter the aforementioned pKa value (pKa of 
benzylamine is 9.3. Hammet c values for the various substiuents can give an 
indication of their effect on the pKa value.) The inhibitors were screened at pH 8 
(7.2 for Lm PyK, see section 2.4.5) and deviations in pKa value from compound to 
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protonated inhibitor may vary in each assay, and the actual concentration of the 
inhibitors will also not be known accurately. It is possible to experimentally 
determine the pKa for each amine however, as the will become evident, trends in this 
library, and other libraries to follow, suggest that the pKa effect may be negligible. 
2.4.3 Further compound testing and general trends. 
An IC50 value was determined for 37 by measuring the activity of Th PFK at 
increasing concentrations of 37 between 0.001 and 5 mM and plotting a dose-
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Curve A Curve B Average 
IC50 0.45 mM 0.37 mM 0.41 mM 
R2 0.9923 0.9951 confidence) 
Table 2.4 IC50 values for the inhibition of Tb PFK by compound 37, determined 
74 from Figure 
It is now clear from Table 2.4 that the IC 5 0 of 37 is 0.41 mM, making it a lead 
compound. This value is comparable to that of another lead compound, 2 1,62  (shown 
in Table 2.1) which had an 1050 value of 0.45 mM. It is worth noting that 21 is 
phosphorylated at the 6-position whereas 37 is not. The unphosphorylated derivative 
17 (Table 2.1) has an IC50 value of 1.1 mM. As there is a twofold difference in 10 50 
values for 17 and 21, phosphorylation of 37 may produce an inhibitor of PFK that 
has an even lower IC 5 0 value. This, however, may only be true if 37 and the 
phosphorylated derivative of 37 bind in the same manner to PFK as 17 and 21 
respectively. For example, inhibitor 17 has been shown to compete with ATP and 
shows a fully mixed-type inhibition with F6P, 62 hence will bind to both the ATP and 
F6P binding sites. However, inhibitor 21 has been shown only to compete with 
ATP,62  hence will bind exclusively to the ATP binding site. If 37 is only competitive 
with either ATP or F6P - therefore already exclusively binding to one site - the 
effect of phosphorylation may not be as dramatic, if any improvement in inhibition is 
seen at all. 
11 M 
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Fluorescence quenching of the wild type enzyme was the method used to determine 
the dissociation constants (Kjs) of the inhibitors, due to naturally occurring 
tryptophan residues in Tb PFK. Table 2.5 shows the Kjs of the two best inhibitors 
from library 1. 74 Table 2.5 also shows the K j values for ATP and F6P, as determined 
by J. Martinez at the Edinburgh University, Institute of Cell and Molecular 
Biology. 74  It can be seen that there are slight differences between these values and 
those determined by S. Claustre (Table 2.262)  but they can be attributed to 
experimental differences, for example, differences in procedure, temperature and the 








Table 2.5 Dissociation constants (Kds) of inhibitors tested against Tb PFK. 74 
Due to the fact that there are some discrepancies between the Kd values of ATP and 
F6P from both the Edinburgh and Toulouse laboratories, it is difficult to comment on 
the actual Kd values and draw any comparisons between the inhibitors in Table 2.5 
and the original inhibitors shown in Table 2.1. However, it can be assumed that each 
set of results is consistent with itself, therefore allowing a comparison of the overall 
trend and hence, a comparison can be made between these inhibitors. 
50 
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The non-phosphorylated inhibitors shown in Table 2.1 have Kj values that are 
similar to that of both ATP and F6P, with the exception of 11 (a twofold higher 
value) which has been shown not to bind at the F6P binding site. 62  The only Kj value 
available for the phosphorylated inhibitors is that of inhibitor 18, which is about a 
twofold higher value than both those of the non-phosphorylated inhibitors, and of the 
natural substrates. Coupled with this apparent increase in Kj value, is a twofold 
reduction in the IC 50 value. As mentioned previously, this relates to the fact that the 
phosphorylated inhibitors bind only at the ATP binding site exclusively, whereas the 
non-phosphorylated inhibitors show binding at both the ATP and F6P binding sites. 
62 
Relating this to 32 and 37, they both have Kd values that are significantly higher in 
value than those of ATP and F6P. In the case of 37, this also has a low IC 50 value 
(comparable to that of the best phosphorylated compounds in Table 2.1). This trend 
in profile suggests that 32 and, in particular, 37, resemble the profiles of the 
phosphorylated inhibitors. Therefore, it is conceivable that these compounds may 
already bind exclusively at the ATP or F6P binding sites and hence, phosphorylation 
of these compounds may not improve inhibition of or binding to PFK. However, 
there are insufficient results to be certain that this is the case; the trends only suggest 
that this is a possibility. Conclusive evidence would only be gained by competition 
experiments and crystal structures with the inhibitors bound. 
Concurrent research by J. Martinez involved attempting to solve the crystal structure 
of Tb PFK. Figures 2.13 - 2.15 are of the solved structure of Tb PFK each figure 
with inhibitor 37 docked in the enzyme. 75,76  As mentioned previously, these type of 
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However, for reasons discussed later in Chapter 5, 37 was docked only into the F6P 
binding site. The purpose here is to illustrate that it is feasible to postulate protein-
ligand interactions by computational methods. 
Figure 2.13 Crystal structure of Th PFK with ADP (top compound) and 37 
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I 
-r 
Figure 2.14 Close ups of Figure 2.13. Top diagram shows a ribbon 
75 ' 76 representation. Bottom diagram shows a stick representation.  
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1  M`WA MMW6 ~4 LIN 
Figure 2.15 Crystal structure of Th PFK showing 37 docked, overlaid with 
F2,6BP (yellow). 75 '76 
These diagrams show the potential binding mode of compound 37 and its proximity 
to ADP. In particular, Figure 2.15 shows the relative positions of compound 37 and 
F6P. It is interesting to note that 37 has the potential to bind to Th PFK in a similar 
manner to F6P, with the position of the furanose scaffold reasonably well conserved. 
2.4.4 Inhibition trends from Library I. 
Although library 1 only consisted of 17 members, some structure-activity 
relationships (SAR5) are evident. Firstly, there is the relationship between the various 
mono-substituted benzyl derivatives. Figure 2.16 displays this information, showing 
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preference in inhibition of the order fluoro > chioro > methyl. However, this trend is 
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Substitution 
Figure 2.16 A graph showing the trends of inhibition of Th PFK between mono-
substituted benzyl derivatives in library 1. 
More distinctive trends to result from the library I inhibitory screens occur with the 
di-substituted benzyl derivatives and are shown in Figure 2.17. This figure shows 
two possible SAR results. The first is that, in general, dichioro derivatives are more 
inhibitory than dimethyl derivatives. However, with only two results, this 
observation is speculative, and a further dichloro derivative would need to be tested 
to support this claim fully. (The ortho - meta dimethyl benzyl derivative did 
continue the general trend by only reducing the enzyme activity to 70 %). 
55 
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Figure 2.17 A graph showing the trends of inhibition of Th PFK between di-
substituted benzyl derivatives in library 1. 
The second trend is that meta - para derivatives are more inhibitory than ortho - 
para derivatives. Again, this claim can only be substantiated by the results from the 
library I screen; for conclusive proof, further di-substituted derivatives would need 
to be synthesised and tested. However, all these trends do lead to the fact that 37 
should be the best inhibitor, which is indeed the case. In the interests of improving 
inhibition, the only other compound that could be synthesised based on the results 
above would be 2,5-anhydro- 1 -deoxy- 1 -(3 ,4-di fluorobenzylamino)-D-mannitol 42 
(Figure 2.18). This compound was synthesised in a yield of 8 %, and its biological 
results, along with those of other non-library synthesised compounds, are discussed 
in Chapter 5. 
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Figure 2.18 Structure of 42. 
Relating these trends to the structure of the ligand binding site of PFK confirmed the 
presence of a hydrophobic pocket. In general, hydrophobic pockets are desirable as 
parts of drug targets because hydrophobic groups need to be part of the potential 
drugs. These in turn are desirable as they improve the pharmacokinetics and the logP 
value of the drug, and hence allow the drug to obey one of the rules in the Lipinski 
Rule of 519  It is also interesting to note that the compounds synthesised in library 1 
fully obey the Lipinski Rule of 5 (logP results by modelling only) confirming these 
types of compounds as suitable leads for further drug development (see Appendix 1). 
The preference for meta —para derivatives suggest that this hydrophobic pocket may 
be extended slightly in this direction, in the orientation that the inhibitor is bound. It 
is difficult to comment further on this in the absence of a crystal structure with the 
inhibitor bound. 
2.4.5 Initial screening method against Lm PyK. 
A similar 5 mM screen method was adopted for initial screens against Lm PyK, as 
were done for PFK, detailed in section 2.4.1; the assay was carried out in 25 mM 
triethanolamine, pH 7.2 (0.4 g/ml PyK, 3 MM MgSO 4 , 3 mM KC1, 0.3 mM ADP, 
0.42 mM NADH, 0.4 mM PEP, LDH 13.8 units). The enzyme couple used to 
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at 340 nm was measured to determine the rate of PyK and hence, the percentage 
remaining activity. 
Pyk 





Figure 2.19 Enzyme couple used in 5 mM screen to measure the effect of 
compound libraries on Lm PyK. LDH = liver dehydrogenase. 
2.4.6 Library 1 screening results against Lm PyK. 
Results from the initial 5 mM screen against PyK are shown in Table 2.6 and 
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Figure 2.20 A graph showing the screening results of library 1 against Litz PyK. 77 
In general the results presented in Table 2.6 show that the compounds in library 1 
partially inhibit or have no effect upon the activity of PyK. The two exceptions to 
this are 34 and 37. These compounds inhibit PyK activity to 42 % and 43 % 
respectively. Although these results may seem slightly disappointing, the presence of 
inhibitors of PyK from library 1 show that the synthesis of further derivatives of 2,5-
anhydro- 1 -deoxy-D-manrntol is worth pursuing. An 10 50 value was determined for 
34 by measuring the activity of Lin PyK at increasing concentrations of 34 between 
0.001 and 5 mM (the dose-response curve for 34 can be found in the appendix). The 
1050 value for 34 against Lm PyK was determined to be 1.6 mM. 78 Further library 
synthesis of these derivatives with a greater variation at the C- 1 position was needed 
to help probe this enzyme further in order to find a more effective inhibitor. 
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2.5 	Conclusion. 
The library 1 screen against Th PFK identified a new inhibitor and lead compound, 
2,5-anhydro-1-deoxy-1-(3,4-dichlorobenzylamiflO)-D-maflflltOl 37 and its IC 50 was 
determined to be 0.41 mM. Possible SAR trends show that the 3,4-dichlorobenzyl 
group appears to be the optimum group for greatest inhibition, and that ligand 
binding is likely to involve interaction with a hydrophobic pocket. However, SAR 
results also show that a 3,4-difluorobenzyl derivative could also prove to have 
significant inhibitory activity. The screening of this compound is discussed in 
Chapter 5. 
Screens of library 1 against Lm PyK showed two compounds to have a moderate 
inhibitory effect, namely 2,5-anhydro- 1 -deoxy- 1 -(2-fluorobenzylamino)-D-mannitol 
34 and 2,5-anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-mannitOl 37. These 
results show that this type of compound can inhibit PyK, but further library synthesis 
was needed in order to gain more effective inhibitors. 
Chapter 3 
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3 	Library 2: Design, Synthesis and Evaluation. 
3.1 	Library 2. 
3.1.1 Library design. 
Having already synthesised the first library, established a new lead compound for Tb 
PFK and shown that these compounds can also inhibit Lm PyK, the decision was 
made to synthesise a second, larger library with greater diversity. The library 
synthesis would use the chemistry and methods described in Chapter 2, but no 
restriction would be placed on the amine building blocks used. Figure 3.1 shows the 
39 primary amines that were used in the synthesis of library 2. Chosen owing to their 
commercial availability and structural and chemical diversity, it was hoped that they 
would have a positive affect on inhibition. One or more of these features would 
hopefully gain attractive interactions with the target enzyme, resulting in inhibitors 
with a greater affinity for the enzyme than already existing inhibitors. These features 
include hydrophobic groups (linear chains, branched chains, rings), hydroxyl groups, 
ethereal groups, an introduction of stereocentres (to hopefully find a preference 
between R and S pendant side-chains), larger aromatic groups (in comparison to the 
benzyl derivatives in Chapter 2) and some compounds that combine two or more of 
these features. 
62 
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Figure 3.1 Amine building blocks used in the synthesis of library 2. 
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3.1.2 Test library synthesis. 
In the synthesis of library 2, it was decided, as with library 1, to synthesise a small 
test library to ensure the chemistry and methods were still suitable now different and 
a wider range of amines were being used. It was decided to make a 5-membered test 
library using amines 43 to 47 shown in Figure 3.1; cyclopentylamine 43, L-(-)-2-
amino-3-phenyl-l-propanol 44, 2-pentylamine 45, 1-(1-adamantyl)-ethylamine 46 
and (±)-phenylpropanolamine 47. The structures and yields of the test library are 
shown in Figure 3.2. [Note: In Chapter 6, Experimental, the test library synthesis has 
been included in the synthesis for library 2, as the methods used were identical and 



















Figure 3.2 Structures and yields of test library (part of library 2). 
With the exception of 51, the test library proved successful with yields ranging from 
23 % - 90 %. Although, no product was yielded for 51, this was not a reason to alter 
or change the method for the synthesis of library 2 as this result could be attributed to 
the bulky and sterically hindered nature of the adamantyl group. The remaining 
compound yields were sufficient to enable characterisation and biological testing. 
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3.1.3 Library 2 synthesis. 
Library 2 synthesis was successful, and in total 38 compounds from the 39-
membered library, including the test library, were synthesised. The structures of 
these compounds can be seen in Figures 3.2, 3.3 and 3.4. 
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Figure 3.4 Structures and yields of the final 19 compounds in library 2. 
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Yields for library 2 ranged between 4 and 90 %, showing a similar spread to the 
yields from library 1. However, enough of each compound was synthesised to allow 
for characterisation and biological testing. The wide ranging yields can again be 
explained by the fact that a general method was employed for all reactions. Reaction 
monitoring did not occur, so some reactions may not have gone to completion. Once 
again, however, an alternative reason could be due to the mass directed purification 
equipment (Waters ZMD). The reasons for this will be discussed in more detail in 
Chapter 4. Although some of the yields may have been low, only one reaction failed; 
the synthesis of 2,5 -anhydro- 1 -deoxy- 1 -(1 -(1 -adamantyl)-ethylamino)-D-mannitol 
51, as previously mentioned in section 3.1.2. Again, as for library 1, the structure for 
these compounds was determined by comparison of 'H and 13C (where available) 
NMR spectra with those of previousy reported compounds. 
61,63 
3.2 	Biological screening and evaluation. 
3.2.1 Screening objectives. 
Following the results from library 1, the primary objective for library 2 was 
hopefully to identify more potent inhibitors of Lm PyK. Indeed, the library was 
designed with this reason in mind, so screening these compounds against PyK was 
the main priority. However, because of the similarity between library 1 and library 2 
(due to the same 2,5-anhydro-D-mannitol scaffold) the decision was made also to test 
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3.2.2 Library 2 screening results against Lm PyK. 
The initial screen for library 2 was the 5 mM screen using the same method as set out 
in section 2.4.5, and the same enzyme couple as shown in Figure 2.18 (the same 
procedure as for library 1). Results from this screen against a tryptophan mutant Lm 
PyK (E451W) are shown in Table 3.1, and graphically in Figure 3•578•  The 
compounds were also tested against wild type Lm PyK and these results are shown in 





49 72.0 ± 10.6 
50 26.3 2.1 
52 79.7 ±3.8 
53 96.7 ± 0.7 
54 49.3 ±10.1 
55 59.7 ± 0.2 
56 103.1±11.0 
57 35.5±1.6 
















71 57.4 ± 4.3 
72 26.4±4.2 








81 85.8 ± 2.0 





Table 3.1 Results of library 2 Screen against E451W Lm PyK. (Errors are 
shown for duplicate or triplicate assays).78 
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Figure 3.5 Graphs showing the results of library 2 Screen against E45 1W 
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Figure 3.6 Graphs showing the results of library 2 Screen against wild type 
Lrn PyK. 78 
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[Note: The results against both the mutant and the wild type enzymes are shown 
because the screen was initially performed on the mutant. This was then repeated for 
the wild type enzyme; however inhibitor 60 had been consumed in the first set of 
assays, therefore has been omitted in Table 3.2 and Figure 3.6. A comparison 
between the results of the mutant and the wild type enzyme assays, however, shows a 
good correlation. The majority of the results are of a similar value, and all trends 
(discussed later) are true for both enzyme forms. All those compounds that have been 
identified as hits (under 36 % remaining activity) with the mutant enzyme, were also 
identified as hits with the wild type enzyme. However, the wild type enzyme 
identified two more compounds as potential hits; 61 and 71. These did show 
inhibitory activity against the mutant, but insufficient to be considered a hit. It can 
therefore be assumed that 60 could also be considered a hit. All discussion that 
follows will refer to the results against wild type Lm PyK unless explicitly stated.] 
The results presented in Table 3.2 and Figure 3.6 (combined with the results from 
Table 3.1) show a wide range of inhibition. Thirteen compounds (highlighted) can be 
identified as potential leads, with the remaining enzyme activity being under 36 %. 
This shows a vast improvement on library 1, the best result being that of 34 which 
gave remaining enzyme activity as 42 %. Indeed, the best result from library 2 was 
obtained by inhibitor 70 (2,5-anhydro- 1 -deoxy-(cycloheptylamino)-D-mannitol), 
which inhibited Lm PyK to 8.0 % of it's original activity. All thirteen compounds are 
shown in Figure 3.7. 
72 
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Figure 3.7 Structures of hits from the library 2 screen against Lm PyK, also 
showing percentage remaining activity from the assays. (*Result  from assay 
against E451W Lm PyK). 
In Figure 3.7, it becomes apparent that the majority of these inhibitors have a bulky 
hydrophobic group, indicating interaction with a hydrophobic pocket on PyK. It is, 
therefore, very likely that all these compounds will be exhibiting their inhibitory 
effect by binding in the same place on the enzyme. Further trends and SARs will be 
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3.2.3 Further compound testing and general trends. 
1050 values were determined for 9 of the 13 inhibitors shown in Figure 3.7, using the 
same method as discussed in section 2.4.7. Table 3.3 shows the results, including 
IC50 values for both 48 and 58 as these compounds showed slight inhibitory activity 
(more so against the E451W mutant than the wild type enzyme). This would also act 
as a check to ensure there is a correlation between the initial screen and the IC 50 
values. (Dose-response curves for each compound can be found in the appendix). 
Ut.] iii .1.1 1 1 
4: 
Table 3.3 1050 values of hit compounds from library 2. The R 2 value gives 
an indication of the reliability of the iC 50 values. This is determined from 
the curve of the dose-response graphs which can be found in the appendix. 
78 
These results indeed do show a correlation with the initial 5 mM screen, indicating 
that this primary screen is a suitable method for identifying possible inhibitors and 
potential lead compounds. The second point to note is that there are 6 compounds 
74 
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with an IC 50  less than 1.6 mM, which is the value determined for inhibitor 34, as 
discussed in Chapter 2. The most potent of these are inhibitors 61 (2,5-anhydro-l-
deoxy1-(R-l-(4-methoxyphenyl)ethYlamiflO)-D-ma1mit0l) with an IC 50 of 0.9 MM, 
and 70 (2,5anhydro-1-deoxy-l-(cycloheptylamino)-D-manllitol) with an IC 50 of 58 
tM, making the latter the new lead compound against Lm PyK. 
The rationale for using 2,5-anhydro-1-deoxy-D-mannitol derivatives as the basis for 
potential inhibitor libraries was due to their structural similarity to F2,6BP, the 
effector for trypanosomal PyK. However, these derivatives are also structurally 
similar to ADP, a natural substrate for PyK. It is due to this that the inhibitors 
synthesised so far could well bind at either the ADP or F6P binding sites. For reasons 
of specificity, it is desirable to have inhibitors that bind to the F6P binding site. It 
was therefore necessary to try to determine where these inhibitors bound. This was 
done by means of competition experiments. 79  The results from these titrations show 
that none of the compounds significantly altered the KMof ADP, but did reduce the 
Vmax - inhibitor 70 to 15.1 % of the uninhibited maximum velocity and inhibitor 78 
to 58.0 %. These results are consistent with inhibition that is non-competitive with 
ADP. Although the results as such cannot conclusively prove that these inhibitors 
bind to the effector site, they do show, however, that as the inhibitors are non-
competitive with ADP, they do not exert their inhibitory effect by binding to the 
ADP site. Therefore they must bind elsewhere on the enzyme, and it is likely that 
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3.2.4 Inhibition trends from library 2. 
Using  the results obtained from the initial 5 mM screen against Lm PyK (both wild 
type and E451W mutant) it is clear that some SAR data can be obtained. The general 
observation that the more effective inhibitors possess a hydrophobic group has 
already been mentioned in section 3.2.2. The following is a more detailed look at the 
results of the screen and how they relate to the structure of the inhibitor and hence, 
the structure of the binding site. 
0 	 Ring 
H 
HO 	OH 
Figure 3.8 A Graph showing the effect of ring size at the I -position upon 
inhibitory activity against Lm PyK. 
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Figure 3.8 shows how the ring size affects the inhibitory activity of the inhibitor. 
Looking at the results for the wild type enzyme, there is a clear pattern between ring 
size and inhibitory activity. As the ring size increases, the percentage remaining 
activity of the enzyme decreases, hence there is an increase in the inhibitory activity 
of the compound. This is true up to the point where ring size is equal to 7 
(cycloheptyl). Here, the optimum ring size has been reached and hence, the 
cycloheptyl derivative is the most effective inhibitor for this group of compounds. As 
the ring size increases again, so does the percentage remaining activity of the enzyme 
thus the inhibitory activity of the compound decreases. This result is what would be 
expected of a hydrophobic cavity of a protein that was able to accommodate alkyl 
rings. As the ring size increases, the greater the interaction it would have with the 
cavity, hence greater inhibition would be observed. At a certain point (in this case at 
the cycloheptyl stage), the ring size would be optimum for the size of the cavity and 
the interactions between the two would be at the greatest (maximum inhibition). As 
soon as the ring size increases again, it becomes too large for the cavity and 
hydrophobic interactions would decrease, resulting in a fall in the level of inhibition. 
The results obtained from the E45 1W mutant are less clear than the wild type 
enzyme. Overlaying the two sets of results (as seen in Figure 3.8) suggests that the 
overall trend may still be evident and that the result of the screen with compound 66 
could be anomalous. However, it could also point to the possibility of the mutated 
residue having an affect on the binding of inhibitors. 
Concurrent research by L. B. Tulloch at the Institute of Cell and Molecular Biology, 
University of Edinburgh, 80  involved using crystallographic methods in order to solve 
the R-state (active state) structure of Lm PyK. Molecular docking was carried out in 
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order to model inhibitor 70 in the effector site of Lm PyK. Initially this was carried 
out on the T-state structure, but this resulted in the cycloheptyl ring pointing away 
from the enzyme and into solvent space. 80 This result seemed highly unlikely, so the 
T-state structure used was unsuitable for molecular docking. However, the procedure 
was repeated on a modified T-state structure, where residue R404 near the effector 
site had been rotated to a position more commonly associated with R-state 
structures. 81  The result from this can be seen in Figure 3.9 (further structures can 
found in section 3.2.5). 
Figure 3.9 Model of 70 docked in Lnz PyK effector site. ° Red indicates a 
negative surface, blue a positive surface, and grey a hydrophobic surface. 
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It is evident from Figure 3.9 that this new model of the effector site for Lm PyK 
provides a more realistic result. The rotation of residue R404 has, in effect, exposed a 
hydrophobic pocket just next to the effector site in which the cycloheptyl group 
interacts; the furanose sugar scaffold binds in the effector site. A closer inspection of 
Figure 3.9 reveals why the 7-membered ring is optimum for binding, and hence for 
inhibitory activity. As already mentioned, a smaller ring size would mean fewer 
hydrophobic interactions with the pocket, but a larger ring size would start to make 
repelling interactions with the hydrophilic residues surrounding the hydrophobic 
pocket. This explains the result shown in Figure 3.8 where some inhibitory activity 
still remains when the ring size is increased to 8 (cyclooctyl). If this SAR was 
brought about exclusively by the size of the hydrophobic pocket, it might be 
expected that most or all inhibitory activity would be lost when the ring size just 
exceeds the optimum (8-membered as opposed to 7-membered). 
The next SAR involves inhibitors that possess a chiral centre in an alpha position to 
the nitrogen (a-chiral). To compare these trends, compounds have been paired so that 
each pairing has two compounds which are diastereomers of each other, with 
opposite configuration at the a-chiral centre. The trends for both the wild type and 
mutant enzymes can be seen in Figure 3.10. Looking primarily at the results for the 
mutant enzyme, it is clear that there is a preference for inhibitors to possess an a-
chiral centre of S-configuration as opposed to R, if an a-chiral centre is present. 
Although in some cases the difference in remaining enzyme activity may only be 
small and therefore within the error of the assays, without exception, the a-S-isomer 
of a compound pairing has the greater inhibitory activity against Lm PyK. It therefore 
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follows that the a-S isomer has a stronger and more favourable interaction with the 
effector site of Lm PyK. The biggest difference in inhibitory activity of a compound 
pair is seen with inhibitors 72 and 73. 
WT screen 
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Figure 3.10 Graphs to show the influence of an a-chiral centre upon 
inhibitory activity against Lm PyK wild type (top graph) and E451W 
mutant (lower graph). 
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With regard to the results from the wild type enzyme, these again show the general 
trend that in a compound pairing, the a-S-isomer is a better inhibitor than the a-R 
isomer. However, two of the results are reversed - compound parings 49 and 53, and 
62 and 63. It is unsure why the results from these inhibitors with the wild type 
enzyme differ from the results with the E451W mutant enzyme, although the 
difference in percentage remaining activity of the wild type enzyme when screened 
with both between 49 and 53 is so small that it could be due to experimental error. It 
is interesting to note that the biggest difference in inhibitory activity of a compound 
pair is again seen with 72 and 73. These inhibitors (a-S- and a-R-2,5-anhydro-1-
deoxy-1-(3-methyl-2-butylamino)-D-mannitol respectively) differ from all the other 
compound pairs as they possess a small, branched hydrophobic chain with no rings 
(aromatic or alkyl) or heteroatoms. The reason for this preference will be discussed 
further in section 3.2.5. 
The final trend involves inhibitors that possess an alkyl chain, whether it is linear or 
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Figure 3.11 Graph to show the effect of an alkyl chain (branched or linear) 
at the 1-position upon inhibitory activity against Lm PyK. 
This trend, again, generally follows what would be expected for alkyl chains 
interacting with a well defined hydrophobic part of the target enzyme (bearing in 
mind that the result for 73 is largely due to the a-chiral centre as discussed earlier). 
The smaller and more highly branched the chain, the stronger the interaction with the 
hydrophobic cavity and the more potent the inhibitor. As the chain length becomes 
longer, more disorder is introduced and, therefore, interactions with the hydrophobic 
cavity will become weaker, leading to a decrease in inhibitor potency. The same 
trends are seen for both the wild type and E45 1W mutant enzymes. 
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3.2.5 Molecular docking models. 
It has already been seen in section 3.2.4 that molecular docking was successfully 
carried out on a modiheci T-state Lin PyK structure with inhibitor 70 in order to gain 
insight into how the lead compound interacts with the effector sight of the enzyme. 80 
Further molecular docking experiments were carried out 80  on other inhibitors. The 




Figure 3.12 Model of 70 docked in Lm PyK effector site showing some 
surrounding residues.80 
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Returning again to the docking of 70 in the effector site of Lm PyK, Figure 3.12 
shows this complex with some enzyme residues labelled that could make possible 
interactions with the inhibitor, as well as other surrounding residues. It is important 
to stress that this is only a model and not a crystal structure, therefore, all interactions 
that are mentioned are only possibilities that arise from molecular modelling. The 
hydrophobic cavity on the left hand side of the picture is created by a deep leucine 
side chain (L408). This is where the cycloheptyl group interacts. The secondary 
hydroxyl on C4 of the inhibitor appears to hydrogen bond to the backbone of the 
enzyme (at the valine residue, V585). The other secondary hydroxyl (on C3 of the 
inhibitor) could potentially interact with the flexible arginine residue (R404). Other 
potential interactions are not easily visible on this structure, but are shown on a 
schematic diagram in Figure 3.13. This structure also alludes to the development of 
these compounds at the 6-hydroxy position in order to extend the inhibitor further 
into the binding site. 
S145 	V585 
Hydrophobic 	 A481 











Figure 3.13 Diagram showing the potential protein-ligand interactions of 
inhibitor 70 in the effector site of Lm PyK, as determined using molecular 
modelling. 
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Figure 3.14 Model of inhibitor 57 docked in Lm PyK effector site.SU  Top 
picture shows the enzyme as a surface representation, bottom shows the 
enzyme as a stick representation. 
85 
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The inhibitor with the third best IC 5 0 against Lin PyK (1.2 mM) was 57. Molecular 
docking was also carried with this inhibitor in the effector site of Lrn PyK and the 
results are shown in Figure 3.14. Looking primarily at the orientation of the furanose 
scaffold, it is interesting to note that the same potential interactions have been 
identified as for inhibitor 70. In particular, the interaction between the C4 hydroxyl 
group of the inhibitor and the backbone of the enzyme (at residue V585) is a lot more 
evident. Whilst the 1,2,3,4-tetrahydronaphthyl moiety interacts in the same place as 
the cycloheptyl group in inhibitor 70, it does not appear to be sitting as deep in the 
hydrophobic pocket and, indeed, the aromatic portion could be repulsively 
interacting with the hydrophilic residues that surround the pocket. This could be a 
reason for why 57 is not as potent as 70. 
Figure 3.15 Model of 68 docked in Lm PyK effector site.80 
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Figure 3.15 shows 68 (another of the best six inhibitors) docked in to the effector site 
of Lm PyK. Again, it is clear that the furanose ring is making the same interactions 
with the enzyme as it was with inhibitors 57 and 70, and its orientation is well 
conserved. It is interesting to note that the naphthyl moiety is in a different 
orientation to that of 57, but in the same orientation as the cycloheptyl group in 70. 
Again, the naphthyl group looks too large for the hydrophobic pocket and could be 
making repulsive interactions. However, this may be partly countered by the R-a-
methyl group which could potentially make a hydrophobic interaction. It is 
postulated that inversion of the configuration of 68 would position the a-methyl 
closer to the nearby hydrophobic portion of the enzyme. Therefore, this model 
potentially explains the preference for the a-S inhibitors over the a-R inhibitors. 
The final model shows inhibitors 72 and 73 docked in to the effector site of Lm PyK 
and is shown in Figure 3.16. As mentioned in section 3.2.4, 72 shows greater potency 
against Lm PyK than 73, and other inhibitors with larger alkyl chains. Firstly, 
although this model shows that there is potential for larger alkyl chains to bind, the 
shape of the hydrophobic pocket is such, that smaller chains are likely to bind more 
effectively due to their more ordered nature. Larger chains would have to experience 
large conformational changes in order to bind effectively. Secondly, it is evident 
from a comparison between the models for 72 and 73, why 72 is the more potent 
inhibitor. The a-S-chiral centre on 72 induces the burying of the methyl group within 
the hydrophobic pocket, the overall effect being that of a favourable protein-ligand 
interaction. The a-R-chiral centre on 73 brings about the exposure of the methyl 
group to solvent space. Hence, this mode of binding is not as favourable as with 72 
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and, therefore, 72 is a more potent inhibitor. This observation is similar to that 
mentioned previously with inhibitor 68, further corroborating the explanation for the 
increased inhibitory activity of a-S compounds over a-R compounds. 
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Figure 3.16 Models of 72 (top) and 73 (bottom) docked in the Lm PyK 




Library 2: Design, Synthesis and Evaluation 
3.2.6 Library 2 screening results against Tb PFK. 
As already mentioned in section 3.2.1, the remainder of any library 2 compounds 
from the biological evaluation against Lm PyK were used in a 5 mM screen against 



































Table 3.4 Results of library 2 screen against Tb PFK. 
82 
It is clear from the results shown in Table 3.4 and Figure 3.17 that the compounds in 
library 2 show little inhibition towards Tb PFK, and that none of the compounds are 
as good an inhibitor as 37 from library 1. 
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Figure 3.17 A graph showing the results of library 2 screen against Tb 
PFK. 82 
3.3 	Conclusion. 
Library 2 was designed and synthesised for biological testing against Lm PyK in 
order to try and identify one or more inhibitors with an 10 50 value less than that of 
inhibitor 34 (1.6 mM). The initial 5 mM screen identified several potential inhibitors, 
and after further evaluation, six of these were found to have an 10 50 value of 1.5 mM 
or less. In particular, 2,5-anhydro- 1 -deoxy- 1 -(cycloheptylamino)-D-mannitol 70, was 
discovered to have an 10 50 value of 58 p.M, confirming this inhibitor as the new lead 
compound against Lm PyK. Competition experiments showed that these compounds 
do not compete with ADP and are therefore likely to bind to the effector site of the 
enzyme, as initially hoped. SAR results from the initial screen showed evidence of 
inhibitor interaction with a hydrophobic pocket in the effector site of Lm PyK, and 
also showed the cycloheptyl ring to be the optimum size for these hydrophobic 
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in the initial screen and shows the potential mode of binding of these inhibitors. It 
also shows potential inhibitor-protein interactions. 
Library 2 was also screened against Th PFK but the results did not show any 
improvement on the inhibitor already identified from library 1 (inhibitor 37), or 
provide any new SAR information. 
92 
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4 	Library 3: Design, Synthesis and Evaluation. 
4.1 	Inhibitor development. 
4.1.1 Overview. 
Results presented in Chapters 2 and 3 have demonstrated that library synthesis has 
led to the discovery of novel inhibitors for both Th PFK and Lm PyK. In the interest 
of creating more potent inhibitors of the target enzymes, it was necessary to develop 
these newly discovered inhibitors. The following two chapters focus on this 
development, in particular the evolving chemistry involved in lead modification, the 
final library synthesised as a result of lead development, and other non-library 
compounds also synthesised as result of lead development. 
4.1.2 Potential lead development. 
Library synthesis has so far concentrated on the reductive amination reaction in order 
to synthesise 2,5-anhydro-1-deoxy-D-maflflitOl derivatives and, as already 
mentioned, this was successful in discovering inhibitors of both Tb PFK and Lm 
PyK. In order to develop these inhibitors further, it was necessary to identify possible 
modifications and reactions that could potentially be performed on these inhibitors. 
Figure 4.1 shows the modifications that could be made and also shows how the 
general inhibitor structure can be dissected in to separate sections; an approach that 
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L HO 	 I[HII HO 	OH] ]L 
Oxidation, 
Other sugars 	Alkylation 	More amines 
Phosphorylation 
Figure 4.1 Potential modifications to general inhibitor structure. 
In total, there are four sites on the general inhibitor structure where modifications can 
be made. First of all', there is the possibility of modifying the 6-position hydroxyl. It 
was thought that oxidation of this group to the acid would not only give a structurally 
and biologically interesting N-substituted sugar amino acid (SAA, see section 4.2 for 
a brief overview), but could also be used in amine (or amino acid) coupling reactions 
(see Figure 4.2), which is of particular interest as it enables the extension of these 
inhibitors in order to gain further binding interactions. Modelling studies suggest that 
this could be important for inhibition of PyK (Chapter 3). As these reactions are well 
known and thoroughly documented throughout the literature 13,83  it seemed an ideal 
basis for the design of a further library. Another modification possible at the 6-
position hydroxyl is phosphorylation. It had been previously reported that 
phosphorylation at this position has led to an improvement of existing inhibitors of 
Tb PFK. 62 Therefore, methods to easily phosphorylate these compounds were 
explored and are discussed in Chapter 5. 
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Figure 4.2 Further, possible inhibitor development of N-substituted sugar-amino 
acids to sugar amino amides. 
The second possible modification that could be made is to change the 
stereochemistry of the furanose scaffold. This can be achieved by using alternative 
amino sugars as the initial starting material for the nitrous deamination reaction (as 
shown in Figure 2.3, Chapter 2). Again, this is discussed in more detail in Chapter 5. 
The next possible modification is the N-alkylation of the secondary amine to a 
tertiary amine. This, again, is also discussed in more detail in Chapter 5. 
Finally, there is the possibility of using yet more primary amines to synthesise more 
secondary amine derivatives as shown in libraries 1 and 2. At this stage, however, it 
was deemed more pertinent to explore other areas of the inhibitors' structure. 
4.2 	Sugar amino acids (SAAs). 
The synthesis of sugar amino acids (SAAs) is one method by which these inhibitors 
could be developed. This section is a brief introduction to both naturally occurring 
and synthetic SAAs. The term sugar amino acid is used to describe a class of 
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compounds with two immediate linkages of amino and carboxyl functionalities to a 
carbohydrate frame or scaffold, as shown in Figure 
4•3•84  The natural diversity that 
these carbohydrates offer is a powerful tool in the area of drug discovery. 
(OH) n 
O-X F NH 21  
(oH) 
FN H 2  
Figure 4.3 General structures of sugar amino acids. 
84 
Naturally occurring SAAs are largely found as construction elements 
84  such as 
neuraminic acid (Figure 4.4) which is often located peripherically on glycoproteins. 
The furanoid SAA (+)-hydantocidin exhibits herbicidal activity 
85-87  whilst siastain B 
inhibits both 8-glucuronidase and N-acetylneuramidase 84 . This belongs to the SAA 


















Figure 4.4 Naturally occurring SAAs. 
Both pyranoid and furanoid SAAs have been synthesised, not only for structural 
interest, but also for various biological uses, especially as mimetics. 84 Whilst there 
have been different methods used to synthesis 5-furanoid SAAs, none have used the 
approach that was proposed in section 4.12, but instead rely heavily on protection 
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techniques of the secondary hydroxyl groups that would lead to an extended 
synthesis if adopted here. A more selective approach was therefore investigated (see 
section 4.3.2). 
4.3 	Synthesis development. 
4.3.1 Development of N-substituted-i -amino-2,5-anhydro-1 -deoxy-D-mannitol 
synthesis. 
It has already been commented upon in Chapters 2 and 3 that some of the yields from 
the library syntheses were poor, originally attributed to the nature of parallel 
synthesis where there is no reaction monitoring and all reactions are subject to the 
same reaction conditions. However, yields remained low when synthesising 37 and 
70 on a larger scale, necessary for further inhibitor and synthesis development. 
Reaction monitoring by TLC (disappearance of 22) and electrospray mass 
spectrometry (ESI) suggested that the reactions had in fact reached or approached 
completion, leading to the conclusion that it was not the reactions that were 
producing poor yields, but the purification method employed for these reactions. As 
mentioned in both Chapters 2 and 3, purification of these reactions was achieved by a 
mass-directed purification system (Waters ZMD). This works in a similar manner to 
a preparative HPLC system (details of sample concentration and running methods 
used can be found in Chapter 6). Figure 4.5 is a simple overview of how purification 
is achieved by this system. 
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Figure 4.5 A schematic diagram showing a mass-directed purification system. 
After the crude sample is injected, it is passed through a preparative scale column, 
which facilitates the separation of the various components in the crude sample. In the 
case of the reductive amination reactions, the crude product contained only the 
desired product and small amount of unreacted starting materials. Flow is then 
directed through a splitter where the majority of flow continues on to the collection 
system (when the system is not collecting, the flow route is directed to waste). 
However, a small portion of the flow (1/1000) is routed to an electrospray mass 
spectrometer where it is analysed. When the desired mass is detected by the mass 
spectrometer (pre-inputted), flow in the collection system is directed for collection. 
When the mass is no longer detected (or falls below a certain threshold value), the 
flow in the collection system is directed back to waste. 
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It is difficult to ascertain where the loss in yield at the purification stage was 
occurring, but even using a low crude sample concentration, small injection volumes 
and multiple injections, the percentage compound return from crude material 
remained low; 500 mg of crude material (using multiple injections) would yield in 
the range of 50 - 150 mg of pure compound (use of this method was also time 
consuming). Initially, the problem was thought to be due to the column, but its 
replacement had no effect on the overall return of isolated compound. Although this 
is a good, rapid system for combinatorial scale reactions (where small amounts of 
compounds suffice for analysis and testing), it seemed as though the persistently poor 
yields obtained would severely inhibit further synthetic scheme and inhibitor 
development. Without being able to find a reason or a cure for the low yielding 
performance of the mass-directed purification method, the decision was made to 
investigate other methods of purification, and, if necessary, adapt the reductive 
amination reaction accordingly. 
The overall transformation of this particular reductive amination reaction is the 
formation of a secondary amine from a primary amine (the aldehyde in the presence 
of a reducing agent is effectively the alkylating agent). As the primary amine is likely 
to be the major impurity in the reaction, the purification technique should facilitate 
the separation of primary from secondary amines. Examples from the literature 
suggested that this indeed was eminently possible, more so with the developing field 
of solid phase chemistry. 89,90 
Solid phase chemistry has been used extensively in the medicinal chemistry area 
over recent years, not only because reactions can be carried out on a small scale and 
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in a combinatorial manner, but the target compounds are synthesised with high purity 
and little contamination, largely due to the fact that the compounds can be washed 
free of contaminants whilst still attached to the bead. However, attractive as this may 
seem, developing the reductive amination reaction on solid phase was deemed 
unsuitable at this point. It may have led to synthetic problems, as well as being 
unsuitable for preparative scale reactions due to low bead loading, both of which 
could have proven to be too time consuming. However, one aspect of solid phase 
chemistry, namely the utilisation of solid phase reagents and scavengers, could still 
be used without the need for moving away from solution phase chemistry. Solid 
phase reagents provide a technique whereby reagents can be administered to 
solution. Due to the fact that the reagent is supported on solid phase, there are no 
contaminants and no excess reagent because it can be removed from the solution by 
filtration after the reaction is complete. Solid phase scavenger reagents are used as a 
means of removing, from solution, any unwanted side products or unreacted starting 
material, leaving only the desired compound in solution which can be isolated, 
simply, by solvent removal. Adaptation of this technique to the reductive amination 
reaction would involve retaining aldehyde 22 and the primary amine in solution and 
supplying the reducing agent by means of solid support. Purification would be 
achieved by using a solid supported scavenging reagent to selectively remove any 
unreacted or excess primary amine. Work previously done in this area 
91-93 had 
discovered that by using an excess of the primary amine, reduction of the preformed 
imine could be achieved by solid supported borohydride. The excess unreacted 
primary amine could be removed by scavenging with a solid supported aldehyde. 
91 
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used as the reducing agent. 92 
Each of the methods mentioned above was tested in order to ascertain, primarily, 
whether this technique could be used successfully in the synthesis of N-substituted-
2,5-anhydro-1-deoxy-1-D-mannitol derivatives, and if so which gives the best 
results. Figure 4.6 together with Table 4.1 show the synthetic scheme, the reagents 
used and the results for each method. 
0 	 1. Resin AorB 	
Cl 
HO 	
0 	/ Cl 	(2 eq, 24 hours) HO 
+ H2 N 	
2 
0 	O OH 
(1.5 eq) 	
0 .CHO 	 H 
(1.1 eq, 72 hours) 
3. Filter, wash and 
remove solvent 
Figure 4.6 Potential new methods for synthesis of N-substituted-1-amino-2,5-
anhydro-l-deoxy-D-mannitol derivatives. Resin A = solid supported 
cyanoborohydride; Resin B = solid supported borohydride. Scavenger resin = 4-
benzoxybenzaldehyde polystyrene. 
Yield Comment 
Mainly primary amine 
starting material (as 
Resin A 75% 
determined by ESl 
and 1 1-1 NMR). 
Product only (as 
Resin B 83% determined by ESI 
and 1 1-1 NMR). 
Table 4.1 Results of using different resins in the synthesis of N-substituted-i-
amino-2,5-anhydro- 1 -deoxy-D-mannitol derivatives, as shown in Figure 4.4. 
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The reactions were carried out in solid phase cartridges and shaking was done on the 
Bohdan MiniBlock synthesiser. The primary amine and aldehyde starting materials 
were shaken in methanol for 2 hours before addition of the reducing agent. The 
results in Table 4.1 show that while both methods appear to produce good yields, the 
method using Resin A (solid supported cyanoborohydride) produced very little of the 
product, and was mostly starting material as determined by 'H NMR and particularly 
electrospray mass spectrometry. However, the result using resin B (solid supported 
borohydride) seemed to be more suitable, giving a yield of 83 % and no remaining 
starting material was detected by 'H NMR or mass spectrometry. The original scale 
for these reactions was based on using 200 mg of 2,5-anhydro-D-mannose 22. In 
order to test this method further, the reaction was tested on a larger scale in the 
synthesis of both 37 and 70 (based on 600 mg of 2,5-anhydro-D-mannose 22 starting 
material). Furthermore, the reactions were also tested on a small scale (50 mg with 
respect to aldehyde 22) in order to investigate whether this reaction would also be 
suitable small-scale parallel synthesis. Figure 4.7 shows the scheme and conditions 
for these reactions and Table 4.2 shows the results obtained. 
+- 
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CHO 	 HO 	OH 
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3. Filter, wash and 
remove solvent 
Figure 4.7 New synthetic scheme for N-substituted-l-amino-2,5-anhydro-l-
deoxy-D-mannitol derivative synthesis. 
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Table 4.2 Results of synthesis using procedure shown in Figure 4.7. *Large scale, 
based on 600 mg of aldehyde 22; 50 mg scale otherwise. TLOW yield caused by 
leakage from the reaction cartridge. 
It can be seen from Table 4.2 that the new reductive amination procedure is versatile 
enough to be used in both combinatorial scale and preparative scale syntheses, 
allowing for further inhibitor development. (Amine 87 is shown in Figure 4.8. This is 
a diastereo-mixture of 62 and 63, synthesised from the racemic amine, as neither the 
R or S amine starting materials were commercially available). 
HO 	
H   
HO 	OH 
87 
Figure 4.8 Amine 87. 
4.3.2 Methods towards the oxidation of Nsubstituted-1-amino-2,5-aflhydrO-l- 
deoxy-D-mannitol derivatives. 
In choosing (and developing) a method for the oxidation of the 6-position hydroxyl, 
it was necessary to find procedures that were mild enough to not oxidise any other 
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functions within the molecule. Crucially, selectivity would be needed between the 
primary and secondary hydroxyl groups. Owing to the poor solubility of these 
compounds in organic solvents (other than methanol), any procedures would 
preferably use water as the solvent. Initially, oxidation was attempted on 15, using 
ruthenium(III)trichloride monohydrate in the presence of sodium periodate to form 




Na104 	 HO 
RuCI,.H2O 
Cd 4 , MeCN, H 2O 
HO 	OH 	 H6' 	OH 
Figure 4.9 Attempted ruthenium tetraoxide catalysed oxidation. 
94 
In this reaction, 2.2 molar % of ruthenium(III) trichloride and 3 equivalents of 
sodium periodate were used. The reaction was allowed to continue for a total of 
seven hours, as no product had been detected by electrospray mass spectrometry. 
However, after the reaction work up, not only was there no product, but there was 
also no recovered starting material. (The starting material could also not be detected 
in the crude reaction mixture by mass spectrometry). This led to the conclusion that 
the ruthenium tetraoxide catalysed oxidation was unsuitable and would therefore not 
be pursued any further. 
Carrettin et al reported the selective oxidation of a primary hydroxyl group using a 
gold catalyst in the presence of aqueous sodium hydroxide, in the oxidation of 
glycerol to glyceric acid 95  (Figure 4.10). However, the use of elevated temperatures 
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and pressures deemed this approach unsuitable for development with N-substituted-
1-amino-2,5-anhydro-1-deoxy-D-mannitol derivatives. 
1 % Au/graphite 
	
OH 
HO '" OH 




60°C, 3h, autoclave 	
OH 
Figure 4.10 Gold catalysed oxidation of glycerol. 95 
However, the method that seemed the most promising was the use of TEMPO free 
radical mediated oxidation (in the presence of a bulk oxidant), owing to its mild 
conditions. Also, under basic conditions the rate of oxidation of primary alcohols is 
faster than that of secondary alcohols, 
96,97 therefore, implying that there is selectivity 
for the oxidation of primary alcohols in the presence of secondary alcohols. 
Interestingly, when this method is performed on primary alcohols in organic 
solvents, the products obtained are the corresponding aldehydes. 
97  When a biphasic 
solvent mixture was used (organic-aqueous), it was found that hydrophilic 
compounds were oxidised to the corresponding carboxylic acids. 
98 When the reaction 
is performed in an aqueous solvent, only the carboxylic acid is obtained. 96 This 
method therefore seemed ideal for the oxidation of the 6-position hydroxyl group in 
N-substituted-i -amino-2,5-anhydro- 1 -deoxy-D-mannitol derivatives. 
An initial attempt at this oxidation was carried out using a slightly modified method 
as described by de Nooy et af9  which used a catalytic amount of TEMPO and 
sodium bromide. This is shown in Figure 4.11. 
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Figure 4.11 Attempted TEMPO-mediated oxidation. 99 
Although this reaction was allowed to continue for 72 hours, only starting material 
was detected in the reaction mixture (using the same methods as mentioned 
previously). Indeed, only the starting material, mixed with inorganic salts was, 
eventually, isolated. At this point a new problem was faced should oxidation be 
successful; the isolation of the oxidised product. Owing to the fact that the starting 
material and the product were highly water soluble, isolation and separation of these 
from the water soluble inorganic salts would be a problem. It was therefore decided 
that it would be necessary to BOC-protect the nitrogen of these compounds, which 
would aid solubility in organic solvents. This would then still be able to undergo a 
TEMPO-mediated oxidation by making use of the biphasic reaction and 
conditions. 96,98,100 
Although BOC-protection may seem to be a facile procedure for these compounds, 
this was not necessarily the case. Developing this reaction exclusively with 37, the 
best conditions used di-tert-butyl dicarbonate (BOC-anhydride, administered in 
dioxane) in a 1:1, water : acetonitrile solution (used to solubilise the starting 
materials) with a final addition of 0.25 equivalents of 4-dimethylaminopyridine 
(DMAP, Figure 4.12). This gave yields within the range of 50 - 60 %, on which no 
improvement was made. However, when applying the same reaction conditions to 
107 
Chapter 4 
	 Library 3: Design, Synthesis and Evaluation 
70, no product formation was observed, and only starting material was isolated; no 
BOC-anhydride was isolated either. 
ci 
BOC2O, OMAP 
dioxane. MeCN, H 20 
HO 	OH 
37 
Figure 4.12 Initial BOC-protection of 37. 
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DMAP acts by activating BOC-anhydride, so the activated species then acts as an 
electrophile towards amines. However, in the presence of a vast excess of water, it 
could be conceivable that water (or any hydroxide ions present) can also act as a 
nucleophile, resulting in hydrolysis of the activated species. This could also explain 
why the yield of the BOC protection of 37 was never greater than 60 %. 
It was therefore decided to minimise the amount of water in the reaction mixture. 
This was achieved by suspending the N-substituted-i -amino-2,5-anhydro- 1 -deoxy-
D-mannitol in acetonitrile and adding water dropwise until the compound was fully 
dissolved. The same procedure was then followed as previously. Figure 4.13 shows 
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R 	 I 
R = 3,4-dichlorobenzyl, 88, 58 % 
R = cycloheptyl, 89, 57 %. 
Figure 4.13 BOC protection of N-substituted-i -amino-2,5 -anhydro- 1 -deoxy-D-
mannitol derivatives. 
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The alteration to this method appeared to solve the problem as the synthesis of N-
BOC-2,5-anhydro-1-deoxy-1-(cycloheptylamino)-D-mannitol 89, occurred in a 57 % 
yield, and the yield for the synthesis of N-BOC-2,5-anhydro-1-deoxy-1-(3,4-
dichlorobenzylamino)-D-mannitol 88 remained unaffected. Purification of 88 and 89 
by flash column chromatography was attempted but drastically reduced the final 
yield. Consequently, the crude material was used for the next step. BOC protection 
was confirmed for both these amines by the presence of a signal in the ' 3C NMR 
spectrum at 8 = 156 - 157 ppm corresponding to the BOC carbonyl carbon atom. 
Further confirmation was gained by FTIR spectroscopy by the presence of a signal at 
1672 cm 1 , a typical vibration for BOC carbonyl stretches. 
Having achieved a successful BOC protection for both 37 and 70, the next step was 
to reattempt the oxidation using a biphasic system. This was attempted using the 
method set out by Davis and Flitsch' °° and is shown in Figure 4.14. 
0 
II 
"NB0C TEMPO, KBr, TBACI HO 	 " NBOC 
NaOCI, NaHCO 3 , brine, 
R R 
HO 	OH 	 DCM 	 HO 	OH 
R = 3,4-dichlorobenzyl, 90, 72 % 
R = cycloheptyl, 91, 38 % 
Figure 4.14 Biphasic oxidation method. 100 
To the biphasic mixture that contained the BOC-protected starting material and 
TEMPO in dichloromethane and a sodium bicarbonate solution of potassium 
bromide and tetrabutylammonium chloride, reagent grade sodium hypochlorite and 
brine in a sodium bicarbonate solution was added. Initial attempts at this reaction 
were unsuccessful, yielding only starting material. No oxidation products could be 
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detected either by NMIR or by mass spectrometry. It was unclear, at first, why this 
reaction did not work, especially as other TEMPO-mediated oxidation procedures 
used very similar conditions to those above. 97  In fact, synthesis of some other sugar 
amino acids also used TEMPO-mediated oxidation. 84,101-103  It was decided that, 
because no oxidation product was being detected, an alternative bulk oxidant would 
be tested, based on an assumption that the reagent grade sodium hypochiorite may 
not be strong enough to re-oxidise the TEMPO oxidation mediator. Therefore, it was 
decided to replace sodium hypochiorite with oxone, as it is known that 
TEMPO/oxone catalyses the oxidation of alcohols to the aldehyde or ketone. 
104 
Adopting this strategy, the aldehyde could be isolated and another method could 
possibly be employed to oxidise the aldehyde to the acid. However, in keeping the 
same conditions as used in Figure 4.13, it was hoped that the acid would be 
synthesised in one pot, as oxone is also known to oxidise aldehydes to acids. 
105 
Unfortunately, this reaction also recovered starting material only, and no oxidation 
product was observed. 
Returning to the idea that the reagent grade sodium hypochlorite was not strong 
enough, the concentration was checked by titrating against a standardised sodium 
thiosulfate solution (the method and calculations for this can be found in the 
appendix). The concentration of the reagent grade sodium hypochiorite was 
determined as 0.086 M. The concentration needed for the oxidation reaction is 1.3 
M.' °°  This is over fifteen times weaker than what is needed. Therefore, the 
concentration of industrial bleach was determined (1.69 M) and was diluted for use 
for the oxidation reaction. Unsurprisingly, the oxidation reaction was now successful, 
affording N-BOC-2,5 -anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-mannonic 
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acid (compound 90) in a 72 % yield and N-BOC-2,5-anhydro-1-deoxy-1-
(cycloheptylamino)-D-mannoniC acid (compound 91) in a 38 % yield. The ' 3C NMR 
spectrum gave confirmation of successful oxidation by a signal at 8 = 174 ppm 
corresponding to the acid carbon atom, and disappearance of signal at 6 = 62 ppm 
corresponding to the now oxidised methylene carbon atom. Again, attempts to purify 
these compounds by flash column chromatography proved unsuccessful as no 
product was returned. The crude material was therefore carried forward for use in the 
next step. 
4.3.3 Amine coupling and deprotection of N-BOC protected mannonic acid 
derivatives. 
Having successfully found a route to N-BOC protected mannonic acid derivatives, 
the objective now (as previously mentioned in section 4.1.2) was to perform amine 
coupling reactions. If successful, these reactions would be used to synthesis a small 
library which, after deprotection, could be tested against the target enzymes. 
Coupling reactions to form amides are widely used and well documented (especially 
in the area of peptide synthesis). 13,83 There are many different reagents available 
depending on the conditions needed, but for this particular reaction it was decided to 
use standard BOC coupling conditions and aromatic amines. The reaction that was 
used as a test is shown in Figure 4.15. 
0 













92, 22 % (74 % crude) 
Figure 4.15 Amine coupling reaction in the synthesis of 92. 
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The reaction shown in Figure 4.15 was successful, and after work up afforded 92 in a 
yield of 74 %. However, this was shown to contain some unreacted starting material 
so was purified using flash column chromatography. Although the overall yield of 22 
% was disappointing, it still left sufficient material to undergo deprotection and 
purification. Coupling was confirmed by the psresence of 2 bands in the IR spectrum 
at 1666 and 1539 cm corresponding to the secondary amide. Deprotection was 
carried out using a standard TFA/dichloromethane procedure (Figure 4.16) and 
afforded 2,5 -anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-benzylmannonamide 
93 in a yield of 71 % after purification by mass directed methods. 
0 	 o 	 ci 
NBOC 







93, 71 % (after ZMD purification) 
Figure 4.16 BOC-deprotection of 92. 
4.4 	Library 3. 
4.4.1 Library 3 synthesis. 
Having successfully identified a synthetic route towards the synthesis of N,N'-  
substituted- i -amino-2,5 -anhydro- 1 -deoxy- 1 -D-mannonamide derivatives, the next 
stage was to synthesise a small library of these compounds based on the structures of 
inhibitors 37 and 70 (Figure 4.17). All the reactions would be synthesised in parallel, 
and purification, after the amine coupling step, would be facilitated by parallel flash 
column chromatography system (Quad3) using pre-packed columns. Table 4.3 shows 
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the results of this synthesis, applying the schemes shown in Figures 4.15 and 4.16. 
0 
where R = 3,4-dichlorobenzyl or, 
cycloheptyl 
HO 	OH 
Figure 4.17 General structure of library 3 compounds. 
Library 3 was synthesised successfully, with yields for the amine coupling ranging 
between 15 - 39 %, and yields for the deprotection yielding between 20 - 99 % (both 
yields being after purification). Due to the low yields of the amine coupling reactions 
and the fact that the products of these reactions were only an intermediate in the 
overall library synthesis, some compounds were used directly in the deprotection 
reaction without any 'H NMR or mass spectrometry characterisation (see Chapter 6). 
The structures of the final compounds were confirmed by 'H NMR and, where 
possible, ' 3C NMR. Full characterisation was achieved for amide 111 showing the 
characteristic signals in the IR spectrum at 1674 and 1541 cm -1 corresponding to the 
secondary amide. Other typical signals include the doublet of doublets corresponding 
to the diasteriotopic C  methylene protons in the 'H NMR spectrum at 8 = 3.2 - 3.5 
ppm, and the carbonyl carbon signal at ö = 169.5 in the ' 3C NMR spectrum. As for 
libraries 1 and 2, the final compounds were established to have high purity by 13 C 




















97,25 % 104,16% 
110,58% 117,77% 
0—  98,24% 111,48% 105,16% 118,99% 
O( 99,25% 106,15% 112,50% 119,50% 
Table 4.3 Library 3 synthesis results. First entry; compound number and yield for 
coupling reaction. Second entry; compound number and yield for deprotection. 
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4.4.2 Library 3 screening results against Tb PFK. 
Library 3 was designed so that inhibitors were synthesised to target not only Th PFK, 
but Lm PyK as well; those compounds with a 3,4-dichlorobenzyl motif would be 
screened against Th PFK, and those with a cycloheptyl motif would be screened 
against Lm PyK. Hence, it is clear from Table 4.3 that compounds 111 and 117 
would be screened against both enzymes, as these compounds contain both motifs. 
Due to the overall low yield of library 3, the inhibitor screen was carried out at a 
final concentration of 1 mM with respect to each inhibitor. 
The results of the 1 mM screen of 8 compounds in library 3, against Tb PFK, are 












Table 4.4 Results of the 1 mM library 3 screen against Tb PFK.' °6 
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Figure 4.18 A graph showing the 1 mM screening results of a library 3 screen 
against Th PFK. 106  
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Figure 4.19 Compounds from library 3 screened against Tb PFK. 
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A comparison of the results shown in Table 4.4 and Figure 4.18 with the previous 
results shows a great improvement in inhibitory activity. Previously, the most potent 
inhibitor against Tb PFK was 37, which inhibited the enzyme to 4.7 % of its original 
activity at a concentration of 5 mM. However, the screening results from library 3 
show a comparable inhibitory effect, but at the lower concentration of 1 mM, 
suggesting that these inhibitors are more potent. Therefore, the IC 50 values for four of 
the above inhibitors were determined; the choice of inhibitors was based on the 
amount of material available for testing. The results are shown in Table 4•5•106 





Table 4.5 IC50 values of four compounds from library 3. The dose-response curves 
can be found in the appendix. 106 
Table 4.5 shows that the inhibitors from library 3 have about a 10-fold increase in 
10 5 0 values compared with the previous lead compounds for Tb PFK (21, Ic50 = 0.45 
mM; 37, IC 5 0 = 0.41 mM), and that inhibitor 110 is a new lead compound with an 
105 0 value of 23 iM. Possible reasons for the inhibitory activity are discussed in 
section 4.4.3. 
In order to ascertain whether the inhibitors bind to the F6P or ATP binding site, 
preliminary competition experiments were also carried out using inhibitor 110.106 
These results showed that KM value for ATP in the presence of the inhibitor 
remained constant whilst the V,,, decreased, indicating that that the inhibitor is 
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unlikely to compete with ATP and therefore is also unlikely to exhibit its inhibitory 
effect by binding at the ATP binding site. However, for F6P the KM value increased 
whilst a decrease is V was observed, indicating that the inhibitor may compete 
with F6P arid, therefore, could inhibit Tb PFK by binding at the F6P binding site. 
4.4.3 Molecular docking model. 
In section 4.4.2 it was seen that inhibitors from library 3 gave 1050 values in the 
micromolar range against Th PFK, which was a marked improvement on the existing 
lead compounds. It was also discovered that the inhibitors are likely to induce their 
effect by binding to the F6P binding site. Using this information, a model of inhibitor 
110 in the F6P binding site of Tb PFK was produced, where the furanose scaffold of 
110 is positioned in the same orientation as the F61? . 107  The models can be seen in 
Figures 4.20 and 4.21. 
From the model shown in Figure 4.20, it is possible to identify potential reasons for 
why the sugar amino amide inhibitors, from library 3, show improved inhibitory 
activity on previous lead compounds. Firstly, the extension of the furanose scaffold 
at the 6-position allows the inhibitor to probe further into the binding pocket and, 
hence, gain favourable interactions. The figure also shows that the pocket is large 
and, therefore, there is scope further for inhibitor development. The use of larger 
groups at the 6-position would act as to probe this pocket more fully in the hope of 
attaining more binding interactions. 
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Figure 4.21 A ribbon representation of inhibitor 110 in the F6P binding site of Tb 
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Secondly, both Figures 4.20 and 4.21 how that there is a potential interaction 
between the carbonyl of amide functionality of the inhibitor and a close by arginine 
residue. This could provide a specific interaction and, as such, would mean that the 
sugar amino amides would bind more strongly to the protein. Previously, this 
position would have been occupied by a hydroxyl group and would, therefore, not be 
an as favourable interaction. 
4.4.4 Library 3 screening results against Lm PyK. 
As has been previously mentioned, library 3 was also designed to include inhibitors 
targeted against Lm PyK. Table 4.6 and Figure 4.21 show the results of a 5 mM 
screen of 7 compounds from library 3 screened against Lm PyK. (Unfortunately 117 
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111 	113 	114 	115 	116 	118 	119 
Compound 
Figure 4.21 A graph showing the screening results of library 3 against Lm PyK. 
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Table 4.6 Compounds from library 3 screened against Lm PyK. 
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The results shown in Table 4.6 and Figure 2.12 suggest that the compounds from 
library 3 show good inhibition against Lm PyK. When compared to the previous 
results from library 2, in particular inhibitor 70, two compounds show similar or 
better inhibition (inhibitors 115 and 118), while most of the other inhibitors tested 
still showed good inhibition. Interestingly, inhibitor 111 exhibited little inhibitory 
effect on Lm PyK, suggesting that the cyclohexyl motif can no longer bind 
effectively to the hydrophobic pocket in the effector site of Lm PyK, presumably due 
to a repulsive interaction caused by the amide functionality. Unfortunately, there was 
insufficient material available to these inhibitors further and obtain IC 50 values. 
4.5 	Conclusion. 
In order to develop further the inhibitors discovered in Chapters 2 and 3, an alterative 
method for reductive amination was identified. This made use of solid supported 
borohydride and the scavenger resin, 4-benzoxybenzaldehyde polystyrene. This also 
bypassed the need for any further purification and resulted in vastly improved yields, 
generally in the range of 78 - 99 %. In the interest of developing the inhibitors 
further, oxidation of the 6-position hydroxyl was investigated. At this point, 
improving the solubility of these compounds in organic solvent was needed, so a 
general method for the BOC-protection of the secondary amine was identified. 
Oxidation was attempted using a biphasic TEMPO mediated method and was 
initially unsuccessful. However, after discovering that the concentration of sodium 
hypochiorite used was too weak, the oxidation was re-attempted and was successful, 
giving the desired 6-position carboxylic acids in yields of 38 - 72 %. These acids 
were then used in a series of amine coupling reactions (using standard BOC reagents 
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and conditions) and deprotection reactions to give rise to library 3; a 14 member 
N,N'-substituted- 1 -amino-2,5-anhydro- 1 -deoxy- 1 -D-mannonamide library. Library 3 
was then screened against both Th PFK and Lm PyK. Against Th PFK, all 
compounds exhibited a higher level of inhibition than shown by previous lead 
compounds. The inhibitors were found to have IC 50 values in the micromolar range, 
the best of which was inhibitor 110 which gave an 10 50 value of 23 RM. Modelling 
of this inhibitor in the F6P binding site suggests that the amide carbonyl may be 
making a binding interaction with the protein which could explain the higher degree 
of inhibition. Also, extension of the furanose scaffold at the 6-position allows the 
inhibitors to probe deeper into the F6P binding pocket, potentially gaining more 
binding interactions. There is the potential for further inhibitor development to probe 
this pocket even further. Against Lm PyK, several compounds showed similar 
inhibitory activity as the lead compound, inhibitor 70. Inhibitor 118 appeared to 
inhibit the enzyme to a higher degree; this cannot be confirmed, however, as there 
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5 	Non-Library Inhibitor Development. 
5.1 	Overview. 
In Chapter 4 it was discussed how the initial N-substituted-2,5-anhydro-1-deoxy-D-
mannitol scaffold was developed in order to make sugar amino amide derivatives, 
which, when tested against Tb PFK, were shown to have inhibitory activity. The final 
results and discussion chapter continues on the theme of further inhibitor 
development, concentrating not only on further modifications to the 6-position 
hydroxyl group, but also introducing additional functionality as shown in Figure 5.1. 
[Ho j[NHfJ 
HO 	O 
Phosphorylation 	Other sugars 	Alkylation 	More amines 
Figure 5.1 Potential modifications to general inhibitor structure. 
Most of this development work was performed to try and gain an understanding of 
how changes affect inhibition of the respective enzyme targets, rather than with a 
view towards library synthesis (although, as will become evident, library synthesis is 
certainly feasible). 
Finally, due to the fact that specificity between target and host enzymes is a very 
important aspect in drug design and drug discovery, the results of some specificity 
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experiments are reported. 
5.2 	Further inhibitor development. 
5.2.1 Further modifications of the 6-position hydroxyl. 
Work by Claustre et al62  has suggested that the introduction of a electronegative 
group at the 6-position may improve inhibitor-protein binding (discussed in Chapter 
2). Using chemistry already developed for the synthesis of N-BOC protected sugar 
amino amides (discussed in Chapter 4), the easiest method of introducing 
electronegativity at the 6-position would simply be to deprotect the N-BOC sugar 
amino acid derivatives, as shown in Figure 5.2. This was attempted by using standard 
BOC-deprotection conditions (TFA in dichioromethane), and the yields after mass 
directed purification are also shown in Figure 5.2. The sugar amino acids 120 and 






TFA/DCM 	 HO 
_1L0 , 	N - R 
HO 	OH 
R = 3,4-dichlorobenzyl, 120, 34 % 
R = cyclohepyl, 121, 57 % 
Figure 5.2 BOC-deprotection of sugar amino acids. 
In Chapter 2, it was mentioned that phosphorylation at the 6-position hydroxyl could 
lead to more potent inhibitors, especially for Tb PFK.62 Therefore attempts were 
made to synthesise phosphorylated derivatives in a manner that would be suitable for 
library synthesis. The main method used by Claustre et a162 is shown in Figure 5.3 
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and employed chiorodiphenyiphosphine as the phosphorylating agent. Subsequent 

















Figure 5.3 General phosphorylation procedure. 
62 
However, the route shown in Figure 5.3 was deemed unsuitable for further 
development for library synthesis as the deprotection step would be difficult to 
perform in parallel on a multi-reaction basis. Furthermore, the yields of this route 
varied quite widely, depending on the initial substrate. 
62,63  It was therefore necessary 
to try to find an alternative method that selectively phosphorylated primary hydroxyl 
groups in the presence of secondary hydroxyl groups. Commercially available 
phosphoramidite reagents seemed an ideal method for this synthesis. Perich and 
Johns 108  had shown that the di-tert-butyl NN-diethylphosphoramidite could 
phosphitylate primary hydroxyl groups which could be subsequently converted to the 
phosphate by oxidation with m-CPBA to give the di-tert-butyl phosphate ester in 
high yields (93 - 98 %). It was hoped that this could also be achieved in a selective 
manner, thereby selectively phosphorylating N-sustituted-2,5 -anydro- 1 -deoxy-D- 
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mannitol derivatives. The tert-butyl protecting groups could then be removed easily 
using mildly acidic conditions. This method is shown in Figure 5.4. 
1) Et2NP(OtBu)2 	 o 
1H-tetrazole II 	0 
dry MeCN 	
tBuo° H 	 IN
2)mCPBA 	 tBuO 	
H 









Figure 5.4 Proposed phosphorylation of N-substituted-2,5-anhydro-l-deoxy-D-
mannitol derivatives. 
The reaction was attempted with both 15 (benzyl derivative) and 37, but no desired 
products were isolated, possibly attributed to the poor solubiltity of the N-sustituted-
2,5-anydro-l-deoxy-D-mannitol derivatives in organic solvents. Therefore, it was 
decided to try the same reaction on the N-BOC protected substrates, thereby 
increasing the solubility of the compounds in organic solvent, and removing the 
potential for the nitrogen to act as a nucleophile towards the phosphitylating agent, 
and in doing so, hindering the reaction progression. The reaction was attempted 
using the N-BOC protected amine 88; however, no product was yielded and only 
starting material was recovered. The method was therefore deemed suitable for 
further investigation. 
Research by Sowa and Oucho' °9  showed that selective phosphorylation of 5'- 
nucleotides was possible by using phosphorus oxychioride in the presence of water 
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and pyridine in acetonitrile. It was discovered that by using a ratio of 2 : 1 : 2 of 
phosphorus oxychioride, water and pyridine, tetrachioropyrophosphate would be 
formed in situ which would act as the phosphorylating agent (Figure 5.5). 
POCI 3 + H 20 + Py 	30 - POCl2(OH) + PyHCI 
POCl2(OH) + POd 3 + Py 30 P203C14 + PyHCI 
Figure 5.5 In situ generation of tetrachloropyrophosphate. 109 
Dichiorophosphoric acid is formed by the reaction of water with phosphorus 
oxychioride (reaction (1) in Figure 5.5) which then reacts with a further equivalent of 
phosphorus oxychloride to form tetrachloropyrophosphate (reaction (2) in Figure 
5.5). It is this species that dichiorophosphorylates primary alcohols, which are 
subsequently hydrolysed to the phosphate in the presence of further equivalents of 
water. The substrates for the reaction were limited to the N-BOC protected 
derivatives, as acetonitrile was the required solvent; hence the reaction was 
performed using 88. Monitoring the reaction by TLC and electrospray mass 
spectrometry, it was initially thought that the reaction had not worked; the TLC only 
showed base-line spots, and there were no peaks in the mass spectrometry spectrum 
at 500 and 502 (negative mode) which would have been expected for the BOC-
protected phosphorylated product. However, after further inspection of the mass 
spectrum, peaks at 400 and 402 were found. It was thought that because hydrolysis 
of the dichiorophosphate would lead to the production of two moles of hydrochloric 
acid as a side product (as well as the formation of phosphoric acid caused by 
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hydrolysis of other side products), these highly acidic conditions would facilitate the 
removal of the BOC group. Therefore, the overall product of this reaction would in 
fact be 2,5 -anhydro- 1 -deoxy- 1 -(3 ,4dichlorobenzylamino)-D-maImitol-6-phOsphate 
122 (as shown in Figure 5.6), which corresponds to the peaks identified in the mass 
spectrum. The reaction was therefore worked up in a manner that would allow for 
isolation of the aqueous layer. After lyophilisation, the crude product was obtained in 
a yield of 95 %. However, because this was likely to include the product in a mixture 
with inorganic salts, it was purified using mass directed methods but led to an overall 
yield of 5%. 
HO 	
" 
NBOC 	 0 
 
CI 
H2O, pyridine, MeCN 	 II 
HO—P- 




88 	 122, 5 % after ZMD purification 
Figure 5.6 Synthesis of 2,5-anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-
mannitol-6-phosphate 122. 
The reason for the low yield may not be solely due to loss of material by the 
purification method (as discussed in Chapter 4), but could also be due to high 
reactivity of phosphorus oxychloride and all other phosphorus intermediates. Indeed, 
when this reaction was attempted on a small scale, no product was obtained either for 
the reaction with 88, or with 89 (cycloheptyl derivative). This was thought to be due 
to the fact that the amount of water needed for the formation of the 
tetrachloropyrophosphate intermediate is so small that it is very difficult to control. 
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that was hoped could be avoided. Due to this reason, and also because 
phosphorylation of these types of compounds do not necessarily lend themselves 
towards further development with regards to making drug-like compounds (based on 
the Lipinski rule of 519), further attempts at phosphorylation were disregarded. 
Phosphate 122 was tested against Tb PFK and the results are shown in section 5.3. 
5.2.2 Furanose scaffold modifications. 
The furanose scaffold structure for all the inhibitors discussed so far is derived from 
2,5-anhydro-D-mannitol and, as has already been shown in Chapter 2, is formed by 
the synthesis of 2,5-anhydro-D-mannose 22 from the nitrous deamination of D-
glucosamine hydrochloride. 6 ' Aldehyde 22 subsequently undergoes a reductive 
amination reaction to synthesise the target compound. Therefore, the easiest method 
by which to obtain inhibitors with a different furanose scaffold would be to repeat 
the nitrous deamination reaction, but using alternative amino-sugars. This, in itself, is 
slightly restrictive as the only other commercially available amino-sugars are D-
galactosamine hydrochloride and D-mannosamine hydrochloride (Figure 5.7). 





HO " 1 fNH30 
OH 
D-Mannosamine hydrochloride 
Figure 5.7 Structures of D-galactosamine hydrochloride and D-mannosamine 
hydrochloride. 
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The nitrous deamination reaction was attempted with both substrates to synthesise 
2,5-anhydro-D-talose 123 and 2,5-anhydro-D-glucose (Figure 5.8). The talose 
derivative, 123, was successfully synthesised in a yield of 87 %, and its structure 
confirmed by comparison of 'H and ' 3C NMR spectra with previously published 
spectra." °  However, the glucose derivative was not formed as analysed by 'H and 
' 3c NMR. 
o 	OH 
HO 












11 1 exchange resin 	HO 
30 
GO32- exchange resin 
HO 	OH 
2,5-anhydo-D-talose, 123, 87 % 
0 
NaNO2 
W exchange resin 	 HO 
C032- exchange resin IV 
HO 	OH 
2,5-anhydo-D-glucose, not formed 
Figure 5.8 Nitrous deamination of amino-sugar substrates. 
The reason for this outcome can be potentially explained by revisiting the 
mechanism for the synthesis of the furanose scaffold. After formation of the 
diazonium ion, the pyranose oxygen facilitates an intramolecular substitution 
reaction by rearside attack of the diazonium carbon. In the case where D-
glucosamine hydrochloride (Figure 2.4, Chapter 2) and D-galactosamine 
hydrochloride (Figure 5.9) are the starting materials, this reaction is possible as, in 
the thermodynamically most stable conformation, the pyranose oxygen is aligned 
correctly for rearside attack in an SN2 type manner (Figure 5.9). However, this is not 
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the case for D-mannosamine hydrochloride; when it has adopted its 
thermodynamically most stable conformation, rearside attack of the pyranose oxygen 
is not favoured, as the leaving group (the diazonium ion) is perpendicular to this 
attack. Therefore, in order for 2,5-anhydro-D-glucose to form, the reaction must 
proceed via the thermodynamically unstable conformation, caused by a ring flip 
(Figure 5.9). As the reactions are carried out at temperatures between 0 and 5 °C, it is 
postulated that 2,5-anhydro-D-glucose would not be formed. Due to this and the 
expense of the starting material D-mannosamine hydrochloride, this reaction was not 
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Figure 5.9 Mechanisms of formation of 2,5-anhydro-D-talose and 2,5-anhydro-
D-glucose. (See Figure 2.4, Chapter 2, for full mechanism). 
Having successfully achieved the synthesis for a different furanose scaffold (in a 
good yield), this meant that a route to a new family of compounds was available, and 
a new library could potentially be synthesised. However, partly due to cost and partly 
due to the fact that the talose structure only differs from the mannose structure by the 
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opposite stereochemistry of one hydroxyl group at the C3 position, it was decided 
only to synthesise two compounds. These are shown in Figure 5. 10, and correspond 
to the best inhibitors from the library 1 5 mM screen against Tb PFK. It was hoped 
that this subtle change in stereochemistry would cause either reduced or enhanced 
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125,20% 
Figure 5.10 Synthesis of 2,5 -anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-
talitol 124, and 2,5-anhydro- 1 -deoxy- 1 -(benzhydrylamino)-D-talitol 125. 
Both compounds were synthesised successfully using the original reductive 
amination procedure as described in section 2.2.1, and were purified using mass 
directed methods. However, both compounds await testing against Tb PFK. 
5.2.3 Tertiary amine formation. 
Until now, all inhibitors that have been synthesised have been secondary amines. In 
the absence of a crystal structure, and in the interest of determining whether the 
secondary amine is essential for inhibitor activity against both Tb PFK and Lm PyK, 
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it was decided that some tertiary amines should be synthesised, based on existing 
inhibitor structures. For these reasons, N-methylation was chosen as a starting point 
and any further attempts at N-alkylation (or indeed library synthesis) would follow 
biological evaluation, if needed. 
Having had great success using solid supported reagents and scavenging reagents for 
the reductive amination reaction described in section 4.3.1, it was decided to utilise 
them again in the synthesis of tertiary amines. In the previous reductive amination 
reactions, the aldehyde was the limiting reagent and the primary amine was in excess 
Therefore 4-benzoxybenzaldehyde polystyrene was used to scavenge the excess 
amine. However, this time a new scavenger amine was needed as the secondary 
amine would be the limiting reagent and the aldehyde would be in excess. Solid 
supported tris(2-aminoethyl)amine (Figure 5.11) is known to scavenge carbonyl 
compounds from solution 93  and hopefully could be employed to scavenge aldehydes, 
in particular formaldehyde, which would be used for N-methylation. 
NH 
NH2 	 0 
Figure 5.11 Solid supported tris(2-aminoethyl)amine and MP-anhydride resin. 
The reaction was carried out using similar conditions to those used previously, 
although the reaction with solid supported borohydride was allowed to continue for 
48 hours as opposed to 24 hours (Figure 5.12). However, monitoring the reaction by 
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electrospray mass spectrometry showed that not all of the starting material had 
reacted. Although by using this method of reaction monitoring the amount of starting 
material cannot be quantified, its presence in the mass spectrum does confirm its 





(2 eq, 48 hours) 
cl cl 
HO 	OH 	 HO 	OH 
+ 	 2. 	
1'NH2 
37 % Formaldehyde solution 
N'' (2 eq) 	
NH, 
(2.5 eq, 24 hours) 
3. Filter and wash 
Figure 5.12 Attempted synthesis of N-methyl-2,5-anhydro-1-deoxy-(3,4-
dichlorobenzylamino)-D-mannitol. 
Therefore, an attempt was made to try to remove the starting material using yet 
another scavenging resin. Previously it was discussed that solid supported 4-
benzoxybenzaldehyde resin scavenged for primary amines selectively (Chapter 4). 
However, in this instance, the starting material is a secondary amine, so the choice in 
scavenger resin needed to reflect this. MP-Anhydride resin (Figure 5.11) is known to 
scavenge secondary amines, 90  therefore two equivalents were added to the reaction. 
However, after a further 120 hours, the mass spectrum still showed a significant peak 
corresponding to the starting material. After work up (which simply involved 
filtering, washing and solvent removal), the proton NMR spectrum showed not only 
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also showed the presence of formaldehyde (ö = 9.6 ppm), indicating that it also had 
not been scavenged successfully. Therefore, due to this, the high costs of the various 
resins and the long reaction times, a different approach was investigated. 
An alternative method for the methylation of amines is by use of the Eschweiler-
Clarke 11,112  This involves the use of formaldehyde in the presence of 
formic acid under reflux conditions and has been used successfully in organic 
synthesis. 113,114 However, recent advances have led to a modification of this 
procedure whereby the reactions can now be carried out quickly and efficiently using 
microwave conditions. 111,116 It was therefore decided to attempt N-methylation using 
the modified Eschweiler-Clarke conditions (Figure 5.13). 
ci 	 Cl 
HCHO, HCO2H, H 20  
5 mins continuous heating 
HO 	 "N 	 HO 
microwave 150 OC, (120W) 
HO 	OH 	 HO 	OH 
126, 25 % (after ZMD purification) 
Figure 5.13 Microwave assisted Eschweiler-Clarke synthesis of N-methyl-2,5-
anhydro- 1 -deoxy-(3 ,4-dichlorobenzylamino)-D-mannitOl 126. 
After mass directed purification, tertiary amine 126 was isolated with a yield of 25 
%. To test this reaction further, N-methylation of 70 (cycloheptyl derivative) was 
attempted, along with the N-ethylation of 37 (using acetaldehyde instead of 
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0 HCHO, HCO,H, H 2O 
microwave 150 O( 	(120W) 
HO 	OH 





127. 59 % (after ZMD purification) 
CI 	 CI Acetaldehyde, HCO,H, H 2O 
H 
microwave 150 *C, 0 20 W)
5 mins continuous heating 
HO 	OH 	 HO 	OH 
128.63% (after ZMD purification) 
Figure 5.14 Synthesis of N-methyl-2,5 -anhydro- 1 -deoxy- 1 -(cycloheptylamino)-D-
marmitol 127 and N-ethyl-2,5-anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-
mannitol 128. 
Having successfully performed N-methylation on both 37 and 70, and also performed 
N-ethylation on 37, these results indicate that the microwave assisted Eschweiler-
Clarke reaction is an ideal method for the formation of tertiary amines. This process 
becomes even more attractive when taking in to account the short reaction times, 
making this method ideal for library synthesis, should the need arise. 
Amines 126 and 128 were screened for inhibitory activity against Tb PFK and the 
results are discussed in section 5.3; 127 still awaits testing against Lm PyK. 
5.3 	Biological results for non-library synthesised compounds. 
5.3.1 Overview. 
Some of the compounds that were synthesised from Chapter 5, along with one other, 
42, that was synthesised as a consequence of the library 1 screening results, were 
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PFK or Lm PyK. This section reports and comments on these final results, and any 
other results, that were obtained. 
5.3.2 Biological results. 
As described in Chapter 2, 2,5 -anhydro- 1 -deoxy- 1 -(3 ,4-difluorobenzylamino)-D-
mannitol 42, (Figure 5.15) was synthesised because the library 1 screening results 
seemed to suggest that this may be a more potent inhibitor of Tb PFK than the lead 





Figure 5.15 2,5 -Anhydro- 1 -deoxy- 1 -(3 ,4-difluorobenzylamino)-D-mannitol 42. 
The Kj of 42 was determined for Tb PFK74  and found to be 85 p.M. This is a higher 
value when compared with that of 37 (Kd = 61 p.M) and indeed when compared to 32 
(Kd = 58 p.M). This shows that 42 does not bind as strongly to Tb PFK as either 37 or 
32, and therefore is likely to be a poorer inhibitor. Although results from the library 1 
screen may have suggested that 42 should be a more potent inhibitor, it still shows 
that it does indeed bind strongly to the target enzyme. As was mentioned in Chapter 
2, trends between the fluoro, methyl and chioro substituted compounds did showed 
similar activities, whilst no di-substituted fluoro compounds had been tested. This 
could also account for the reason why 42 is less potent than 37. 
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Continuing with Kd values, the value for 2,5-anhydro-1-deoxy-1-(3,4-
dichlorobenzylamino)-D-maimitol-6-phOSPhate 122 against Th PFK was also 
determined and found to be 110 tM. 74  Again, this is higher than the value for 37, and 
indeed for other phosphorylated compounds as investigated by Claustre et al. 62 It 
shows that phosphate 122 is less potent than the 37, and it is also likely to be less 
potent than other phosphorylated derivatives as previously discussed (Chapter 2). It 
also confirms that phosphorylation at the 6-position does not necessarily lead to 
improvement in inhibition, as alluded to in Chapter 2. 
The final biological results are concerned with tertiary amines 126 and 128 (from 
section 5.2.3). These were screened against Tb PFK using the 5 mlvi screen 







Table 5.1 Results of inhibitor screening of amines 126 and 128 against Tb PFK 








E6 -----  
4—  
C, 	3 
37 	 126 	 128 
Compound 
Figure 5.16 A Graph showing the inhibitor screening results for amines 126 
and 128 against Th PFK compared with 37•82 
The results shown in Table 5.1 and Figure 5.16 shows that inhibition of Th PFK 
caused by 126 and 128 is similar to that caused by 37. As the results are low and 
similar in value, it is difficult to comment further. An 10 50 value was determined for 
126 and was found to be 0.33 mM, an improvement on the IC 50 value for inhibitor 37 
(0.41 mM). This clearly shows that the secondary amine is not essential for 
inhibitory activity, and the —NH appears not to make any hydrogen bonding 
interactions with the enzyme. Therefore, further synthesis of tertiary amines would 
be necessary to optimise inhibition, especially using the sugar amino amide 
inhibitors from library 3. 
In the absence of a crystal structure of Tb PFK with inhibitors bound, competition 
experiments were also carried out with 12682  to help ascertain whether these 
compounds compete with F6P or ADP, and therefore indicate the mode of binding. 
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Inhibitor KM ATP (mM) KM F613 (mM) Vmax ATP Vmax F6P 
No inhibitor 0.053 0.29 100 100 
126 0.052 1.65 56.9 65.5 
Table 5.2 Results of competition experiments of inhibitor 126 against Tb PFK. 82 
The competition experiment results show that there is a change in both the KM and 
Vmax values for F6P when incubated with inhibitor 126 (KM shows a 6-fold increase), 
whereas for ATP, there is no change in KM value. This indicates that 126 competes 
with 176P and is therefore highly likely to bind to the F6P binding site, 82  as was also 
shown with inhibitor 110 from library 3. 
5.3.3 In vivo screening results. 
In inhibitor design and development, it is important (as has been mentioned earlier) 
to take in to account factors that may affect bioavailability (such as the Lipinski Rule 
of 519)  However, these are only guidelines and do not guarantee inhibitors or 
potential drugs to have in vivo activity. Therefore, ED 5 0 values were determined for 
four compounds; 37, the lead against Tb PFK from library 1; 70, the lead against Lm 
PyK from library 2, and two other inhibitors from library 2, 57 and 59. These results 
are shown in Table 53117 
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Table 5.3 Results of in vivo screening of a selection of inhibitors on 
trypanosomatid cells. 117 
The results shown in Table 5.3 show that the inhibitors developed do indeed inhibit 
trypanosomatid cell growth in the in vivo assay. It is interesting to note that the best 
of these inhibitors is 37 with an ED50 of 0.15 mM. The results are encouraging as 
they show that the inhibitors are not only active against their target enzymes, but also 
show in vivo activity which is crucial if further lead and drug development is to be 
successful. 
5.4 	Inhibitor specificity. 
It is important in the context of drug discovery, design and development that 
specificity between target and non-target proteins is achieved. Particularly important 
in the area of infectious disease is the specificity needed between the host and target 
(in this case parasite) proteins. As was reported in Chapter 1, trypanosomatid 
glycolytic enzymes are considered ideal targets due to the low similarity with their 
mammalian counterparts. For obvious reasons, it is undesirable to have a drug that 
affects the patient as well as the disease, although this has not always been possible 
for the treatment of trypanosomal diseases. 34,36  In performing the inhibition assays, it 
is also important that enzymes in the assay couple are not being inhibited by the 
compounds being tested. This ensures that the results obtained are due to inhibition 
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of the target enzyme, and not to a side inhibition of enzymes present in the coupled 
assay. 
Therefore, inhibitor 126 was screened against mammalian (rabbit muscle) PFK to 
ascertain whether it was specific for the trypanosomatid enzyme (see Figure 5.17) 
and was also tested against the auxiliary enzymes involved in the enzyme couple: 
these results are also shown in Figure 5.17. 
120 
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e 	100  
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Auxiliary enzymes Rabbit muscle PFK 	Th PFK 
Enzymes 
Figure 5.17 Screening results of inhibitor 126 against auxiliary assay and 
mammalian enzymes (inhibitor concentration = 1 mM, average of 2 results). 
75 
It is clear from these results that inhibitor 126 is completely selective for the Th PFK 
and does not inhibit the mammalian enzyme. Confidence is also gained by the fact 
that the screening results are solely due to inhibition of Th PFK and cannot be 
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5.5 	Overall summary and conclusion. 
The primary aim of this research was to improve on already existing inhibitors for Th 
PFK as well as identifying new inhibitors of Lm PyK. Methods to try to achieve this 
include library synthesis and screening (based on already known inhibitors) and 
rational inhibitor development. 
By means of library design and synthesis, a new lead compound for Tb PFK was 
identified; 2,5-anhydro- 1 -deoxy- 1 -(3 ,4-dichlorobenzylamino)-D-mannitol 37 which 
has an IC50 value of 0.41 mM. Further to this, 2,5-anhydro-l-deoxy-1-
(cycloheptylamino)-D-mannitol 70 was identified as a lead compound for the 
inhibition of Lm PyK, with an 1050 of 58 pM. A comparison of all the results from 
the biological screens of the libraries synthesised, allowed for the compilation of 
structure activity relationships. Competition and in silico docking experiments 80  for 
Lm PyK inhibitors suggested that 70 competes with F2,6BP and, therefore, binds to 
the effector site: potential protein-ligand interactions were also identified. 
Further inhibitor development identified four main areas where modification can be 
achieved. Notably, this lead to the development of a third library, the a-furanoid 
sugar amino amides. Biological testing of these compounds against Tb PFK showed 
much improved inhibition and identified a new lead compound, 2,5-anhydro-1-
deoxy- 1(3 ,4-dichlorobenzylamino)-D-3 ,4-dichlorobenzylmannonamide 110, with an 
IC50 value of 23 tM. Testing of these compounds against Lm PyK again showed that 
the sugar amino amides have at least comparable inhibitory activity compared with 
70, although IC50 values have not been determined. 
Other areas of inhibitor development identified routes to inhibitors with an 




Non-Library Inhibitor Development 
secondary amine in the case of all the other inhibitors), both of which can be easily 
adapted for further library synthesis. This led to the identification of the tertiary 
amine N-methyl-2,5 -anhydro- 1 -deoxy-(3 ,4-dichlorobenzylamino)-D-mannitol 126 as 
an improved inhibitor of Tb PFK, compared with the initial lead compounds 21 and 
37, with an 10 50 of 0.33 mM. Figure 5.18 shows the progress of lead development, 







14, Ic50 = 3 mM 
/ 
cl 	 0 	 CI 
CI— 
HO 	OH 
110, IC,0 =23pM  




HO ' OH 
126, IC,0 = 0.33 mM 
Lm PyK 
? 
	 HO 	 —0 
HO 	OH 
70, IC,0 = 58 1iM 
Figure 5.18 A scheme showing the main areas of inhibitor development for both 
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Finally, specificity experiments had also shown that 126 is specific for the 
trypanosmatid enzyme, and does not affect the mammalian enzyme. 
Overall, not only has the primary objective been achieved, but the way has been 
paved for further inhibitor design and synthesis, due to the routes developed. All 
inhibitors fall within the Lipinski rule of 5 boundaries (see appendix), and coupled 
with the specificity data, make all the inhibitors mentioned, suitable lead compounds 
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6 	Experimental. 
6.1 	General techniques. 
6.1.1 Instrumentation. 
'H and ' 3 C NMR were recorded on Bruker AC 250 or AC 360 instruments. Chemical 
shifts (ö) are recorded in parts per million (ppm) downfield of tetramethylsilane and 
were referred to residual undeuterated solvent present in the deuterated solvent of the 
sample (e.g. CH30H in CD3 0D). 
Electrospray ionisation mass spectroscopy (ESI) was carried out on a Micromass VG 
Platform II instrument. Solvents used were either water or acetonitrile : water (1 : 1, 
0.1 % acetic acid) in either positive or negative scan modes. Fast Atom 
Bombardment (FAB) high resolution mass spectra were recorded on a Kratos 
MS50TC instrument. 
Infra-red absorption spectroscopy was performed on a Perkin-Elmer FT-JR Paragon 
1000 spectrometer, and Vmax values are quoted in cm -1 . 
Optical rotations were performed at room temperature on an AA1000 polarimeter 
from Optical Activity Ltd (measurements made at the sodium D-line). 
Concentrations are given in gIlOOml. 
Thin layer chromatography was performed on Merck DC-Alufolien Kieselgel 60F 245 
0.2 mm pre-coated plates. Components were visualised by u.v. fluorescence or by 
potassium permanganate or ninhydrin stains. 
Melting points were obtained on Gallenkamp melting point apparatus. 
Parallel synthesis was peformed using the following instruments: Bohdan Neptune 






Microwave synthesis was performed using the CEM Discover microwave and 
Explorer autosampler. 
Mass directed purification was carried out on a Waters ZMD mass spectrometer with 
Waters 600 HPLC using MassLynx version 3.5 and FractionLynx software. The 
HPLC column used was a Waters Xterra, C18, 60 x 21.20 mm, 5 u microns. 
Parallel flash column chromatography was carried out using Quad3 parallel 
purification system using pre-packed columns. 
6.1.2 Mass directed purification methods. 
All samples for purification were made to ca 50 mg/ml in acetonitrile : water (1 1, 
0.1 % acetic acid). A flow rate of 20 ml/min was used, and the sample injection 
volume was 500 jil. The following methods were used sample elution: 
ZMD Method 1. 
Positive ion mode, CV = 25 
Run time = 12 minutes. 
Time (minutes) Water, (0.1 % TFA) % MeCN (%) 
0 98 2 
1 98 .2 
9 70 30 
10 98 2 




ZMD Method 1 a. 
Negative ion mode, CV =25 
Run time = 12 minutes. 
Time (minutes) Water, (0.1 % TFA) % MeCN (%) 
0 98 2 
1 98 2 
9 70 30 
10 98 2 
12 98 2 
ZMD Method 2. 
Run time = 12 minutes 
Time (minutes) 10 MM NH4(HCO3), % MeCN (%) 
0 98 2 
1 98 2 
9 70 30 
10 98 2 
12 98 2 
ZMD Method 2a. 
Run time = 16 minutes 
Time (minutes) 10 MM NH4(HCO3), % MeCN (%) 
0 98 2 
1 98 2 
14 70 30 





ZMD Method 2b. 
Run time =20 minutes 
Time (minutes) 10 MM NH4(HCO3), % MeCN (%) 
0 98 2 
1 98 2 
17 70 30 
18 98 2 
20 98 2 
ZMD Method 2c. 
Run time =26 minutes 
Time (minutes) 10 MM NH 4(HCO3), % MeCN (%) 
0 98 2 
1 98 2 
24 70 30 
26 98 2 
6.2 	Library 1: Design, Synthesis and Evaluation. 
6.2.1 Synthesis of 2,5-anhydro-D-mannose, 22.61 
0 	 OH 
6 	Q 	If 
HO 	 " i 	HO 
\ 	 + 	 OH 
HO 	OH 	 HO 	OH 
D-Glucosamine hydrochloride (2.0 g) was dissolved in water (50 ml) and stirred at 0 
°C for approximately 5 hours. Sodium nitrite (1.6 g, 2.5 eq.) was then added, 
followed by cautious addition of Amberlite 120 H resin (47 ml), maintaining the 
temperature between 0 - 5 T. The reaction was then left to stir at 0 °C for 18 hours 
before the resin was removed by filtration. The solution was then neutralised by 
portion-by-portion addition of Dowex C03 2 resin. The resin was removed by 
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filtration and the remaining solution was lyophilised to yield the title compound as a 
pale yellow hygroscopic solid (1.33 g, 88%). 
Rf= 0.42,63  CH202 : MeOH (8: 2) 
'H NMR (250 MHz, D20), ö (ppm): 3.50 - 3.75 (3H, m, H-2, 2 x H-6), 3.78 - 3.86 
(1H, m, H-5), 3.95 (1H, t, J43 = J4 ,5 = 5.5 Hz, H-4), 4.10 (1H, t, J34 = J3 ,2 5.5 Hz, 
H-3), 5.00 (1H, d, Ji,2 = 5.5 Hz, H-i gem-diol), 8.35 (s, H-i aldehyde). 
' 3C NMR (63 MHz, D20), 8 (ppm): 61.2 (C6), 76.8 (C4), 77.8 (0), 83.2 (C5), 84.6 
(C2), 90.0 (C-i gem-diol). 











Sodium cyanoborohydride (0.15 g, 0.7 eq.) was added to a solution of 22 (0.55 g, 1 
eq.) and aniline (0.29 ml, 1 eq.) in methanol (10 ml). The solution was stirred for 2 
hours maintained at pH 6, by dropwise addition of HC1 (0.5 M) in methanol. The 
solvent was then removed under reduced pressure, and the resulting residue was 
dissolved in acetonitrile : water (1 : 1, 0.1 % acetic acid) and purified using mass 
directed purification (ZMD Method 1). Removal of the solvent by lyophilisation 
afforded the title compound as an off-white solid (0.41 g, 50 %). 
'H NMR (250 MHz, CD 30D), 6 (ppm): 3.23 (1H, dd, Jgem = 13.0 Hz, Jia,2 = 7.0 Hz, 
1 X H-i), 3.36 (1H, dd, Jgem = 13.0 Hz, Jlb,2 = 3.5 Hz, 1 X H-i), 3.65 (1H, dd, Jgem 
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12.0 Hz, J56a = 5.6 1, 1 X H-6), 3.70 (1H, dd, Jgem = 12.0 Hz, J56b  3.5 Hz, 1 x 11-6), 
3.93 - 3.98 (1H, m, H-5), 4.01 - 10 (3H, m, H-2, H-3, H-4),6.65 - 6.85 (3H, m, H-9, 
H-10, H-i 1), 7.15 - 7.25 (2H, m, H-8, H- 12). 
' 3C NMR (63 MHz, CD30D), 8 (ppm): 46.2 (C 1), 62.2 (C6), 77.9 (C4), 79.5 (C3), 
82.1 (C2), 84.1 (C5), 113.1 (C9, CI 1), 117.2 (CO), 128.9 (C8, C12),149.0 (C7). 
ESI: [M + H] = 240.2 
6.2.3 Synthesis of 2,5-anhydro-1-deoxy-1-benzylamino-D-mannitol, 15.61 
9 
6 	Q 	





HO 	OH 	 12 
Sodium cyanoborohydride (0.23 g, 0.7 eq.) was added to a solution of 22 (0.87 g, 1 
eq.) and benzylamine (0.59 ml, 1 eq.) in methanol (15 ml). The solution was stirred 2 
hours at pH 6, maintained by dropwise addition of HC1 (0.5 M) in methanol. The 
solvent was then removed under reduced pressure and the resulting residue was 
dissolved in acetonitrile:water (1:1, 0.1 % acetic acid) and purified using mass 
directed purification (ZMD Method 1). Removal of the solvent by lyophilisation 
afforded the title compound as a white solid (1.30 g, 96 %). 
'H NMR (250 MHz, CD30D), 8 (ppm): 2.73 (1H, dd, Jgem = 12.5 Hz, Jla,2 = 7.5 Hz, 
1 X H1), 2.82 (111, dd, Jgem = 12.5 Hz, JIb,2 = 3.59 Hz, 1 x H-i), 3.58 - 3.75 (3H, m, 
H-2, 2 x H-6), 3.77— 3.83 (3H, m, H-5, 2 x H-7), 3.89— 3.97 (211, m, H-3, H-4), 7.10 
—7.30 (5H, m, H-9 to H-13). 




79.5 (2C, C2, 0), 85.2 (C5), 128.8— 129.9 (5C, C9 to C13), 131.3 (C8). 
ESI: [M +Na] = 276.1 
6.2.4 Procedure for the synthesis of N-aryl-1 -amino-2,5-anhydro-1-deoxy-1 -D-
mannitols using parallel synthetic method: A 4-membered test library. 
Using the Bohdan Neptune reagent manager, a methanolic solution of 22 (0.35 M, 1 
eq.) was added to four, 2 ml reactors, contained within the Bohdan MiniBlock 
synthesiser. An arylamine (1 eq.) was then added to each reactor. The MiniBlock 
synthesiser was then shaken for 20 minutes before addition of a methanolic solution 
of sodium borohydride (2.4 M, 0.7 eq.). HC1 in methanol (0.5 M) was added 
dropwise to each reactor so that each solution was maintained at pH 6. The Mini-
Block was shaken for a further 30 minutes. The pH was again adjusted (if necessary) 
by dropwise addition of HC1 in methanol (0.5 M). The MiniBlock was then shaken 
for a further 90 minutes, checking the pH of the reactors every 30 minutes. The 
reaction mixtures where then transferred to a microtitre plate and the solvent 
removed under vacuum. The residues were then dissolved in acetonitrile : water (1 
1, 0.1 % acetic acid) and purified using mass directed purification. 
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6.2.4.2 	2,5-Anhydro-1-deoxy-1-benzylamino-D-mannitOl, 15.61 
9 
6 10 1 
HO 
 
.- -- ' H 	 11 
13 
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From m-aminobenzoic acid, using ZMD method la, gave 16 as a yellow oil (20 %). 
'H NMR (250 MHz, CD30D), 8 (ppm): 3.38 - 3.42 (2H, m, 2 x H-i), 3.60 - 3.90 
(3H, m, H-2,2 x H-6),4.00 — 4.10 (1H, m, H-5),4.10 — 4.25 (2H, m, H-3, H-4), 7.45 
—7.60 (1H, m, H-12),7.70 — 7.90 (1H, m, H-i 1), 8.15 - 8.3 (2H, m, H-8, H-b). 
' 3C NMR (63 MHz, CD30D), 8 (ppm): 45.9 (C 1), 62.2 (C6), 77.9 (C4), 79.4 (0), 
82.0 (C2),84.1 (C5),113.5 (C8),117.0 (CIO), 118.2 (C12),128.8 (Cii), 133.0 (C9), 
151.1 (C7), 169.0 (C13). 
ESF: [M - Hf = 282.0 (exp. 282.3). 
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6.2.4.4 	2,5Anhydro-1-deoxy-1-(m-nitropheny1amiflO)-D-maflflitOl, 17.61 
NO2 
61  - k i/ 
8 
HO 	






From 3-nitroaniline, using ZMD Method la, gave 17 as yellow solid (50%). 
'H NMR (250 MHz, CD30D), ö (ppm): 3.38 (2H, 2dd, Jgem = 14.5 Hz, Jla,2 = 6.0 Hz, 
JIb,2 = 3.5 Hz, 2 X H-i), 3.68 (2H, 2dd, Jgem = 12.0 Hz, J5,6a = 5.5 Hz, J5,6b  3.5 Hz, 2 
x H-6), 3.83 - 3.90 (1H, m, H-2), 3.93 - 4.03 (3H, m, H-3, H-4, H-5), 6.95 - 7.05 
(1H, m, H- 10), 7.20— 7.32 (1H, m, H-i 1), 7.38 - 7.48 (2H, m, H-8, H- 12). 
' 3C NMR (63 MHz, CD30D), 8 (ppm): 44.6 (C 1), 61.3 (C6), 76.9 (C4), 78.4 (0), 
81.2 (C2), 83.3 (CS), 107.4 (C8), 110.4 (CIO), 119.5 (C12), 120.9 (CI 1), 149.0 - 
149.5 (2C, C7, C9). 
ESF: [M - H] - = 283.1 (exp. 283.2). 
6.2.5 Synthesis of library 1: N-benzyl-1-amino-2,5-anhydro-1-deOXy-D-
mannitol derivatives. 
Using the Bohdan Neptune reagent manager, a methanolic solution of 22 (0.7 M) 
was added to 17 x 2 ml reactors each containing a benzylamine derivative (100 mg, 
pre-weighed by Sigma-Aldrich Filling Station) in equimolar quantities. The Bohdan 
MiniBlock synthesiser that contained the reactors was then shaken for 15 minutes. 
Sodium cyanoborohydride in methanol (2.4 M, 0.7 eq.) was added to each reactor, 





MiniBlock was then shaken for a further 2 hours, monitoring the pH of each reactor, 
and adjusting the pH if necessary. The reaction mixtures were then transferred to a 
microtitre plate and the solvent removed under reduced pressure. The residues were 
dissolved in acetonitrile : water (1:1, 0.1 % acetic acid) and purified using mass 
directed purification (ZMD Method 1). 
6.2.5.1 	2,5-Anhydro-1-deoxy-1-(2,4-dichlorobenzylamino)-D-mannitol, 25. 
CI 
HO 
6 ~0 2'-.. 
ci 
13 
HO 	OH 	 12 
From 2,4-dichlorobenzylamine, yield = 28 mg, 15 %. 
'H NMR (250 MHz, CD30D), 8 (ppm): 3.30 - 3.37 (2H, m, 2 x H-i), 3.70 (2H, 2dd, 
Jgem = 11.5 Hz, J56a = 5.5 Hz, J5,6b = 3.5 Hz, 2 x H-6), 3.89 - 34.02 (3H, m, H-2, H-
3, H-5), 4.17 —4.27 (3H, m, H-4, 2 x H-7), 7.28 - 7.57 (3H, m, Ar-H). 
' 3C NMR (63 MHz, CD30D), ö (ppm): 39.2 (Cl), 48.1 (C7), 61.2 (C6), 76.7 (C4), 
78.9 (C3, C2), 84.9 (C5), 127— 131 (3C, dO, C12, C13), 132 - 135 (2C, C9, CI 1). 





6.2.5.2 	2,5Anhydro1-deoxy-1-(3-chlorobenzYlamiflO)-D-maflflit06 26. 
CI 
9 	10 HO 
6 	Q 	1 
2 
T- H 	 11 3 	 10
NO 	OH 	 12 
From 3-chlorobenzylamine, yield = 14 mg, 7 %. 
'H NMR (250 MHz, CD 30D), 6 (ppm): 3.01 - 3.15 (2H, m, 2 x H-i), 3.47-4.11 
(8H, m, H-2, H-3, H-4, H-5, 2 x H-6, 2 x H-7), 7.01 - 7.47 (4H, m, 4 x Ar-H). 
ESI: [M + H] 4 = 288.0 ["Cl], 289.9 [37C1]. 
6.2.5.3 	2,5Anhydro1deoxy-1-(4-ch1orobenZY1amiflO)-D-maflflit0l, 27. 
'12 





From 4-chlorobenzylamine, yield = 15 mg, 7 %. 
'H NMR (250 MHz, CD 30D), 6 (ppm): 3.30 - 3.35 (2H, m, 2 x H-i), 3.73 (2H, 2dd, 
Jgem 12.0 Hz, J5,6a 6.0 Hz, J5,6b = 3.0 Hz, 2 x H-6), 3.95 - 4.07 (3H, m, H-2, H-3, 
H-5), 4.16-4.79 (3H, m, H-4, 2 x H —7), 7.49-7.68 (4H, m, 4 x Ar-H). 




6.2.5.4 	2,5Anhydro1-deoxy-1-(2-ch1OrObeflZY1amifl0)-D-maflfl1t0l, 28. 
CI 
6 




From 2-chlorobenzylamine, yield = 12 mg, 6 %. 
'H NMR (250 MHz, CD30D), S (ppm): 3.37 - 3.40 (2H, m, 2 x H-i), 3.62 - 3.80 
(3H, m , H-3,2 x H-6), 3.97 —4.09 (2H, m, H-2, H-5), 4.32 —4.49 (3H, m, H-4, 2 x 
H-7), 7.44 - 7.57 (4H, m, 4 x Ar-H). 
ESI: [M +H] 	288.1 [35C1], 290.1 [37C1]. 





6 	 1 
5 	2 
IF 	 12 
HO OH 
From 4-methylbenzylamine, yield = 82 mg, 37 %. 
'H NMR (250 MHz, CD30D), S (ppm): 2.33 (3H, s, 3 x H-14),3.26 - 3.29 (2H, m, 2 
x H- 1), 3.76 - 3.80 (3H, m, H-3, 2 x H-6), 3.95 - 4.26 (5H, m, H-2, H-4, H-5, 2 x H-
7), 7.22 —7.51 (4H, m, Ar-H). 






6.2.5.6 	2,5-Anhydro-1-deoxy-1-(3-methylbenzylamino)-D-maflflitOl, 30. 
9 	14 
HO 





From 3-methylbenzylamine, yield = 80 mg, 36 %. 
'H NMR (250 MHz, CD30D), 8 (ppm): 2.33 (3H, s, 3 x H-14), 3.27 - 3.28 (2H, m, 2 
x H- 1), 3.61 - 3.72 (3H, m, H-3, 2 x H-6), 3.91 - 4.23 (5H, m, H-2, H-4, H-5, 2 x H-
7), 7.17 - 7.38 (4H, m, Ar-H). 
ESI: [M + H] = 268.0. 
6.2.5.7 	2,5Anhydro-1-deoxy-1-(2-methylbenzy1amino)-D-maflflitO1, 31. 
14 
H 	
6 	 1 
O 
5 	2 
H 	 11 




From 2-methylbenzylamine, yield = 179 mg, 81 %. 
'H NMR (250 MHz, CD3 0D), 5 (ppm): 2.45 (3H, s, H-14), 3.32 - 3.37 (2H, m, 2 x 
H- 1), 3.67 - 3.75 (3H, m, H-3, 2 x H-6), 3.95 - 4.05 (2H, m, H-2, H-5), 4.18 - 4.42 
(3H, m, H-4, 2 x H-7), 7.26 - 7.49 (411, m, Ar-H). 
' 3C NMR (63 MHz, CD 30D), ö (ppm): 17.5 (Me), 39.6 (Cl), 47.6 (0), 61.0 (C6), 
76.5 (C4), 78.4 (0), 78.7 (C2), 84.1 (C5), 128.3 - 130.2 (4C, ClO - C13), 136.2 - 





ESI: [M + H] = 268.0 (exp. 268.3). 







From benzhydrylamine, yield = 32 mg, 18 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 3.20 - 3.23 (2H, m, 2 x H-i), 3.67 - 3.80 
(3H, m, H-3, 2 x H-6), 3.92 - 3.97 (2H, m, H-2, H-4), 4.14 —4.17 (1H, m, H-5), 5.64 
(1H, s, 1-1-7), 7.41 —7.53 (1 OH, m, Ar-H). 
' 3C NMR (63 MHz, CD3 0D), 8 (ppm): 48.0 (C 1), 61.2 (C6), 65.2 (C7), 76.7 (C4), 
78.9 (C2 and 0), 84.6 (CS), 126.4 - 128.6 (bC, 10 x ArC-H), 135.0 - 136.7 (2C, 
C8, C8'). 









6 	Q 	1 
HO-/ 28 
	10 N,t' - 
12 
HO 	OH 
From trifluoromethyl benzylamine, yield = 80 mg, 36 %. 
'H NMR (250 MHz, CD30D), 6 (ppm): 3.31 - 3.36 (2H, m, 2 x H-i), 3.67 - 4.05 
(5H, m, H-2, H-3, H-4, 2 x H-6), 4.19 —4.41 (3H, m, H-5, 2 x 11-7), 7.42 —7.98 (4H, 
m, Ar-H). 









From 2-fluorobenzylamine, yield = 184 mg, 85 %. 
'H NMR (250 MHz, CD30D), 6 (ppm): 3.38 - 3.41 (2H, m, 2 x H-i), 3.72 - 3.87 
(3H, m, H-3, 2 x H-6), 4.02 - 4.02 (2H, m, H-2, H-4), 4.41 - 4.56 (3H, m, 11-5, 2 x 
H-7), 7.39 - 7.77 (4H, m, Ar-H). 
' 3c NMR (63 MHz, CD30D), 6 (ppm): 43.7 (C 1), 48.1 (C7), 60.7 (C6), 76.1 (C4), 
78.0 (C3),78.3 (C2), 83.5 (C5), 115.1-131.5 (5C, ArC), 158.6 (ArC-F) 





ESI: [M+H] + =272.1. 
6.2.5.11 	2,5-Anhydro-1-deoxy-1-(4-fluorobenzylamino)-D-mannitol, 35. 
9 








From 4-fluorobenzylamine, yield = 139 mg, 64 %. 
'H NMR (250 MHz, CD3 0D), 8 (ppm): 3.12 - 3.27 (2H, m, 2 x H-i), 3.63 - 3.72 
(3H, m, H-3, 2 x H-6), 3.89 - 3.98 (2H, m, H-2, H-4), 4.10 - 4.25 (3H, m, H-5, 2 x 
H-7), 7.08-7.18 (2H, m, H- 10, H-12), 7.44-7.57 (2H, m, H-9, H-13). 
13  NMR (63 MHz, CD30D), 8 (ppm): 41.9 (Cl), 49.9 (C7), 61.0 (C6), 76.4 (C4), 
78.1 (C3), 78.5 (C2), 83.6 (CS), 115.5 (2C, dO, C12), 128.4 (C8), 130.7 - 131.9 
(2C, C9, C13), 164.6 (C 11). 
' 9F NMR (235 MHz, CD30D), ö (ppm): -76.6. 





6.2.532 	2,5-Anhydro-1-deoxy-1-(3fluorobenzy1amino)-D-maflflitO1, 36. 
F 




H O  OH 	
12 
From 3-fluorobenzylamine, yield = 44 mg, 20 %. 
'H NMR (250 MHz, CD 3 0D), 8 (ppm): 3.17 - 3.47 (2H, m, 2 x H-i), 3.63 - 4.03 
(5H, m, H-2, H-3, H-4, 2 x H-6), 4.17 —4.32 (3H, m, H-5, 2 x H-7), 7.17 - 7.36 (3H, 
m, H-9, H- 11, H-13), 7.44-7.50 (1H, m, H-12). 
ESI: [M+H] 272.1. 









From 3,4-dichlorobenzylamine, yield = 12 mg, 7 %. 
[aID = + 5.7 ° (c 0.7, MeOH). 
'H NMR (250 MHz, CD30D), 8 (ppm): 2.72 (1H, dd, Jgem = 12.5 Hz, Jla,2 = 7.5 Hz, 
H-la), 2.79 (1H, dd, Jgem = 12.5 Hz, Jlb,2 = 3.5 Hz, H-lb), 3.61 - 4.03 (8H, m, H-2, 
14-3, H-4, H-5, 2 x H-6, 2 x 1-1-7), 7.24 (1 H, dd, J,2,,3 = 8.0 Hz, J9,13 = 2.0 Hz, H- 13), 





' 3C NMR (63 MHz, CD30D), ö (ppm): 50.1 (Cl), 51.3 (C7), 61.5 (C6), 76.9 (C2), 
79.2 (CS), 81.7 (C4), 83.5 (C3), 127.4 - 129.6 (3C, C9, C12, C13), 129.9 - 131.3 
(2C, dO, Cli), 139.9 (C8). 
ES1: [M + H] = 322.1 [35C1 - 35 C1]. 
HRMS FAB (+ve) found mlz = 322.06074 and 324.05862 [M + H] +, C 13H 18N04C12 
requires 322.06129 (2 x 35C1) and 324.05834 (35C1 + 37C1). 
Decomposes> 190 T. 











HC' 	OH  
1 
From 2,5-dimethylbenzylamine, yield =42 mg, 20 %. 
'H NMR (250 MHz, CD3 0D), 6 (ppm): 2.24 (3H, s, ArCH3), 2.29 (3H, s, ArCH3), 
3.19-3.30 (2H, m, 2 X H- 1), 3.56 (1H, dd, Jgem = 11.5 Hz, J5,6a = 5.5 Hz, H-6a), 3.64 
(1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.80 (1H, t, J2,3 = J3,4 = 4.5 Hz, H-3), 
3.83 - 3.97 (2H, m, H-2, H-4), 3.98 - 4.19 (3H, m, H-5, 2 x H-7), 7.00 - 7.24 (3H, 
m, Ar-H). 












\ ( N J 




From 2,4-dimethylbenzylamine, yield = 81 mg, 39%. 
'H NMR (250 MHz, CD30D), 6 (ppm): 2.32 (3H, s, ArCH 3), 2.39 (3H, s, ArCH3), 
3.31 —3.35 (2H, m, 2 X H- 1), 3.68 (1H, dd, Jgem = 11.5 Hz, J5,6a = 5.5 Hz, H-6a), 3.76 
(1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.93-4.06 (3H, m, H-2, H-3, H-4), 
4.12 —4.30 (3H, m, H-5, 2 x H-7), 7.07 - 7.51 (3H, m, Ar-H). 
' 3 C NMR (63 MHz, CD30D), 8 (ppm): 17.3 (Me-C), 19.2 (Me-C) 39.4 (Cl), 48.5 
(C7), 61.2 (C6), 76.7 (C4), 78.7 (C3), 78.9 (C2), 84.5 (CS), 126.4— 129.6 (3C, CIO, 
C12, C13),136.8 - 139.0 (3C, C8, C9, CI 1). 
ESI: [M+H]282.i. 





c 11 	 3 	 13 12 
HO 
OH 
From 3 ,4-dimethylbenzylamine, yield =44 mg, 21 % 
'H NMR (250 MHz, CD30D), 6 (ppm): 2.29 (6H, s, 2 x ArCH3), 3.22 - 3.43 (2H, m, 





11.5 Hz, J56b = 3.5 Hz, I-I-6b), 3.67 - 4.20 (611, m, H-2, H-3, H-4, 1-1-5, 2 x H-7), 
7.14 —7.34 (3H, m, Ar-H). 
' 3 C NMR (63 MHz, CD30D), 8 (ppm): 17.8 (2 x Me-C), 42.2 (Cl), 50.2 (C7), 61.2 
(C6), 76.7 (C4), 78.7 (2C, C2, 0), 84.3 (CS), 125.5 - 130.2 (3C, C9, C12, C13), 
136.8-137.5 (3C, C8, ClO, Cii). 
ESf4 : [M + H] = 282.1 (exp. 282.2). 
6.2.5.17 	2,5-Anhydro-1-deoxy-1-(4-phenylbenzylamino)-D-mannitol, 41. 




From 4-phenylbenzylamine, yield = 42 mg, 23 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 2.12 - 2.29 (21-1, m, 2 x H-i), 3.47 - 4.24 
(81-1, m, H-2, H-3, H-4, H-5, 2 x H-6, 2 x H-7), 7.43 - 7.81 (91-1, m, Ar-H). 
ESI: [M + H] = 330.1 (exp. 330.2). 
6.2.6 Biological screens. 
6.2.63 	5 mM Inhibitor screen vs Tb PFK. 
In a 1 ml cuvette was placed 100 mM inhibitor solution (40 l, made up with 0.1 M 
triethanolamine, pH 8.0), 12.5 p.g/ml PFK (16 p1), made up to 760 p.1 with 0.1 M 
triethanolamine, pH 8.0 and was incubated for 2 minutes. The reaction was started by 
1VTd  
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addition of the substrate mix (40 jil, 40 MM M902, 40 mM F6P, 20 mM ATP, 6 mM 
NADH, 34 units/ml G3PDH, 18 units/ml aldolase, 20 units/ml TIM), gently agitated 
and the decrease in absorbance at 340 nm measured for 2 minutes (using Lambda 
Bio). The initial rate was then calculated using UV kinlab. A control rate with no 
inhibitor present was also determined. The rate for each inhibitor assay was 
expressed as a percentage of the control assay. 
6.2.6.2 	5 mM Inhibitor screen vs Lm PyK. 
To a 1 ml cuvette was added the substrate mix (500 gl, 50 mM triethanolamine, pH 
7.2, 50 mM KCI, 6 mM MgSO4, 0.6 mM ADP, 0.84 mM NADH, 27.6 units/ml 
LDH), 0.04 mg/ml PyK (10 itl), 100 mM inhibitor solution (50 jtl, made up with 0.1 
M triethanolamine, pH 7.5) and made to 992 pJ by addition of water. The mixture 
was incubated for 2 minutes before the reaction was started by addition of 50 .tM 
PEP (50 p1). The mixture was gently agitated and the decrease in absorbance at 340 
mn was measured for 2 minutes (using Lambda Bio). The initial rate was then 
calculated using UV kinlab. A control rate with no inhibitor present was also 
determined. The rate for each inhibitor assay was expressed as a percentage of the 
control assay. 
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6.2.7 Synthesis 	of 	2,5-anhydro-1 -deoxy-1-(3,4-difluorobenzylamiflO)-D- 
mannitol, 42. 
6 	 1 
HO 	
5 	2 ,-__ 




Aldehyde 22 (0.5 g, 1 eq.) and 3,4-difluorobenzylamine (0.36 ml, 1 eq.) were 
dissolved in methanol (10 ml) and stirred for 20 minutes. Sodium cyanoborohydride 
(0.13 g, 0.7 eq.) was added and the reaction was stirred for 3 hours, maintaining the 
pH at 6 by dropwise addition of HC1 in methanol (0.5 M). The solvent was then 
removed under reduced pressure and the resulting residue was dissolved in 
acetonitrile:water (1:1, 0.1 % acetic acid) and purified using mass directed 
purification (ZMD Method 2). The resulting solution was lyophilised and the title 
compound was afforded as a white solid (74 mg, 8 %). 
'H NIVIIR (250 MHz, CD 3 0D), ö (ppm): 2.74 (1H, dd, Jgem = 12.5 Hz, Jla,2 = 7.5 Hz, 
H-la), 2.82 (1H, dd, Jgem = 12.5 Hz, Jib,2 = 4.0 Hz, H-lb), 3.63 (1H, dd, Jgem = 11.5 
Hz, J5,6a = 6.0 Hz, H-6a), 3.74 (1H, d, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.79 (2H, 
s, 2 x H-7), 3.81 - 3.97 (4H, m, H-2, H-3, H-4, H-5), 7.15 —7.33 (5H, m, 5 x Ar-H). 
NIMR (63 MHz, CD30D), 8 (ppm): 50.0 (Cl), 51.4 (C7), 61.5 (C6), 76.9 (C4), 
79.2 (C3),81.7 (C5), 83.6 (C2),116.1 - 124.1 (3C, C9, C12, C13),136.3 (C8), 147.5 
—152.5 (2C, ClO, dl). 
ESI: [M + H] = 290.0. 
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6.3 	Library 2: Design, Synthesis and Evaluation. 
6.3.1 Synthesis of library 2: Nsubstituted-1-amino-2,5-anhydrO-1-deOXY-D-
mannitol derivatives. 
Using the Bohdan Neptune reagent manager, a methanolic solution of 22 (0.5 M) 
was dispensed in to 39 x 5 ml reactors, each containing an amine in equimolar 
quantities. The Bohdan MiniBlock synthesiser that contained the reactors was shaken 
for 15 minutes. Sodium cyanoborohydride in methanol (2.4 M, 0.7 eq.) was added to 
each reactor before adjusting the pH to 6 by dropwise addition of HC1 in methanol 
(0.5 M). The MiniBlock was then shaken for a further 2 hours, monitoring the pH of 
each reactor, and adjusting the pH if necessary. The reaction mixtures were then 
transferred to a microtitre plate and the solvent removed under pressure. The residues 
were dissolved in water : acetonitrile (1:1, 0.1 % acetic acid) and purified using the 
mass directed purification. 






From cyclopentylamine, using ZMD Method 2, yield = 179 mg, 90 %. 
'H NMR (250 MHz, CD30D), 6 (ppm): 1.62-2.08 (8H, m, H-8 - H-1 1), 3.15-3.30 
(311, m, 2 x H- 1, H-7), 3.59 —4.15 (6H, m, H-2, H-3, H-4, H-5, 2 x H-6). 




(C 1), 58.8 (C7), 61.1 (C6), 76.6 (C4), 78.6-78.8 (2C, C2, 0), 83.8 (C5). 
ESI: [M+Hf 232 . 1 . 
6.3.1.2 	2, 5Anhydro1deoxy1-N-(2S-2-amiflO-3-PheflYl-l-hYdr0XYPr0PYl)- 
D-mannitol, 49. 
HO 
6 	0 	1 
HO 
HO 	OH 
From L-(-)-2-amino-3-phenyl-1-propanol using, ZMD Method 2, yield = 74 mg, 37 
%. 
1 H NMIR (250 MHz, CD3OD), 6 (ppm): 2.82 - 3.33 (5H, m, 2 x H-i, H-7,2 x H-8), 
3.47 - 3.77 (5H, m, H-2, 2 x H-6, 2 x H-9), 3.92 - 4.17 (3H, H-3, H-4, H-5), 7.24 - 
7.36 (5H, m, Ar-H). 
' 3C NMR (63 MHz, CD30D), 6 (ppm): 34.0 (C8), 46.9 (Cl), 58.2 (0), 60.2 (C7), 
61.2 (C6), 76.8 (C4), 78.9 (0), 79.9 (C2), 84.2 (CS), 126.0 - 128.5 (5C, Ar-CH), 
136.2 (ArC-R). 






6.3.1.3 	2,5-Anhydro-1-deoxy-1-(2-pentylamino)-D-mannitol, 50. 
6 	Q 	1 	 10 
HO 
HO 	OH 
From 2-pentylamine using, ZMD Method 2, yield = 64 mg, 32 %. 
'H NIvIR (250 MHz, CD3OD), 8 (ppm): 0.97 (3H, t, J10,,, = 7.0 Hz, 3 x H-1 1), 1.29 
(3H, d, J7,8 = 6.5, 3 x H-7), 1.64 - 2.12 (4H, m, 2 x H-9, 2 x H- 10), 3.07 - 3.32 (3H, 
m, 2 x H- 1, H-8), 3.52 - 3.92 (6H, m, H-2, H-3, H-4, H-5, 2 x H-6). 
ES11 : [M+H]234.i. 








From (±)-phenylpropanolamine hydrochloride, using ZMD Method 2, yield =23 mg, 
11%. 
'H NMR (250 MHz, CD3OD), 8 (ppm): 1.01 (3H, dd, J= 2.5 Hz, J= 6.5 Hz, 3 x H- 





m, H-2, H-3), 3.91 - 4.01 (2H, m, H-4, H-5), 4.79 (1H, t, J7,8 = 4.5 Hz, H-8), 7.23 - 
7.44 (5H, m, Ar-H). 
' 3 C NMR (63 MHz, CD3 OD), ö (ppm): 12.0 and 12.4 (C9),48.1 (Cl), 57.9 and 58.4 
(C7), 61.3 (C6), 73.5 (C4), 76.9 (0), 79.4 (C2), 81.9 (C5), 83.8 and 84.2 (C8), 
125.5 (2C, CI 1, C15), 126.5 (C13), 127.4 (2C, C12, C14),141.7 (C I O). 
ES]T: [M + H] = 298.2. 










From D-(+)-2-amino-3-phenyl-1-propanol, using ZMD Method 2, yield = 26 mg, 13 
%. 
'H NIMIR (250 MHz, CD3OD), ö (ppm): 2.65 - 3.00 (5H, m, 2 x H-i, H-7,2 x H-8), 
3.35 - 3.78 (511, H-2, 2 x H-6, 2 x H-9), 3.80 - 4.05 (3H, m, H-3, H-4, H-5), 7.23 - 
7.36 (5H, m, Ar-H). 
' 3 C NMR (63 MHz, CD3 OD), ö (ppm): 36.3 (C8), 48.7 (CI), 60.6 (C7), 61.4 (C9), 
61.7 (C6), 76.9 (C4), 79.2 (0), 82.1 (C2), 83.7 (CS), 125.5 (C13), 127.7 (2C, Cli, 
C15), 128.4 (2C, C12, C14), 138.2 (C 10). 














From 2-aminoindan hydrochloride, using ZMD Method 2, yield = 30 mg, 15 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 2.60 - 2.82 (4H, m, 2 x H-i, 1 x H-8, 1 x H-
9), 3.07 (2H, ddd,H gem = 15.5 Hz, J7,8 anti 	anti = 7.0 Hz, J7,8 s, =J,9 F,, = 3.5 Hz, 
1 x H-8, 1 x H-9), 3.45 - 3.63 (3H, m, 2 x H-6, H-7), 3.68 - 3.87 (4H, m, H-2 - 
6.97 - 7.08 (4H, m, H- 10 - H-13). 
13 C NMR (63 MHz, CD30D), 8 (ppm): 38.3 (2C, C8, C9), 49.4 (C 1), 58.7 (C7), 61.5 
(C6), 77.0 (C4), 79.4 (0), 81.8 (C5), 83.7 (C2), 123.6 (2C, Cli, C12), 125.7 (2C, 
CIO, C13),140.6 (C14, C15). 
ESI: [M + H] = 280.2 (exp. 280.2). 
6.3.1.7 	2, 5Anhydro1deoxy-1-(1R,2S-2-hydrOXY-1-ifldaflamifl0)D 
mannitol, 55. 
HO 













1 H NIvIIR (250 MHz, CD 3 0D), 8 (ppm): 2.87 - 3.15 (4H, m, 2 x H-i, 2 x H-9), 3.64 
(1H, dd, Jgem = 12.0 Hz, J5,6a = 5.5 Hz, H-6a), 3.73 (1H, dd, Jgem = 12.0 Hz, J5,6b = 
3.5 Hz, H-6b), 3.82 - 4.04 (4H, m, H-2 - H-5), 4.08 (1H, d, J7,8 = 5.0 Hz, H-7), 4.58 
(1H, dt, J7 ,8 = J8,9 sr = 5.0 Hz, J8,9 anti = 4.0 Hz, H-8), 7.17 - 7.44 (4H, m, H-10 - H-
13). 
13 C NIIVIR (63 MHz, CD30D), 8 (ppm): 38.3 (C9), 49.2 (C 1), 61.4 (C6), 65.3 (C7), 
71.2 (C8), 77.0 (C4), 79.3 (0), 82.1 (C5), 83.5 (C2), 123.8 - 127.0 (4C, C 1 - 
C13), 140.2— 141.7 (2C, C14, C15). 
ESI: [M+H]=296.1. 





7 	15 50- 	* N 10 HO





From (1S,2R)-1-amino-2-indanol, using ZMD Method 2, yield = 12 mg, 6 %. 
1 H NMR (250 MHz, CD3013), ö (ppm): 2.90 - 3.17 (4H, m, 2 x H-i, 2 x H-9),3.61 - 
3.74 (2H, m, 2 x H-6), 3.88 —4.06 (4H, m, H-2 - H-5), 4.10 (1H, d, J7,8 = 5.0 Hz, H-
7), 4.56 (iH, dt, J7,8 = J8,9,yn = 5.0 Hz, J8,9 anti = 3.5 Hz, H-8), 7.15 - 7.40 (H, m, H-
10—H-13). 
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From 1,2,3 ,4-tetrahydro- 1 -naphthylamine hydrochloride, using ZMD Method 2a, 
yield =24 mg, 12 %. 
'H NMR (250 MHz, CD3OD), 6 (ppm): 1.68 - 1.94 (4H, m, 2 x H-8,2 x H-9),2.67 - 
3.03 (4H, m, 2 x H- 1, 2 x H- 10), 3.55 - 3.75 (2H, m, 2 x H-6), 3.79 - 4.05 (5H, m, 
H-2, H-3, H-4, H-5, H-7), 7.08 - 7.36 (4H, m, H-i 1 - H-14). 
13 C NMIR (63 MHz, CD3OD), 6 (ppm): 18.5 (C9), 27.0 (C8), 28.4 (C 10), 48.5 (C 1), 
55.0 (C7), 61.5 (C6), 77.0 (C4), 79.5 (0), 82.5 (C5), 84.0 (C2), 125.0 - 128.3 (4C, 
CI  - C14),136.0 — 137.5 (2C, C15, C16). 
ES1: [M + H] = 294.3. 
6.3.1.10 	2, 5-Anhydro-1-deoxy-1-(cyclobutylamino)-D-mannitOl, 58. 
8 
6 	Q 	1 









'H NMR (250 MHz, CD3OD), 6 (ppm): 1.82 —2.32 (6H, m, 2 x H-8,2 x H-9,2 x H-
10), 3.07 - 3.10 (2H, m, 2 x H-i), 3.66 - 4.03 (7H, m, H-2, H-3, H-4, H-5, 2 x H-6, 
H-7) 
13 C NMR (63 MHz, CD30D), 6 (ppm): 13.6 (C9), 25.8 - 26.3 (2C, C8, dO), 46.5 
(C 1), 51.4 (C7), 61.2 (C6), 76.9 (C4), 78.7 (0), 79.1 (C5), 84.4 (C2). 
IESI: [M+H] + = 218.1. 
6.3.1.11 	2, 5-Anhydro-1-deoxy-1-(hexylamino)-D-mannitol, 59. 
n52  1 	7 	9 	11 HO 
H 	8 	10 	12 
OH 
From hexylamine, using ZMD Method 2, yield = 12 mg, 6 %. 
'H NMR (250 MHz, CD 3OD), 6 (ppm): 0.87 (3H, t, J11,12 = 6.5 Hz, 3 x H-12),1.24 — 
1.64 (8H, m, H-8 - H-1 1), 2.60-2.89 (4H, m, 2 X H-i, 2 X H-7), 3.60 (1H, dd, Jgern 
= 11.5 Hz, J5,6a = 5.5 Hz, H-6a), 3.69 (1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 
3.78 - 3.96 (4H, m, H-2, H-3, H-4, H-5). 















From (S)-(—)-1-(4-methoxyphenyl)-ethylamine, using ZMD Method 2, yield = . 8 mg, 
4 %. 
1 H NMR (250 MHz, CD 30D), 6 (ppm): 1.36 (3H, d, J7,14 = 6.5 Hz, 3 x H-14), 2.59 - 
2.63 (2H, m, 2 x H-i), 3.57 - 3.93 (9H, m, H-2, H-3, H-4, H-5, 2 x H-6, -0CH3), 
4.06 (1H, q, J7 ,14 = 6.5 Hz, H-7), 6.84 - 6.92 (2H, m, H- 10, H- 12), 7.24 - 7.32 (2H, 
m, H-9, H-13). 
13C NMR (63 MHz, CD30D), 6 (ppm): 21.3 (C14), 48.7 (Cl), 54.0 (-0CH3), 57.1 
(C7), 61.2 (C6), 76.7 (C4), 79.2 (0), 81.3 (C5), 83.3 (C2), 113.1 (2C, CIO, C12), 
127.2 (2C, C9, C13),134.8 (C8),158.3 (CI I). 





6.3.1.13 	2, 5Anhydro1-deoxy-1-(R-1-(4-methoXyphenY!)et1lYlaminO)-D 
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From (R)-(+)-1-(4-methoxyphenyl)-ethylamine using ZMD method 2, yield = 35 mg, 
18%. 
'H NMR (250 IVflIz, CD 30D), 5 (ppm): 1.41 (3H, d, J7,14 = 6.5 Hz, 3 x H-14), 2.56 
(1H, dd, Jgem = 12.5 Hz, Jia,2 = 8.0 Hz, H-la), 2.73 (1H, dd, Jgem = 12.5 Hz, Jlb,2 = 
3.0 Hz, H-lb), 3.65 - 4.05 (10H, m, H-2, H-3, H-4, H-5, 2 x -6, H-7, -0CH3), 6.98 
(2H, d, f9,10 = J12,13 = 9.0 Hz, H-b, H-12), 7.32 (2H, d, J9,io = J12 , 13 = 9.0 Hz, H-9, 
H-13). 
13 C NMR (63 MHz, CD3 0D), ö (ppm): 22.0 (C14), 49.5 (Cl), 54.5 (-OCH3), 56.7 
(C7), 61.3 (C6), 76.8 (C4), 79.3 (0), 81.5 (C5), 83.4 (C2), 113.4 (2C, dO, C12), 
127.4 (C9, C13), 135.9 (C8), 158.0 (C 11). 
ESI: {M + Hf = 298.1. 
HRMS FAB (+ve) found m/z = 298.16550 [M + H]+, C 15H24N05 requires 
298. 16545. 



















From (S)-(4-fluorophenyl)-ethylamine, using ZMD Method 2, yield = 23 mg, 13 %. 
'H NMR (250 MHz, CD3OD), 6 (ppm): 1.36 (3H, d, J7 ,14 = 6.5 Hz, 3 x H-14), 2.61 
(2H, d, JIa, 2 = Jlb,2 = 5.5 Hz, 2 x H-i), 3.56 - 3.93 (7H, m, H-2, H-3, H-4, H-5, 2 x 
H-6, H-7), 7.01 —7.10 (2H, m, H- 10, H- 12), 7.34-7.42 (2H, m, H-9, H-13). 
' 3 C NMR (63 MHz, CD 30D), 6 (ppm): 21.9 (C14), 49.1 (C 1), 57.1 (C7), 61.5 (C6), 
77.0 (C4), 79.5 (C3), 81.9 (C5), 83.6 (C2), 114.4 (2C, C I O, C12), 127.7 (2C, C9, 
C13), 139.5 (C8), 159.5 (Cli). 
ES1: [M+H]286.1. 
6.3.1.15 	2, 5-Anhydro-1-deoxy-1-(R-(4-fluorophenyl)ethylamino)-D- 
mannitol, 63. 
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'H NMR (250 MHz, CD3OD), 6 (ppm): 1.38 (3H, d, J7,14 6.5 Hz, 3 x H-14), 2.53 
(1H, dd, Jgem = 12.5 Hz, Jia,2 = 7.5 Hz, H-la), 2.71 (1H, dd, Jgem = 12.5 Hz, JIb,2 = 
3.5 Hz, H-i), 3.63 - 3.96 (711, m, H-2, H-3, H-4, H-5, 2 x H-6, H-7), 7.03 - 7.12 
(211, m, H-10, H-12), 7.34 - 7.44 (211, m, H-9, H-13). 
13C NMR (63 MHz, CD 30D), 6 (ppm): 22.0 (C14), 48.6 (Cl), 56.7 (C7), 61.6 (C6), 
77.1 (C4), 79.4 (0), 81.9 (5), 84.0 (C2), 114.5 (2C, dO, C12), 127.8 (2C, C9, C13), 
139.9 (C 11), 159.9 (C 11). 
ESI: [M + H] = 286.2. 
6.3.1.16 	2, 5Anhydro-1-deoxy-1-(S-(4-chlorophenyl)e1IlylamiflO)-D- 
mannitol, 64. 
14 






From (5)-(4-chlorophoenyl)-ethylamine, using ZMD Method 2a, yield = 18 mg, 9 %. 
'H NIMIR (250 MHz, CD30D), 6 (ppm): 1.37 (311, d, J7,14 = 6.5 Hz, 3 x H-14),2.61 
(2H, d, Jla,2 = JIb,2 = 5.5 Hz, 2 x H-i), 3.57 - 3.94 (7H, m, H-2, H-3, H-4, H-5, 2 x 
H-6, H-7), 7.36 (4H, s, H-9, H- 10, H-12, H-13). 
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From (R)-(4-chlorophoenyl)-ethylamine, using ZMD Method 2a, yield = 15 mg, 8 %. 
1 H NIvIIR (250 MHz, CD3OD), 8 (ppm): 1.37 (3H, d, J7,14 = 6.5 Hz, 3 x H-14), 2.51 
(1H, dd, Jgem = 12.5 Hz, .Jl a,2 = 8.0 Hz, H-la), 2.70 (111, dd, Jgem = 12.5 Hz, .'lb,2 = 
3.0 Hz, H-lb), 3.59 - 3.97 (7H, m, H-2, H-3, H-4, H-5, 2 x H-6, H-7), 7.36 (4H, s, 
H-9, H-10, H-12, H-13). 
FS1: [M + HI = 302.2 ["Cl], 304.2 [ 37C1]. 
6.3.1.18 	2,5Anhydro-1-deoxy-1-(cyclohexylamiflO)-D-mannht0l, 66. 
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From cyclohexylamine, using ZMD Method 2, yield =23 mg, 12 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 1.11 - 1.43 (10H, m, 5 x -CH2- 
cyclohexane), 2.61 - 2.72 (1H, m, H-7), 2.88 (1H, dd, Jgem = 12.5 Hz, Jia,2 = 8.0 Hz, 





Hz, J5,6a = 5.5 Hz, H-6a), 3.72 (1H, Jgem = 12.0 Hz, J5,6b = 3.5 Hz, H-6b), 3.82 - 4.00 
(4H, m, H-2, H-3, H-4, H-5). 
' 3C NIvIR (63 MHz, CD30D), ö (ppm): 24.0 (2C, C9, Cli), 25.0 (CIO), 30.9 (2C, 
C8, C12), 47.4 (C 1), 56.3 (C7), 61.5 (C6), 77.0 (C4), 79.4 (0), 81.2 (C5), 84.1 (C2). 
ES1: [M + H] = 246.3. 
6.3.1.19 	2,5Anhydro1-deoxy-1-(S-1-(1-naphthyl)ethylamiflO)-D-maflflitOl, 
67. 
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From (S)-(—)-1-(1-naphthyl)-ethylamine, using ZMD Method 2b, yield = 35 mg, 18 
%. 
1 H NIMR (250 MHz, CD3OD), 8 (ppm): 1.52 (3H,d, J7,18 = 6.5 Hz, 3 x H-18), 2.71 
(1H, dd, .Jgem = 12.5 Hz, Jia,2 = 7.0 Hz, H-la), 2.81 (1H, dd, Jgem = 12.5 Hz, Jlb,2 = 
4.0 Hz, H1b), 3.61 (1H, d, Jgem = 11.5 Hz, J5 , 66 = 5.5 Hz, H-6a), 3.72 (1H, dd, Jgem = 
11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.76-3.99 (4H, m, H-2, H-3, H-4, H-5), 4.79 (1H, q, 
= 6.67 Hz, H-7), 7.46 - 8.22 (7H, m, Ar-H). 
NIvIIR (63 MHz, CD30D), 8 (ppm): 21.4 (C18), 49.1 (C 1), 52.4 (C7), 61.5 (C6), 
77.0 (C4), 79.4 (C3), 82.0 (C5), 83.7 (C2), 121.9— 128.1 (7C, Ar-CH), 129.0— 131.5 
(2C, C16, C17), 134.0 (C8). 
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From (R)-(+)-1-(1-naphthyl)-ethylamine, using ZMD Method 2c, yield = 26 mg, 13 
%. 
'H NIVIR (250 MHz, CD3OD), 8 (ppm): 1.53 (3H, d, f7 ,18 = 6.5 Hz, 3 x H-18), 2.71 
(1H, dd, Jgem = 12.5 Hz, Jla,2 = 7.5 Hz, H-la), 2.84 (1H, dd, Jgem = 12.5 Hz, .Jlb,2 = 
3.5 Hz, H1b), 3.63 (1H, dd, Jgem = 12.0 Hz, J5,6a = 5.5 Hz, H-6a), 3.71 (1H, dd, Jgem 
= 12.0 Hz, J5,6b = 3.5 Hz, H-6b), 3.77 - 3.99 (4H, m, H-2, H-3, H-4, H-5), 4.79 (1H, 
q, f7,18 = 6.70 Hz, H-7), 7.48 - 8.19 (7H, m, Ar-H). 
ES1: [M+H] 	318.1. 
6.3.1.21 	2, 5Anhydro1deoxy1-N-(6-aminO-2-methY12hYdr0XYhePtYl)D 
mannitol, 69. 
14 	 OH 
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'H NMIR (250 MHz, CD 3OD), ö (ppm): 1.13 (3H, d, J7,14 = 6.5 Hz, 3 x H-14),1.18 
(6H, s, 3 x H-12,3 x H-13),1.23 - 1.50 (6H, m, 2 x H-8,2 x H-9,2 x H-b), 2.73 - 
2.98 (3H, m, 2 X H- 1, H-7), 3.63 (1H, dd, Jgem = 11.5 Hz, J5,6a 5.5 Hz, H-6a), 3.70 
(1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.80-3.96 (4H, m, H-2, H-3, H-4, H-
5) 
ESt3 : [M + H] = 292.3. 
6.3.1.22 	2,5-Anhydro-1-deoxy-1-(cycloheptylamino)-D-maflflitOl, 70. 
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From cycloheptylamine, using ZMD Method 2, yield =66 mg, 33 %. 
[aID = 6.70 (c 1.7, MeOH). 
'H NMR (250 MHz, CD30D), 8 (ppm): 1.27 - 1.91 (12H, m, 6 x —Cl 2-
cycloheptane), 2.65 - 2.84 (3H, m, 2 x H-i, H-7), 3.60 (1H, dd, Jgem = 12.0 Hz, .15,6a 
= 5.5 Hz, H-6a), 3.68 (1H, dd, Jgem = 12.0 Hz, J5,6b = 3.5 Hz, H-6b), 3.78 - 3.93 (4H, 
m, H-2, H-3, H-4, H-5). 
' 3C NMR (63 MHz, CD 30D), 6 (ppm): 23.6 (2C, C9, C12), 27.3 (2C, ClO, Cii), 
33.0 (2C, C8, C13), 48.4 (Cl), 58.6 (C7), 61.5 (C6), 77.0 (C4), 79.5 (0), 81.6 (C2), 
84.1 (CS). 




HRMS FAB (+ve) found mlz = 260.18594 [M + H], C 13H26N04 requires 
260.18618. 
Decomposes> 225 T. 
6.3.1.23 	2, 5Anhydro1deoxy-1-(cyclooctylamiflO)-D-maflflit0l, 71. 
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From cyclooctylamine, using ZMD Method 2a, yield = 54 mg, 27 %. 
'H NIMIR (250 MHz, CD 30D), ö (jpm): 1.51 - 1.82 (14H, m, 7 x —CH2- cylooctane), 
2.73 - 2.85 (2H, m, 1 x H-i, H-7), 2.91 (1H, dd, Jgem = 12.5 Hz, Jlb,2 = 3.5 Hz, H-
la), 3.64 (1H, dd, Jgem = 11.5 Hz, J5,6a = 5.5 Hz, H-6a), 3.72 (1H, dd, Jgem = 11.5 Hz, 
.'5,6b = 3.5 Hz, H-6b), 3.82 - 3.98 (4H, m, H-2, H-3, H-4, H-5). 
13C NMR (63 MHz, CD30D), 8 (ppm): 23.4 (2C, C9, C13), 25.0 (C 11), 26.1 (2C, 
ClO, C12), 31.0 (2C, C8, C14), 48.4 (C 1), 57.4 (C7), 61.5 (C6), 77.0 (C4), 79.5 (0), 
81.7 (C5),84.1 (C2). 















From (5)-3-methyl-2-butylamine, using ZMD Method 2, yield = 31 mg, 16 %. 
1 H NMR (250 MHz, CD 3 0D), 6 (ppm): 0.89 (3H, d, J8,9 = 7.0 Hz, 3 x H-9), 0.94 
(3H, d, J8j0 = 7.0 Hz, 3 x H-b), 1.74— 1.90 (1H, m, H-8), 2.52-2.63 (1H, m, H-7), 
2.75 - 2.88 (2H, m, 2 X H-i), 3.63 (1H, dd, Jgem = 11.5 Hz, .15,6a = 5.5 Hz, H-6a), 3.70 
(1H, dd, Jgem = 11.5 Hz, J5,6b = 4.0 Hz, H-6a), 3.82-3.99 (4H, m, H-2, H-3, H-4, H-
5). 
13 C NMR (63 MHz, CD3OD), 6 (ppm): 13.1 (C9), 15.3 (C  1 0), 18.0 (C 11), 31.0 (C8), 
48.2 (C 1), 57.6 (C7), 61.5 (C6), 77.1 (C4), 79.6 (0), 81.8 (C5), 84.4 (C2). 
ESi: [M + H]+ = 233.9. 
6.3.1.25 	2, 5Anhydro-1-deoxy-1-(R-3-methyl-2-butylaminO)-D-maflflitOl, 73. 
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From (R)-3-methyl-2-butylamine, using ZMD Method 2a, yield = 37 mg, 19 %. 
IM 
Chapter 6 	 Experimental 
'H NMR (250 MHz, CD301)), 8 (ppm): 0.87 (3H, d, J8,9 = 7.0 Hz, 3 x H-9), 0.92 
(3H, d, J8,10 = 7.0 Hz, 3 x H-b), 1.71 (1H, m, H-8), 2.50 - 2.60 (1H, m, H-7), 2.70 
(1H, dd, Jgem = 12.5 Hz, JIa,2 = 8.5 Hz, 1 X H-i), 2.91 (iH, dd, Jgem = 12.5 Hz, Jlb,2 = 
3.0 Hz, ix H-i), 3.64 (iH, dd, Jg = 12.0 Hz, J5,6a = 5.5 Hz, 1 x H-6), 3.71 (iH, dd, 
Jgem = 12.0 Hz, J5,6b = 3.5 Hz, 1 x H-6), 3.82 - 3.98 (4H, m, H-2, H-3, H-4, H-5). 
"C NMZR (63 MHz, CD3OD), ö (ppm): 13.2 (C9), 15.4 (C 10), 17.9 (C 11), 30.8 (C8), 
48.7 (Cl), 58.2 (C7), 61.2 (C6), 76.7 (C4), 79.3 (0), 81.6 (CS), 83.6 (C2). 
ES11 : [M + H] = 234.2. 
6.3.1.26 	2,5Anhydro-1-deoxy-1-N-(2-amino-5-methylheXYl)-D-maflflitOl, 74. 
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From 2-amino-5-methylhexane, using ZMD Method 2a, yield =49 mg, 25 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 0.93 (6H, d, Jio,ii =Jio,, = 6.5 Hz, 3 x H-1 1, 
3 x H- 12), 1.09 (3H, d, J7,13 = 6.5 Hz, 3 x H- 13), 1.19 - 1.64 (5H, m, 2 x H-8, 2 x H-
9, H-b), 2.59-2.94 (3H, m, 2 x H-i, H-7), 3.63 (1H, dd, Jgem = 11.5 Hz, .15,6a = 5.5 
Hz, H-6a), 3.71 (1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.81 —3.96 (4H, m, H-
2, H-3, H-4, H-5). 
' 3 C NMR (63 MHz, CD 301)), 8 (ppm): 17.8 (C13), 21.0 (Cli), 21.2 (C12), 27.5 




82.0 (C5), 84.0 (C2). 
ESI: [M + H] = 262.3. 
6.3.1.27 	2,5Anhydro1deoxy1-N-(2-amino-6-tflethYlhePtYl)-D-maflnit0l, 
75. 
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From (±)-L-amino-6-methylheptane, using ZMD Method 2b, yield =41 mg, 21 %. 
1 H NMR (250 MHz, CD30D), 8 (ppm): 0.90 (6H, d, J11,12 = J1 1,13 = 6.5 Hz, 3 x H-12, 
3 x H-13), 1.10 (3H, d, J7,14 = 6.5 Hz, 3 x H-14), 1.16— 1.64 (7H, m, 2 x H-8, 2 x H-
9, 2 x H-b, H-1 1), 2.68-2.95 (3H, m, 2 x H-i, H-7), 3.62 (1H, dd, Jgem = 11.5 Hz, 
= 5.5 Hz, H-6a), 3.71 (1H, d, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.80-3.96 
(4H, m, H-2, H-3, H-4, H-5). 
NMR (63 MHz, CD 30D), 8 (ppm): 17.4 (C9), 21.0 - 22.9 (3C, Ci2, C13, C14), 
27.2 (CI 1), 35.6 (CIO), 38.4 (C8), 48.6 (CI), 52.9 (C7), 61.5 (C6), 77.0 (C4), 79.5 
(C3), 81.8 (C5), 84.0 (C2). 












From (R)-sec-butylamine, using LIVID Method 2a, yield = 32 mg, 16 %. 
'H NMR (250 MHz, CD3OD), 8 (ppm): 1.00 (3H, t, J8,9 = 7.5 Hz, 3 x H-9),1.26 (311, 
d, J7,10 = 6.5 Hz, 3 x H-b), 1.41 - 1.85 (2H, m, 2 x H-8),2.97 - 3.25 (3H, m, 2 x H-
1, H-7), 3.66 (1H, dd, Jgem = 12.0 Hz, J5,6a = 5.5 Hz, H-6a), 3.74 (1H, dd, Jgem = 12.0 
Hz, J5,6b = 3.5 Hz, H-6b), 3.91 —4.16 (4H, m, H-2, H-3, H-4, H-5). 
' 3 C NIMR (63 MHz, CD3013), ö (ppm): 8.1 (C9), 14.7 (C 10), 25.2 (C8), 46.0 (C 1), 
54.9 (C7), 60.7 (C6), 76.1 (C4), 78.3 (0), 78.8 (C5), 83.0 (C2). 












From endo-2-aminonorbomane hydrochloride, using ZMD Method 2a, yield = 23 





'H NIvIIR (250 MHz, CD30D), 6 (ppm): 1.32 - 2.48 (811, m, 4 x —CH 2- norbornane), 
2.71 —2.92 (2H, m, 2 x H- 1), 3.10— 3.16 (1H, m, H-7), 3.67-3.72 (2H, m, 2 x H-6), 
3.85 - 3.99 (4H, m, H-2, H-3, H-4, H-5). 
ES1: [M + H] = 258.2. 
6.3.1.30 	2, 5Anhydro-1-deoxy-1-N-(exo-2-aminonorbornyl)-D-tflaflflitOl, 78. 
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From exo-2-aminonorbornane, using ZMD Method 2a, yield = 30 mg, 15 %. 
'H NIVIR (250 MHz, CD3 OD), 6 (ppm): 1.15 - 1.75 (8H, m, 4 x —CH 2- norbornane), 
2.68 - 2.95 (3H, m, 2 X HA, H-7), 3.62 (1H, dd, Jgem = 11.5 Hz, J5,6a = 5.5, H-6a), 
3.68 (1H, dd, Jgem = 11.5 Hz, J5,6b = 3.5 Hz, H-6b), 3.76 - 3.97 (4H, m, H-2, H-3, H-
4, H-5). 
13 C NMR (63 MHz, CD 30D), 6 (ppm): 26.1 (Cli), 27.3 (CIO), 33.7 (C9), 35.1 
(C13), 38.1 (C8), 39.4 (C12), 48.7 (Cl), 61.2 (C7), 61.5 (C6), 77.0 (C4), 79.6 (0), 
81.6 (C5), 84.4 (C2). 


















From 1-methyl-3-phenylpropylamine, using ZMD Method 2a, yield = 31 mg, 16 %. 
1 H NMR (250 MHz, CD 30D), ö (ppm): 1.12 (3H, dd, J7R,14 = 6.0 Hz, J7S,14 = 2.5 Hz, 
3 x H-14),1.51 - 1.92 (2H, m, 2 x H-8), 2.53 - 2.90 (5H, m, 2 x H-i, H-7, 2 x H-9), 
3.57 - 3.94 (6H, m, H-2, H-3, H-4, H-5, 2 x H-6), 7.09 - 7.27 (5H, m, Ar-H). 
' 3 C NMR (63 MHz, CD 3OD), 6 (ppm): 17.7 (C16), 31.4 (C8), 37.6 (C9), 48.5 (C 1), 
52.2 (C7), 61.5 (C6), 77.0 (C4), 79.5 (0), 82.0 (C5), 83.9 (C2), 125.0 (C13), 127.5 
(4C, Cii, C12, C14, C15), 141.4 (C 10). 
ESI: [M + Hf = 296.4. 
6.3.1.32 	2,5Anhydro-1-deoxy-1-N-(R-2-amino-4-methyl-1-hYdrOXYbUtYl)-D- 
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1 H NMR (250 MHz, CD30D), 8 (ppm): 0.95 (6H, d, J9,10 = J9 , 1 I = 6.5 Hz, 3 x H-10, 
3 x H-1 1), 1.23— 1.42 (2H, m, 2 x H-8),1.61 - 1.77 (iH, m, H-9), 2.70-2.82 (2H, 
m, 1 X Wi, H-7), 2.94 (1H, dd, Jgem = 12.0 Hz, .Jlb,2 = 3.5 Hz, H-lb), 3.33 - 3.74 
(4H, m, 2 x H-6,2 x H-12),3.81 - 3.99 (4H, m, H-2, H-3, H-4, H-5). 
ES1: [M + H] = 264.1. 
6.3.1.33 	2, 5-Anhydro-1-deoxy-1-N-(S-2-amino-4-methyl-1-hydroxybutyl)-D- 
mannitol, 81. 
HO 	
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From (S)-leucinol, using ZMD Method 2a, yield = 29 mg, 15 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 0.95 (6H, d, J9,10 = J9,11 = 6.5 Hz, 3 x H-10, 
3 x H-i 1), 1.30 (2H, t, J7 ,8 = J8,9 = 7.0 Hz, 2 x H-8),1.60 - 1.77 (1H, m, H-9), 2.68 - 
2.83 (211, m, 1 X H1, H-7), 2.92 (iH, dd, Jgem = 12.5 Hz, J,b,2 = 3.5 Hz, H-lb), 3.38 
- 3.72 (4H, m, 2 x H-6, 2 x H- 12), 3.81 - 3.96 (4H, m, H-2, H-3, H-4, H-5). 
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From (5)-methoxy-2-propylamine, using ZMD Method 2a, yield = 39 mg, 20 %. 
1 H NMR (250 MHz, CD 3 0D), 6 (ppm): 1.03 (3H, d, f7 , 1 0 = 6.55 Hz, 3 x H-b), 2.82 
- 3.00 (3H, m, 2 x H-i, H-7), 3.21 - 3.27 (5H, m, 2 x H-8, 3 x H-9), 3.56 (iH, dd, 
Jgem = 11.5 Hz, J5,6a = 5.5 Hz, H-6a), 3.64 (1H, dd, Jgem = 11.5 Hz, J5,6b = 3.65 Hz, H-
6b), 3.76 - 3.92 (4H, m, H-2, H-3, H-4, H-5). 




5 	2 	 OH 
HO 
6 0 1".' N:C7 
HO 	OH 
From (±)-2-amino-1-butanol, using ZMD Method 2a, yield = 26 mg, 13 %. 
'H NMR (250 MHz, CD3OD), 6 (ppm): 0.92 (3H, t, J9,10 = 7.5 Hz, 3 x H-b), 1.35 - 
1.64 (2H, m, 2 x H-9), 2.55 - 2.05 (3H, m, 2 x H-i, H-7), 3.38 - 3.98 (8H, m, H-2, 





ESI: [M + H] = 236.2. 
	
6.3.1.36 	2, 5-Anhydro-1-deoxy-1-(1-indanamino)-D-mannitol, 84. 
8 	9 
6 
HO* 	 N H 	14 
~O2 
 
HO 	OH 13 	
11 
12 
From 1-aminoindan, using ZMD Method 2a, yield = 19 mg, 10 %. 
'H NMR (250 MHz, CD 30D), 8 (ppm): 1.85 - 1.99 (1H, m, 1 x H-8), 2.32 - 2.46 
(1H, m, 1 x H-8), 2.77 - 3.10 (4H, m, 2 x H-i, 2 x H-9), 3.62 (1H, dd, Jgem = 11.5 
Hz, J5,6a = 6.0 Hz, H-6a), 3.70 (iH, dd, Jgem = 11.5 Hz, J5,6b  3.5 Hz, H-6b), 3.81 - 
4.00 (4H, m, H-2, H-3, H-4, H-5), 4.33 (1 H, m, H-7), 7.15 —7.42 (4H, m, 4 x Ar-H). 
ES1: [M + H] = 280.1. 
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From 3-amino-3-phenyl-l-propanol, using ZMD Method 2a, yield = 35 mg, 18 %. 





(2H, m, 2 x H- 1), 3.38 - 3.93 (9H, m, H-2, H-3, H-4, H-5, 2 x H-6, H-7, 2 x H-9), 
7.21 - 7.33 (5H, m, 5 x Ar-H). 
' 3C NIIvIIR (63 MHz, CD30D), 8 (ppm): 39.1 (C8), 48.5 (C 1), 58.7 (C9), 60.0 (C7), 
61.6 (C6), 77.1 (C4), 58.7 (0), 82.0 (C5), 83.5 (C2), 125.7 (C13), 126.6 - 127.7 
(4C, Cli, C12, C14, C15), 142.2 (C 10). 
ESf1 : [M+H] ::= 298.1. 
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From L-(—)-2-amino-3-phenyl-1-propanol, using ZMD Method 2a, yield = 17 mg, 9 
%. 
'H NMR (250 MHz, CD3 OD), 6 (ppm): 2.65 - 2.94 (5H, m, 2 x H-i, H-7, 2 x H-9), 
3.37 - 3.96 (8H, m, H-2, H-3, H-4, H-5, 2 x H-6, 2 x 11-8), 7.15 - 7.32 (5H, m, 5 x 
Ar-H). 





6.4 	Library 3: Design, Synthesis and Evaluation. 
6.4.1 Synthesis 	of 	2,5-anhydro-1-deoxy-1 -(3,4-dichlorobenzylamino)-D- 
mannitol 37 using solid phase reagents and scavenger resins. 
9 	CI 
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3,4-Dichlorobenzylamine (0.44 ml, 1.5 eq.), was added to a solution of aldehyde 22 
(0.36 g, 1 eq.) in methanol (10 ml) in a solid phase reaction cartridge. The cartridge 
was sealed and placed on a shaker for 2 hours. Borohydride resin (1.17 g, 2 eq., 3.8 
mmol/g) was added and the cartridge was shaken for a further 24 hours. 4-
Benzoxybenzaldehyde polystyrene (0.76 g, 1.1 eq., 3.2 mmol/g) in dichioromethane 
(4 ml) was added before leaving the reaction to shake for a further 72 hours. After 
ESMS mass spectroscopy (positive) confirmed no more 3,4-dichlorobenzylamine to 
be present in solution, the resin was removed by filtration and was washed with 
methanol (3 x 5 ml) and dichioromethane (5 ml). All filtrates were combined and the 
solvent removed under reduced pressure to yield the title compound as a white solid 




6.4.2 Synthesis of 2,5-anhydro-1-deoxy-1-(cycloheptylamino)-D-mannitol 70, 
using solid phase reagents and scavenger resins. 
9 
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Cycloheptylamine (0.47 ml, 1.5 eq.), was added to a solution of aldehyde 22 (0.40 g, 
1 eq.) in methanol (16 ml) in a solid phase reaction cartridge. The cartridge was 
sealed and placed on a shaker for 2 hours. Borohydride resin (1.30 g, 2 eq., 3.8 
mmollg) was added and the cartridge was shaken for a further 24 hours. 4-
Benzoxybenzaldehyde polystyrene (0.78 g, 1.1 eq., 3.2 mmollg) in dichioromethane 
(4 ml) was added before leaving the reaction to shake for a further 72 hours. After 
ESMS (positive) confirmed no more 3,4-dichlorobenzylamine to be present in 
solution, the resin was removed by filtration and was washed with methanol (3 x 5 
ml) and dichloromethane (5 ml). All filtrates were combined and the solvent 
removed under reduced pressure to yield the title compound as a white solid (0.61 g, 
94%). 
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6.4.3 Parallel synthesis of amines 57, 59, 60, 76, 77, 78 and 87 using solid phase 
reagents and scavenger resins. 
To separate solutions of aldehyde 22 (50 mg, 1 eq.) in methanol (2 ml) contained in 
solid phase reaction cartridges, were added different amines (1.5 eq.). The cartridges 
were shaken for 2 hours whereupon borohydride resin (0.16 g, 2 eq., 3.8 mmol/g) 
was added. The reactions were shaken for a further 24 hours before addition of 4-
benzoxybenzaldehyde polystyrene (0.11 g, 1.1 eq., 3.2 mmol/g) in dichioromethane 
(1.5 ml). The reactions were again shaken for 72 hours before removal of the resin by 
filtration. The resins were washed with methanol (3 x 2 ml) and dichioromethane (2 
ml) and the filtrates for each reaction were combined. The solvent was removed 
under reduced pressure to yield the desired compounds as white solids. 





















6.4.3.2 	2,5-A nhydro-1-deoxy-1-(hexylamino)-D-mannitol, 59. 
6 	 1 	 7 	9 	11 
HO 
H 	8 	10 	12 
OH 
From hexylamine, yield = 73 mg, 95 %. 
6.4.3.3 	2, 5-Anhydro-1-deoxy-1-(S-1-(4-methoxyphenyl)elhylamino)-D- 
mannitol, 60. 
14 
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From (5)-(-)-1-(4-methoxyphenyl)-ethylamine, yield = 30 mg, 33 %. 
6.4.3.4 	2, 5-Anhydro-1-deoxy-1-(R-sec-butylamino)-D-mannitol, 76. 
HO 	 , 89 
OH 















From endo-2-aminonorbomane hydrochloride, yield =70 mg, 87 %. 
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From exo-2-aminonorbornane, yield = 77 mg, 96 %. 






T- 13 1 	11 F 
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2 
From (±)-(4fluorophenyl)-ethylamine, yield = 71 mg, 80 %. 
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'H NIvIIR (250 MHz, CD 30D), ö (ppm): 1.42 (3H, dd, J7R,14 = 6.5 Hz, J7S,14 = 1.5 Hz, 
3 x H-14), 2.54 - 2.79 (3H, m, 2 x H- 1, H-7), 3.61 - 3.99 (6H, m, H-2, H-3, H-4, H-
5, 2 x H-6), 7.08 (2H, m, H-10, H- 12), 7.36 - 7.43 (2H, m, H-9, H-13). 
13 C NTVIIR (63 MIHz, CD30D), ö (ppm): 21.5 (C14), 48.5 (Cl), 54.9 (-OCH3), 57.1 
(C7), 62.2 (C6), 76.6 (C4), 79.1 (0), 80.9 (C5), 83.0 (C2), 114.6 (2C, C I O, C12), 
128.3 (2C, C9, C13), 138.0 (C8), 157.5 (CI 1). 
ES[': [M + H] = 286.0. 
6.4.4 Synthesis of N-BOC-2,5-anhydro-1-deoxy-1-(3,4-dichlorobeflZylamiflO)-
D-mannitol (BOC protection of amine 37), 88. 
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To a stirring mixture of amine 37 (0.96 g, 1 eq.) in acetonitrile (10 ml), water was 
added dropwise until 37 had dissolved. Di-tert-butyl dicarbonate (0.64 g, 1 eq.) in 
dioxane (2 ml) was added and the reaction was cooled to 0 °C. 4-
Dimethylaminopyridine (0.091 g, 0.25 eq.) was added then and the reaction was 
stirred for 2 hours. After addition of water (10 ml), the reaction was extracted in to 
ethyl acetate (3 x 10 ml). The organic layer was washed with sat. NaHCO 3 (2 x 10 
ml) and the combined aqueous layers were neutralised with 2M HC1 before being re-





acidified to pH 1 before another re-extraction with ethyl acetate (3 x 10 ml). All 
organic layers were combined and washed with 5 % NaHSO4 (2 x 5 ml), dried over 
Na2 SO4, filtered and the solvent removed under reduced pressure to yield the title 
compound as a pale yellow oil (0.73 g, 58 %). 
Rf = 0.27 CH2C12 MeOH (9.5 0.5) 
FTIR thin film (cm'): 3398 br (OH), 2978 and 2932 (CH), 1672 (C=O). 
'H NMIR (250 MHz, CDC13), 6 (PPM):  1.34 (9H, s, 9 x H-16), 3.24 - 3.46 (2H, m, 2 
x H-i), 3.59 - 3.73 (2H, m, 2 x H-6), 3.75 - 4.14 (4H, m, H-2, H-3, H-4, H-5), 4.37 
(2H, s, 2 x H-7), 6.98 (1H, dd, J12j3 = 8.0 Hz, J9,13 = 2.0 Hz, H-13), 7.24 (1H, d, J9,13 
= 2.0 Hz, H-9), 7.32 (1H, d, f,2,13 = 8.0 Hz, H-12). 
13 C NIMR (63 MHz, CDCI3), 6 (ppm): 28.2 (3C, 3 x C16), 48.2 (C2), 51.0 (C7), 62.1 
(C6), 76.6 (C4), 78.5 (0), 81.2 (C15), 82.3 (C5), 82.9 (C2), 126.4 - 130.3 (3C, C9, 
C12, C13),131.0 — 132.3 (2C, CIO, CI 1), 132.3 (C8),156.6 (C14). 
ESi: [M + Na] = 444.2 [ 35Cl - 35C1]. 
6.4.5 Synthesis 	of N-BOC-2,5-anhydro-1-deoxy-1 -(cycloheptylamino)-D- 









To a stirring mixture of amine 70 (1.10 g, 1 eq.) in acetonitrile (15 ml), water was 
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added dropwise until 70 had dissolved. Di-tert-butyl dicarbonate (0.93 g, 1 eq.) in 
dioxane (3 ml) was added and the reaction was cooled to 0 °C. 4-
Dimethylaminopyridine (0.13 g, 0.25 eq.) was then added and the reaction was 
stirred for 2 hours. After addition of water (10 ml), the reaction was extracted in to 
ethyl acetate (3 x 10 ml). The organic layer was washed with sat. NaHCO3 (2 x 10 
ml) and the combined aqueous layers were neutralised with 2M HC1 before being re-
extracted with ethyl acetate (2 x 10 ml). The combined aqueous layers were then 
acidified to pH 1 before another re-extraction with ethyl acetate (3 x 10 ml). All 
organic layers were combined and washed with 5 % NaHSO4 (2 x 5 ml), dried over 
Na2SO4, filtered and the solvent removed under reduced pressure to yield the title 
compound as a pale yellow oil (0.88 g, 57 %). 
1 H NMR (250 MHz, CDC13), ö (PPM):  1.37 - 1.78 (21H, m, 6 x —CH2- cycloheptane, 
9 x H-16), 3.05 - 3.39 (2H, m, 2 x H-i), 3.64 - 4.32 (7H, m, H-2, H-3, H-4, H-5, 2 x 
H-6, H-7). 
' 3 C NMR (63 MHz, CDC13), 8 (ppm): 23.5 - 27.8 (4C, C9 - C12), 28.3 (3C, 3 x 
C16), 33.2 - 35.3 (2C, C8, C13), 47.2 (Cl), 60.9 (C7), 62.6 (C6), 77.0 (C4), 78.4 
(C3), 80.4 (C15), 83.4 (C5), 83.6 (C2), 156.9 (C14). 
ESf: [M+Na]=382.1. 
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6.4.6 Synthesis of N-BOC-2,5-anhydro-1 -deoxy-1 -(3,4-dichlorobenzylamino)-
D-mannonic acid (oxidation of 88), 90. 
H04(.t 1 1 





N-BOC protected amine 88 (0.13 g, 1 eq.) and TEMPO (3 mg, 6 mol %) were 
dissolved in CH 202 (1 ml). A solution of KBr (0.4 M), tetrabutylammonium chloride 
(0.3 M) in sat. NaHCO3 (1 ml) was added and the solution was cooled to 0 °C and 
stirred vigorously. A solution of sodium hypochlorite (1.3 M, 0.75 ml), sat. NaHCO3 
(0.33 ml) and brine (0.66 ml) were added dropwise over a period of 30 minutes. The 
reaction was then allowed to stir for a further 2 hours. The two layers were then 
separated and the organic phase was washed with water (3 x 10 ml). The aqueous 
layers were combined and acidified to pH 1 with HCl (2 M) before extracting with 
ethyl acetate (3 x 10 ml). The organic layer was then dried over Na 2 SO4, filtered and 
the solvent removed under reduced pressure to yield the title compound as an off 
white solid (97 mg, 72  
Decomposes> 150 °C 
FTIR thin film (cm'): 3417 br (OH), 2978 and 2932 (CH), 1667 (2 x C=O). 
'H NMR (250 MHz, CDC13), 6 (PPM):  1.47 (9H, s, 9 x H-16), 3.24 - 3.47 (211, m, 2 
x H-i), 3.84 - 4.40 (611, m, 11-2, H-3, H-4, 11-5, 2 x H-7), 5.93 (1H, s broad, acid 
OH), 6.98 (1H, d, J12,13 = 7.5 Hz, H-13), 7.24 (1H, s, H-9), 7.31 (1H, d, J1 2, 1 3 = 7.5 
Hz, H-12). 
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' 3 C NMR (63 MHz, CDC13), ö (ppm): 28.2 (3 x C16), 48.0 (Cl), 51.0 (C7), 78.0 
(C4), 79.7 (0), 81.5 (C15), 81.8 (C5), 83.9 (C2), 126.5 - 130.3 (3C, C9, C12, C13), 
131.0— 132.3 (2C, CIO, C12),138.3 (C8),156.4 (C14),174.1 (C6). 
ESF: [M - H] - = 434.1 [35C1 - 35C1]. 
6.4.7 Synthesis 	of N-BOC-2,5-anhydro-1 -deoxy-1 -(cycloheptylamino)-D- 
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N-BOC protected 89 (0.49 g, 1 eq.) and TEMPO (3 mg, 2 mol %) were dissolved in 
CH202 (5 ml). A solution of KBr (0.4 M), tetrabutylammonium chloride (0.3 M) in 
sat. NaHCO3 (5 ml) was added and the solution was cooled to 0 °C and stirred 
vigorously. A solution of sodium hypochiorite (1.3 M, 3.5 ml), sat. NaHCO3 (1.6 ml) 
and brine (3.3 ml) were added dropwise over a period of 45 minutes. The reaction 
was then allowed to warm up to room temperature and stir for 24 hours. The two 
layers were then separated and the organic phase was washed with water (8 x 10 ml). 
The aqueous layers were combined and acidified to pH 1 with HC1 (2 M) before 
extracting with ethyl acetate (8 x 10 ml). The organic layer was then dried over 
Na2 SO4, filtered and the solvent removed under reduced pressure to yield the title 
compound as a viscous yellow oil (0.19 g, 38 %). 
NMIR (250 MHz, CDC1 3), (PPM):  1.38 - 1.74 (21H, m, 6 x —CH 2- cycloheptane, 
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9 x H-16), 3.18 - 3.41 (2H, m, 2 x H- 1), 3.42 - 5.06 (5H, m, H-2, H-3, H-4, H-5, H-
7). 
Esr: [M - H] 372.1. 
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To a solution of 90 (0.1 g, 1 eq.) and benzylamine (25 p.1, 1 eq.) in CH 202 (i ml), 
was added BDCI (0.11 g, 1.3 eq.), HOBt (0.09 g, 1.5 eq.) and DIPEA (0.18 ml, 2.2 
eq.). The reaction was allowed to stir at room temperature for 20 hours before 
quenching with NaCl (2 M, 2 ml). The two layers were separated and the aqueous 
phase was extracted with CH202 (2 x 3 ml). All organic phases were combined and 
washed with water (2 x 3 ml) and HC1 (0.5 M, 2 x 3 ml) before being dried over 
Na2 SO4 . The mixture was then filtered and the solvent removed under reduced 
pressure to yield an orange glassy solid (90 mg, 74 %). This was purified by flash 
column chromatography on silica gel eluting with CH202 : MeOH (9.5 : 0.5). The 
solvent was removed to yield the title compound as a glassy yellow solid (26 mg, 22 
%). 
Rf= 0.26 CH202 : MeOH (9.5: 0.5) 
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FT1IR thin film (cm'): 3398 br (OH), 2926 (CH), 1666 (C=O BOC, amide I), 1539 
(C=O amide II). 
'H NMIR (250 MHz, CDC13), 8 (PPM): 1.34 (9H, s, 9 x H-16),3.31 - 3.45 (2H, m, 2 
x H-i), 3.91 - 4.09 (3H, m, H-2, H-3, H-4), 4.27 (1H, d, J4 ,5 = 4.0 Hz, H-5), 4.37 - 
4.53 (4H, m, 2 x H-7, 2 x H-17), 6.93 —6.98 (2H, m, H-9, H-13), 7.15 —7.31 (6H, H-
13, H- 19 —H-23). 
13 C NMR (63 MHz, CDC13), 8 (ppm): 28.2 (3C, 3 x C16), 42.8 (C17), 77.5 (C4), 
79.7 (C3),81.1 (C15), 83.2 (C2), 83.8 (C5), 126.3 -132.4 (bC, C9 - C13 and C19 - 
C23),137.3 - 138.5 (2C, C8, C18),156.1 (C14), 171.7 (C6). 
ESI: [M+H] = 525.1 [35C1- 35C1]. 
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The N-BOC protected sugar amino amide 92 (22 mg) was dissolved in CH 202 (2 ml) 
and trifluoro acetic acid (1 ml) was added. The reaction was stirred for 2 hours before 
quenching with water (1 ml). The two phases were separated and the aqueous phase 
was extracted with ethyl acetate (2 x 2 ml). The organic phases were combined, dried 
over Na2SO4, filtered and the solvent removed to yield a yellow oil. This was 





directed purification (ZMD Method 1). Removal of the solvent by lyophilisation 
afforded the title compound as a yellow solid (12 mg, 71 %). 
FTIR thin film (cm): 3330 br (OH), 3066 (amide NH), 2964 and 2845 (CH), 1671 
(amide I), 1543 (amide II). 
'H NIvIR (250 MHz, CD3OD), 8 (ppm): 3.22 - 3.43 (211, m, 2 x H-i), 3.99 (1H, t, 
.12,3 = J3,4 = 2.0 Hz, H-3), 4.24 (2H, s, 2 x H-7), 4.34 - 4.53 (511, m, H-2, H-4, H-5, 2 
x H-14), 7.22 - 7.31 (511, m, H-16 - H-20), 7.33 (111, dd, J2,13 = 8.5 Hz, f9,13 = 2.0 
Hz, H-13),7.62 (1H, d, J12,13 = 8.5 Hz, H-12),7.72 (1H, d, .19,13 = 2.0 Hz, H-9). 
13C NMR (63 MHz, CD3 0D), 8 (ppm): 41.7 (C14), 48.1 (C 1), 49.2 (C7), 77.9 (C4), 
79.5 (0), 81.9 (C2), 85.2 (C5), 126.5 - 128.9 (3C, C9, C12, C13), 130.4 - 131.2 
(2C, dO, Cli), 137.7 (C8),172.0 (C6). 
ES1T1 : [M + H]+ = 425.1 [35 C1 - 35Cl]. 
6.4.10 Synthesis of library 3: Synthesis of NN'-substituted-1-amino-2,5-
anhydro-1-deoxy-1-D-mannonamide derivatives. Part 1: Amine coupling. 
The N-BOC protected sugar amino acids 90 and 91 (1 eq.) were dissolved in CH 202 
(1 ml) and placed in to 10 ml reaction tubes (6 x 90, 7 x 91). To each tube a different 
amine was added (1 eq., 7 amines used in total) along with EDCI (1.3 eq.), HOBt 
(1.5 eq.) and DfPEA (2.2 eq.). The reactions were allowed to stir for 20 hours before 
quenching with NaCl (2 M, 1 ml). For each reaction, the two phases were separated 
and the aqueous phase extracted with CH 2CH2 (2 x 2 ml). The organic phases were 
combined and washed with water (2 x 2 ml) and HC1 (0.5 M, 2 x 2 ml). The solutions 





pressure to yield the crude products. The compounds were purified using the Quad3 
parallel purification system, using pre-packed columns, eluting with CH202 : MeOH 
(9.5 : 0.5). Solvent removal yielded the desired compounds. 
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From allylamine and 90, yield =63 mg, 29 %. 
FTIR thin film (cm-1 ): 3399 br (OH), 2977 and 2927 (CH), 1665 (C=O BOC, amide 
I), 1536 (C=O amide II). 
'H NMR (250 MHz, CDC1 3), 5 (PPM): 1.32 (9H, s, 9 x H-16),3.35 - 3.46 (2H, m, 2 
x H-i), 3.76 (111, t, J2,3 = J3 ,4 = 5.5 Hz, H-3), 3.91 - 4.38 (7H, m, H-2, H-4, H-5, 2 x 
H-7, 2 x H-17), 5.02 - 5.14 (2H, m, 2 x H-19), 5.63 - 5.79 (1H, m, H-18), 6.77 (1H, 
s, NH amide), 6.99 (1H, d, .112 , 1 3 = 7.5, H-13), 7.24 - 7.58 (2H, m, H-9, H-12). 
13 C NMR (63 MHz, CDC13), 5 (ppm): 28.2 (3C, 3 x C16), 41.2 (C17), 48.5 (Cl), 
51.2 (C7), 77.7 (C4), 79.8 (0), 81.0 (C15), 83.3 (C2), 84.0 (C5), 116.6 (C19), 126.2 
—130.3 (3C, C9, C12, C13), 131.0— 132.4 (2C, CIO, CI 1), 133.2 (C18),138.6 (C8), 



















From 3-nitroaniline and 90, yield = 76 mg, 30 %. 
FTIR thin film (cm'): 3375 br (OH), 2926 (CH), 1671 (C=O BOC, amide 1), 1532 
(C=O amide II). 
1 H NN'IR (250 MHz, CDC13), 8 (PPM): 1.38 (9H, s, 9 x H-16), 3.31 - 3.55 (2H, m, 2 
x H-i), 4.04 (1H, m, 1 x H-3), 4.16 - 4.78 (5H, m, H-2, H-4, H-5, 2 x H-7), 6.99 
(1H, dd, .J12 , 1 3 = 8.0 Hz, J9, 1 3 = 1.5 Hz, H-13), 7.20— 7.38 (3H, m, H-9, H-12, H-21), 
7.72 - 7.84 (2H, m, H-20, H-22), 8.35 (1H, s, 11-18), 8.67 (1H, s, NH amide). 
13  NMR (63 MHz, CDC13), 8 (ppm): 28.2 (3C, 3 x C16), 48.3 (Cl), 53.3 (C7), 77.6 
(C4), 80.1 (C3), 81.3 (C15), 83.8 (C2), 84.5 (CS), 114.7 (C18), 119.2 (C20), 125.6-
132.4 (7C, C9 - C13, C21, C22),137.7 (C8),138.4 (C17),156.2 (C14),170.3 (C6). 
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From 4-nitroaniline and 90, yield = 30 mg, 25 %. 
Rf= 0.20 CH202 : MeOH (9.5: 0.5) 
1 H NIvIR (250 MHz, CDC13), 8 (PPM): 1.41 (9H, s, 9 x H-16), 3.32 - 4.47 (8H, m, 2 
x H- 1, H-2, H-3, H-4, H-5, 2 x H-7), 6.54 - 6.57 (1H, m, Ar-H), 6.98 - 7.36 (3H, m, 
H-9, H-12, H13), 7.63 - 7.66 (1H, m, Ar-H), 7.98 - 8.14 (2H, m, 2 x Ar-H). 



















From 3,4-dichlorobenzylamine and 90, yield = 33 mg, 25 %. 
Rf= 0.14 CH202 : MeOH (9.5 : 0.5) 





x H- 1), 3.81 - 4.41 (8H, m, H-2, H-3, H-4, H-5, 2 x H-7, 2 x H-17), 6.99 (2H, H- 13, 
H-23), 7.20— 7.32 (4H, m, H-9, H- 12, H- 19, H-22). 
6.4.10.5 	N-BOC-2, 5Anhydro-1-deoxy-1-(3,4-dichlorObeflZY1amiflO)-D- 
cycloheptylmannonamide, 98. 
19  
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From cycloheptylamine and 90, yield = 28 mg, 24 %. 
Rf= 0.11 CH202 : MeOH (9.5 :0.5) 
1 H NMR (250 MHz, CDC13), 8 (PPM): 1.31 - 1.55 (21H, m, 6 x —CH2- cycloheptane, 
9 x H-16), 3.31 - 3.51 (2H, m, 2 x H- 1), 3.80 - 4.46 (7H, m, H-2, H-3, H-4, H-5, 2 x 


















From aniline and 90, yield =28 mg, 25 %. 
Rf= 0.11 CH202 : MeOH (9.5 :0.5) 
1 H NIv[R (250 M1Hz, CDC13), 8 (PPM):  1.36 (9H, s, 9 x H-16), 3.28 - 3.50 (211, m, 2 
x H-i), 3.82 - 4.46 (6H, m, H-2, H-3, H-4, H-5, 2 x H-7), 6.94 - 7.31 (8H, m, H-9, 
H-12, H-13, H-18 - H-22). 
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From benzylamine and 91, yield = 36 mg, 26 %. 
Rf= 0.13 CH202 : MeOH (9.5 : 0.5) 





9 x H-16),3.38 (2H, s, 2 x H-i), 3.45 - 3.54 (iH, m, H-7), 3.98 - 4.47 (6H, m, H-2, 
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From allylamine and 91, yield = 31 mg, 39 %. 
'H NMR (250 MHz, CDC13), ö (PPM): 1.27 - 1.67 (21H, m, 6 x -CH 2- cycloheptane, 
9 x H-16),3.30 - 4.45 (9H, m, 2 x H-i, H-2, H-3, H-4, H-5, H-7, 2 x H-17), 5.07 - 
5.24 (2H, m, 2 x H-19), 5.68 - 5.85 (1H, m, H-18). 
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From 3-nitroaniline and 91, yield = 31 mg, 33 %. 
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From 4-nitroaniline and 91, yield = 30 mg, 21 %. 
Rf= 0.09 CH202 : MeOH (9.5 : 0.5) 
1 H NMR (360 MHz, CDC1 3), 6 (PPM):  1.44 - 1.72 (21H, m, 6 x -CH 2- cycloheptane, 
9 x H- 16), 3.35 - 4.75 (7H, m, 2 x H- 1, H-2, H3, H-4, H-5, H-7), 6.60 (214, d, J18,19 = 
= 9.0 Hz, H-18, H-22), 8.03 (2H, d, J18,19 = J21,22 = 9.0 Hz, H-19, H-21). 
6.4.10.11 	N-BOC-2, 5-Anhydro-1-deoxy-1-(cycloheptylamino)-D-3,4- 
diclorobenzylmannonamide, 104. 
9 
8 	 10 
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Rf = 0.14 CH202 : MeOH (9.5: 0.5) 
1 H NIvIIR (250 MHz, CDC13), 8 (PPM): 1.38 - 1.70 (21H, m, 6 x -CH2- cycloheptane, 
9 x H-16), 3.30 - 3.55 (3H, m, 2 x H- 1, H-7), 3.94 - 4.42 (6H, m, H-2, H-3, H-4, H-
5, 2 x H- 17), 7.02 - 7.07 (1H, m, H-23), 7.27 - 7.34 (2H, m, H-19, H-22). 
6.4.10.12 	N-BOC-2, 5-Anhydro-1-deoxy-1-(cycloheptylamino)-D- 
cycloheptylmannonamide, 105. 
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From cycloheptylamine and 91, yield = 14 mg, 16 %. 
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From aniline and 91, yield = 13 mg, 15 %. 
Rf = 0.13 CH202 MeOH (9.5 0.5) 
6.4.11 Synthesis of library 3: Synthesis of N,N'-substituted-1-amino-2,5-
anhydro-1-deoxy-1 -D-mannonamide derivatives. Part 2: BOC-deprotection. 
BOC-protected amino mannonamides (from part 1) were dissolved in CH 202 (1.5 
ml). Trifluoroacetic acid (1 ml) was added and the reactions were stirred for 2 hours. 
The solvent was then removed under reduced pressure and the residue dissolved in 
acetonitrile : water (1 	1, 0.1 % acetic acid) and purified using mass directed 






6.4.11.1 	2, 5-Anhydro-1-deoxy-1-(3,4-dichlorobenzylamino)-D- 
allylmannonamide, 107. 
16a H CI 
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From 104, yield = 41 mg, 82 %. 
'H NMIR (250 MHz, CD 3OD), 8 (ppm): 3.28 (1H, dd, .Jgem = 13.0 Hz, Jla,2 = 3.0 Hz, 
H-la), 3.44 (1H, dd, Jgem = 13.0 Hz, J,b,2 = 9.5 Hz, H-lb), 3.75 - 3.94 (2H, m, 2 x H-
14), 3.97 (1H, t, J2,3 = J3 ,4 = 2.0 Hz, H-3), 4.27 (1H, d, Jgem = 13.5 Hz, 1 x H-7), 4.33 
(1H, d, Jgem = 13.5 Hz, 1 x H-7), 4.35 (1H, t, J3,4 = J4 ,5 = 2.0 Hz, H-4), 4.3,8 - 4.41 
(1H, m, H-2), 4.44 (1H, d, J4,5 = 2.0 Hz, H-5), 5.08 (1H, dq, J15,16b = 10.5 Hz, J14,16b 
J16a,16b = 1.5 Hz, H-16b), 5.23 (1H, dq, J15,16a = 17.0 Hz, J14,16a = J16a,16b = 1.5 Hz, 
H-16a), 5.75 - 5.90 (1H, m, H-15), 7.45 (1H, dd, J12,13 = 8.5 Hz, J9j3 = 2.0 Hz, H-
13), 7.63 (1H, d, J12,13 = 8.5 Hz, H-12), 7.73 (1H, d, J9,1 3 = 2.0 Hz, H-9), 8.11 (1H, t, 
J14,NH-amide = 6.0 Hz, exchanges in D20, NH-amide). 
NMR (63 MHz, CD3OD), 8 (ppm): 40.4 (C 14), 48.1 (C 1), 49.0 (C7), 77.8 (C4), 
79.6 (C3), 81.7 (C2), 85.4 (CS), 114.2 (C16), 129.0 - 131.3 (3C, C9, C12, C13), 
132.2-132.9 (2C, ClO, CI 1), 133.3 (2C, C8, C15), 170.9 (C6). 
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From 95, yield = 15 mg, 23 %. 
'H NMR (250 MHz, CD30D), ö (ppm): 3.34 (1H, dd, 1 x H-i), 3.42 (iH, dd, 1 x H-
1), 4.04 (1H, t, J2,3 = J3 ,4 = 2.0 Hz, H-3), 4.31 (1H, d, Jgem = 13.5 Hz, 1 x H-7),4.28 
(1H, d, Jgem = 13.5 Hz, 1 x H-7), 4.48 (1H, t, J3,4 = J4 ,5 = 2.0 Hz, H-4), 4.53 - 4.59 
(iH, m, H-2), 4.62 (iH, d, J4,5 = 2.0 Hz, H-5), 7.28 (iH, dd, .112,13 = 8.5 Hz, J9,13 
2.0 Hz, H-13), 7.58 (1H, t, J17,18 = J18,19 = 8.0 Hz, H-18), 7.66 (1H, d, J17,18 = 8.5 Hz, 
H-12), 7.77 (1H, d, J913 = 2.0 Hz, H-9), 7.95 - 7.99 (2H, m, H-17, H-19), 8.63 (1H, 
t, J15,17 = JI 5,19 = 2.0 Hz, H-15). 





6.4.11.3 	2, 5-Anhydro-1-deoxy-1-(3,4-dichlorobenzylamino)-D-4- 
nitrophenylmannonamide, 109. 









From 96, yield = 5 mg, 20 %. 
'H NMR (360 MHz, CD 3OD), 8 (ppm): 3.34 (1H, dd, Jgem = 13.0 Hz, Jia,2 = 3.0 Hz, 
H-la), 3.50 (1H, dd, Jgem = 13.0 Hz, J, b,2 = 9.5 Hz, H-lb), 4.04 (1H, t, J2 ,3 = J3,4 = 2.0 
Hz, H-3), 4.32 (1H, d, Jgem = 13.0 Hz, 1 X H-7), 4.38 (1H, d, Jgem = 13.0 Hz, 1 x H-
7), 4.49 (1H, t, J3,4 = J4,5 2.0 Hz, H-4), 4.54 - 4.59 (111, m, H-2), 4.62 (1H, d, J4,5 = 
2.0 Hz, H-5), 7.47 - 7.91 (5H, m, H-9, H-12, H-13, H-15, H-19), 8.23 - 8.57 (2H, m, 
H-16, H-18). 
ES1: [M + H] = 456.0 [35C1 - 35C1], 458.0 [35C1 - 37C1], 460.0 [37C1 - 37C1] (exp. 



















From 97, yield = 16 mg, 58 %. 
1 H NMR (360 MHz, CD30D), 8 (jpm): 3.28 (1H, dd, Jgem = 13.0 Hz, .Jl a ,2 = 3.0 Hz, 
H-la), 3.46 (1H, dd, Jgem = 13.0 Hz, Jlb,2 = 9.5 Hz, H-lb), 4.01 (1H, t, J2 , 3 = J3,4 = 
1.51 Hz, H-3), 4.24 - 4.34 (4H, m, 2 x H-7, 2 x H-14), 4.38 (1H, s, NH amine), 4.42 
(1H, t, J3,4 = J4,5 = 1.5 Hz, H-4), 4.44 —4.48 (1H, m, H-2), 4.51 (1H, d, J4,5 = 1.5 Hz, 
H-5), 7.19 - 7.27 (2H, m, H-13, H-20), 7.41 - 7.73 (4H, m, H-9, H12, H-16, H-19), 
8.54 (1H, t, J14,NH-amide = 6.5 Hz, NH-amide). 
ESI: [M + H] + = 493.1 [35C1 - 35C1 - 35C1 - 35C1]. 
6.4.11.5 	2, 5-Anhydro-1-deoxy-1-(3,4-dichlorobenzylamino)-D- 
cycloheptylmannonamide, 111. 
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FTJIR thin film (cm'): 3398 br (OH), 3074 (amide NH), 2965, 2935 and 2878 (CH), 
1674 (amide I), 1541 (amide II). 
[a] D = 10.00 (c 0. 1, MeOH). 
1 H NMR (250 MHz, CD 3OD), ö (ppm): 1.43 - 1.91 (12H, m, 6 x -CH 2-
cycloheptane), 3.27 (1H, dd, Jgem = 13.0 Hz, Jla,2 = 3.5 Hz, H-la), 3.43 (1H, dd, Jgem 
= 13.0 Hz, Jlb,2 = 9.5 Hz, H-lb), 3.78 - 3.90 (1H, m, H-14), 3.94 (1H, t, J2,3 = J3,4 = 
2.0 Hz, H-3), 4.27 - 4.32 (3H, m, H-4, 2 x H-7), 4.36 - 4.42 (2H, m, H-2, H-5), 7.44 
(1H, dd, J12,13 = 8.5 Hz, J9,13 = 2.0 Hz, H-13), 7.64 (1H, d, J12,13 = 8.5 Hz, H-12), 7.73 
(1H, d, J9,13 = 2.0 Hz, H-9). 
13C NIMR (63 MHz, CD30D), S (ppm): 22.3 —22.5 (2C, C16, C19), 27.1 - 27.4 (2C, 
C17, C18), 33.6 - 33.9 (2C, C15, C20), 48.1 (C 1), 49.1 (C7), 49.9 (C14), 77.8 (C4), 
79.5 (C3), 81.7 (C2), 85.2 (CS), 129.0 - 131.3 (3C, C9, C12, C13), 132.2 - 133.0 
(2C, ClO, CI 1), 138.0 (C8),169.5 (C6). 
ESI: [M + H]+ = 431.2 [35C1 - 35C1]. 
FIRMS FAB (+ve) found mlz = 43 1.15032 and 43 1.14748 [M + Hf, C20H29N204C12 























From 99, yield = 10 mg, 50 %. 
'H NMR (250 MHz, CD30D), 6 (ppm): 3.34 (1H, dd, Jgem = 13.0 Hz, Jia,2 = 3.0 Hz, 
H-la), 3.49 (1H, dd, Jgem = 13.0 Hz, Jib,2 = 9.5 Hz, H-lb), 4.00 (1H, t, J2,3 = J3,4 = 2.0 
Hz, H-3), 4.27 (1H, d, Jgem = 11.5 Hz, 1 X H-7), 4.34 (1H, d, Jgem = 11.5 Hz, 1 x H-
7), 4.44 (1H, t, J3,4 = J4,5 = 2.0 Hz, H-4), 4.47 - 4.53 (1H, m, H-2), 4.56 (1H, d, J4,5 
2.0 Hz, H-5), 7.10 —7.75 (8H, m, H-9, H-12, H-13, H-15 - H-19). 
6.4.11.7 	2, 5Anhydro-1-deoxy-1-(cycloheptylamino)-D-benZy1maflflOfla1flide, 
113. 
9 
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From 100, yield = 17 mg, 60 %. 





cycloheptane), 3.22 - 3.43 (3H, m, 2 x H-i, H-7), 3.99 (iH, t, J2,3 = J3,4 = 2.0 Hz, H-
3), 4.33 - 4.52 (5H, m, H-2, H-4, H-5, 2 x H-14), 7.19 - 7.33 (5H, m, 5 x Ar-H). 
13C NIvIR (63 MHz, C133013), 6 (ppm): 23.0 - 23.1 (2C, C9, Ci2), 27.7 (2C, ClO, 
C1 1), 29.6— 30.0 (2C, C8, C13), 41.7 (C14), 45.6 (Cl), 58.9 (C7), 77.9 (C4), 79.6 
(0), 82.0 (C2), 85.4 (C5), 126.3 (C18), 126.5 (2C, C16, C20), 127.6 (C17, C19), 
127.8 (C 18), 171.0 (C6). 
ES1: [M+H] 	363.1. 
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From 101, yield = 10 mg, 43 %. 
1H NIVIR (250 MHz, CD 30D), 6 (ppm): 1.47 - 2.16 (12H, m, 6 x —CH 2-
cycloheptane), 3.22 - 3.44 (3H, m, 2 x H-i, H-7), 3.80 - 3.88 (2H, m, 2 x H-14), 
3.97 (1H, t, J2,3 = J3,4 = 2.0 Hz, H-3), 4.31 —4.38 (2H, m, H-2, H-4), 4.33 (1H, d, J4 , 5 
= 2.0 Hz, H-5), 5.09 (1H, dq, J15,16b = 10.5 Hz, J14,16b =J16a,16b = 1.5 Hz, H-16b), 5.24 
(1H, dq, J15,16a = 17.0 Hz, J14,16b = .'16a,16b = 1.5 Hz, H-16a), 5.76 - 5.91 (1H, m, H-
15) 















From 102, yield = 9 mg, 36 %. 
'H NMR (250 MHz, CD30D), 8 (ppm): 1.47 - 2.17 (12H, m, 6 x –CH2-
cycloheptane), 3.29 - 3.50 (3H, m, 2 x H-i, H-7), 4.05 (1H, t, J2,3 = J3,4 = 2.0 Hz, H-
3), 4.43 - 4.52 (2H, m, H-2, H-4), 4.61 (1H, d, J4,5 = 2.0 Hz, H-5), 7.59 (1H, t, J17,18 
= J18,19 = 8.0 Hz, H-18), 7.92-8.04 (2H, m, H-17, H-19), 8.64 (1H, t, J15,17 =J15,19 = 
2.0 Hz, H- 15). 
13C NMR (63 MHz, CD3 0D), 8 (ppm): 23.0 - 23.1 (2C, C9, C12), 26.7 - 27.3 (2C, 
CIO, CI 1), 29.7 - 30.3 (2C, C8, C13), 45.6 (Cl), 58.9 C7), 77.6 (C4), 79.8 (0), 
82.1 (C2), 85.4 (C5), 114.4 (C15), 118.1 (C17), 125.5 (C19), 129.0 (C18), 138.4 
(C14),148.0 (C16),169.9 (C6). 
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From 103, yield = 12 mg, 50 %. 
1 11 NMR (250 MHz, CD30D), 6 (ppm): 1.46 - 2.16 (12H, m, 6 x —CH 2-
cycloheptane), 3.32-3.49 (3H, m, 2 x H-i, H-7), 403 (iH, t, J2,3 =J3,4 = 2.0 Hz, H-
3), 4.45 - 4.50 (2H, m, H-2, H-4), 4.60 (1H, d, J4 ,5 = 2.0 Hz, H-5), 7.88 (2H, d, J15,16 
= J,8,19 = 9.5 Hz, H-15, H-19), 7.91 (1H, s, NH-amide), 8.13 (2H, d, J,5,16 = J18,,9 = 
9.5 Hz, H-16, H-18). 
ES1: [M + H]+ = 394.3. 
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From 104, yield = 10 mg, 77 %. 




cycloheptane), 3.22 - 3.45 (3H, m, 2 x H-i, H-7), 4.0 (1H, t, J2,3 = J3 ,4 = 1.5 Hz, H-
3),4.34 — 4.46 (5H, m, H-2, H-4, H-5, 2 x H-14),7.19 - 7.53 (3H, m, H-16, H-19, H-
20). 
6.4.11.12 	2, 5-Anhydro-1-deoxy-1-(cycloheptylamino)-D- 
cycloheptylmannonamide, 118. 
16 	 9 
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From 105, yield = 11 mg, 99 %. 
'H NMR (250 MHz, CD30D), 8 (ppm): 1.44 - 2.16 (24H, m, 12 x x —CH2-
cycloheptane), 3.19 - 3.42 (3H, m, 2 x H-i, H-7), 3.80 - 3.93 (2H, m, H-2, H-14), 
3.95 (1H, t, J2,3 = J3,4 = 2.0 Hz, H-3), 4.32 (1H, t, J3,4 = J4,5 = 2.0 Hz, H-4), 4.37 (114, 
d, J4,5 = 2.0 Hz, H-5). 
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From 106, yield = 5 mg, 50 %. 
'H NMR (250 MHz, CD3OD), 6 (ppm): 1.45 - 2.15 (12H, m, 6 x —CH2-
cycloheptane), 3.25 - 3.47 (3H, m, 2 x H-i, H-7), 4.01 (1H, t, J2,3 = .13,4 = 2.5 Hz, H-
3), 4.40 —4.47 (2H, m, H-2, H-4), 4.54 (111, d, J4,5 = 2.5 Hz, H-5), 7.04 - 7.15 (1H, 
m, H-17),7.23 - 7.37 (2H, m, H-16, H-18), 7.50 — 7.57 (2H, m, H-15, H-19). 
ESI: [M + H] = 349.3. 
6.5 	Non-Library Inhibitor Development. 
6.5.1 Synthesis 	of 	2,5-anhydro-1-deoxy-1-(3,4-dichlorobeflZylamiflo)-D- 
mannonic acid (deprotection of 90), 120. 







HO 	OH 	 12 
The N-BOC protected sugar amino acid 90 (54 mg) was dissolved in CH 202 (1.5 





The solvent was then removed and the residue dissolved in acetonitrile : water (1 : 1, 
0.1 % acetic acid) and purified using mass directed purification (ZMD Method 2). 
Removal of the solvent by lyophulisation afforded the title compound as a white solid 
(17 mg, 34 %). 
'H NMR (250 MHz, CD30D), 8 (ppm): 2.77 (1H, dd, Jgem = 12.5 Hz, Jia,2 = 7.5 Hz, 
H-la), 2.88 (1H, dd, Jgem = 12.5 Hz, Jlb,2 = 3.5 Hz, H-lb), 3.75 - 3.88 (3H, m, H-3, 2 
x H-7), 4.08 - 4.22 (3H, m, H-2, H-4, H-5), 7.31 (1H, dd, f12,13 = 8.5 Hz, f9,13 = 2.0 
Hz, H-13), 7.50 (1H, d, J12,13 = 8.5 Hz, H-12), 7.55 (111, d, f9,13 = 2.0 Hz, H-9). 
13 NMR (63 MHz, CD30D), 8 (ppm): 49.4 (Cl), 50.9 (C7), 79.2 (C4), 80.2 (0), 
82.4 (C2),84.3 (C5), 127.7 — 132.2 (5C, C9 - C13),138.8 (C8),171.8 (C6). 
ESl: [M + H] = 336.2 [35C1 - 35C1]. 
6.5.2 Synthesis of 2,5-anhydro-1 -deoxy-1 -(cycloheptylamino)-D-mannonic acid 
(deprotection of 91), 121. 
9 
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The N-BOC protected sugar amino acid 91 (31 mg) was dissolved in CH202 (1.5 
ml). Trifluoroacetic acid (1 ml) was added and the reaction was stirred for 1 /2 hours. 
The solvent was then removed and the residue dissolved in acetonitrile : water (1 : 1, 
0.1 % acetic acid) and purified using mass directed purification (ZMD Method 2). 
231 
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Removal of the solvent by lyophilisation afforded the title compound as a white solid 
(13 mg, 57%). 
1 H NIMR (250 MHz, CD3OD), ö (ppm): 1.09 - 1.84 (12H, m, 6 x -Cl 2 -
cycloheptane), 2.78 - 3.20 (3H, m, 2 x H-i, H-7), 3.63 - 4.03 (4H, m, H-2 - H-5). 
ES1: [M+H]=274.i. 
6.5.3 Synthesis 	of 	2,5-anhydro-1-deoxy-1 -(3,4-dichlorobenzylamino)-D- 
mannitol-6-phosphate, 122. 







HO 	OH 	 12 
A stirring solution of phosphorous oxychloride (0.39 ml, 4.4 eq.) was cooled to 0 °C 
before addition of water (50 R I, 2.8 eq.), pyridine (0.37 ml, 4.8 eq.) and acetonitrile 
(0.5 ml). The N-BOC protected amine 88 (0.4 g, 1 eq.) was added and the reaction 
was stirred for 3 1/4  hours, maintaining the temperature between 0 and 2 T. Crushed 
ice was then added and the reaction was allowed to stir for a further hour. CH 2C12 (5 
ml) was added and the two layers separated. The aqueous layer was washed with a 
further portion of CH 2C12 (5 ml), neutralised by NaOH (0.5 M) and washed with 
Et20 (2 x 5 ml) and CH2C12 (2 x 5 ml). The solution was then lyophilised to yield a 
pale yellow solid (0.40 g, 95 %). This was dissolved in acetonitrile : water (1: 1, 0.1 
% acetic acid) and purified using mass directed purification (ZMD Method 2). 
Removal of the solvent by lyophilisation yielded the title compound as a white solid 
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(18 mg, 5 %). 
'H NMR (250 MHz, D20), 6 (ppm): 3.20 - 3.36 (2H, m, 2 x H-i), 3.87 (4H, m, H-3, 
H-4, 2 x H-6), 4.11 —4.33 (4H, m, H-2, H-5, 2 x H-7), 7.37 (1H, dd, J12,13 = 8.5 Hz, 
J9,13 = 2.5 Hz, H-13), 7.59 (1H, d, J12,,3 = 8.5 Hz, H-12), 7.64 (1H, , J9,13 = 2.5 Hz, 
H-9) 
31 P NMR (101 MHz, D20),8 (ppm): 3.08. 
ESr: [M - H] - = 399.7 [35C1 - 35C1]. 
6.5.4 Synthesis of 2,5-anhydro-D-talose, 123.110 
0 







+ 	 OH 
HO'' OH 
D-Galactosamine hydrochloride (1.00 g, 1 eq.) was dissolved in water (20 ml) and 
stirred at 0 °C for approximately 4 hours. Sodium nitrite (0.80 g, 2.5 eq.) was then 
added followed by cautious addition of Amberlite 120 H resin (20 ml), maintaining 
the temperature between 0 - 5 T. The reaction was then left to stir at 0 °C for 18 
hours before the resin was removed by filtration. The solution was then neutralised 
by portion by portion addition of Dowex C03 2 resin. The resin was removed by 
filtration and the remaining solution was lyophilised to yield the title compound as a 
pale brown hygroscopic solid. (0.65 g, 87%). 





(1H, m, H-5), 4.02 - 4.10 (2H, m, H-3, H-4), 4.82 (1H, d, J1,2 = 4.5 Hz, H-i gem-
diol). 
' 3 C NMIR (63 MHz, D20), 6 (ppm): 60.6, (C6), 72.2 (C4), 37.1 (0), 81.4 (C2), 83.4 
(C5),90.5 (Ci gem-diol). 
6.5.5 Synthesis of 2,5-anhydro-1 -deoxy-1 -(3,4-dichlorobenzylamino)-D-talitol, 
124. 
9 	ci 
6 	 1 




3,4-Dichlorobenzylamine (0.24 ml, 1 eq.) was added to a solution of aldehyde 123 
(0.29 g) in methanol (10 ml) and was stirred for 1 hour. Sodium cyanoborohydride 
(0.11 g, 1 eq.) was added and the reaction was stirred for 30 minutes at pH 6, 
maintained by dropwise addition of HC1 in methanol (0.5 M). The solvent was then 
removed under reduced pressure and the resulting residue was dissolved in 
acetonitrile : water (1 : 1, 0.1 % acetic acid) and purified using mass directed 
purification (ZMD Method 2). Removal of the solvent by lyophilisation afforded the 
title compound as a white solid (0.11 g, 19 %). 
'H NMR (250 MHz, CD 3 OD), 6 (ppm): 2.66 (1H, dd, Jgem = 12.5 Hz, Jia,2 = 7.0 Hz, 
H-la), 2.84 (1R, dd, Jgem = 12.5 Hz, Jlb,2 = 3.0 Hz, H-lb), 3.69 - 3.90 (4H, 2 x H-6, 
2 x H-7), 3.92 - 4.06 (3H, m, H-2, H-3, H-5), 4.14 (1H, t, J3,4 = J4 ,5 = 4.0 Hz, H-4), 
7.30 (1H, dd, J1,13 = 8.0 Hz, J9,13 = 2.0 Hz, H-13), 7.47 (1H, d, J12,13 = 8.0 Hz, H- 
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12), 7.55 (1 H, d, J9,13 = 2.0 Hz, H-9). 
' 3C NMIR (63 MHz, CD30D), 8 (ppm): 50.5 (Cl), 51.3 (C7), 60.4 (C6), 71.3 (C4), 
74.1 (C3), 79.3 (C2), 80.3 (C5), 126.8 - 129.6 (3C, C9, C12, C13), 129.3 - 131.3 
(2C, dO, Cli), 139.8 (C8). 
ESI: [M + H] = 321.7 [35 C1 - 35C1]. 
6.5.6 Synthesis of 2,5-anhydro-1-deoxy-1 -(benzhydrylamino)-D-talitol, 125. 
6 	0 2 
HO 	 7% 4 
HO 	OH 
Aminodiphenylmethane (0.31 ml, 1 eq.) was added to a solution of aldehyde 123 
(0.29 g) in methanol (10 ml) and was stirred for 1 hour. Sodium cyanoborohydride 
(0.11 g, 1 eq.) was added and the reaction was stirred for 4 hours, at pH 6, 
maintained by dropwise addition of HC1 in methanol (0.5 M). The solvent was then 
removed under reduced pressure and the resulting residue was dissolved in 
acetonitrile : water (1 : 1, 0.1 % acetic acid) and purified using mass directed 
purification (ZMD Method 2). Removal of the solvent by lyophilisation afforded the 
title compound as a white solid (0.12 g, 20 %). 
1 H NMR (250 MHz, CD30D), 6 (ppm): 2.63 (1H, d, Jgem = 12.0 Hz, Jia,2 = 7.0 Hz, 
H-la), 2.80 (1H, dd, Jgem = 12.0 Hz, Jlb,2 = 3.5 Hz, H-lb), 3.70 - 3.82 (2H, m, 2 x H- 
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6), 3.92 - 4.05 (3H, m, H-2, H-3, H-5), 4.13 (1H, t, J3,4 = J4 ,5 = 4.0 Hz, H-4), 5.14 
(1H, s, H-7), 7.10 - 7.42 (1 OH, m, 10 x Ar-H). 
' 3 C NMR (63 MHz, CD3 0D), ö (ppm): 49.8 (C 1), 60.4 (C6), 66.7 (C7), 71.3 (C4), 
74.1 (C3), 79.6 (C2), 80.3 (C5), 126.1- 127.6 (b C, 10 x Ar-CH), 143.1 - 144.2 (2C, 
2 x ArC-CH-). 
ES1: [M + H]+ = 330.1. 
6.5.7 Synthesis of N_methyl-2,5-anhydro-1-deoxy-(3,4-dichlorObeflZylamiflO)-
D-mannitol, 126. 
10 




13 14 	 12 
HO 	OH 
Amine 37 (0.31 g, 1 eq.) was dissolved in water (2.4 ml) and placed in a microwave 
tube. Formic acid (40 pi, 1.1 eq.) and formaldehyde solution (37 %, 88 .d, 1.1 eq.) 
were added and the tube was sealed. The tube was placed in a CEM discover 
microwave and heated for 5 minutes at 150 °C (120 W). The solvent was then 
removed under reduced pressure and the residue re-dissolved in water : acetonitrile 
(1: 1, 0.1 % acetic acid) and purified using mass directed purification (ZMD Method 
2). Removal of the solvent by lyophilisation yielded a pale brown oily solid (80 mg, 
25 %). 
NIMIR (250 MHz, d6-DMSO), 8 (ppm): 2.06 (3H, s, 3 x H-14),2.34 - 2.50 (2H, m, 





H-5), 7.14 (1H, d, J12,13 = 8.5 Hz, H-13),7.40 — 7.46 (2H, m, H-9, H-13). 
13 C NIvIR (63 MHz, d6-DMSO), 8 (ppm): 42.4 (C14), 59.3 (Cl), 60.2 (C7), 61.6 
(C6), 76.8 (C4), 79.4 (C3), 81.4 (C2), 83.7 (C5), 128.7 - 130.6 (5C, C9 - C13), 
140.5 (C8). 
ESI: [M+H]F = 336.1 [35C1- 35C1]. 









I 13 	12 
14 
HO 	OH 
Amine 70 (50 mg, 1 eq.) was dissolved in water (0.5 ml) and placed in a microwave 
tube. Formic acid (9 jtl, 11 eq.) and formaldehyde solution (37 %, 17 jtl, 1.1 eq.) 
were added and the tube was sealed. The tube was placed in a CEM discover 
microwave and heated for 5 minutes at 150 °C (120 W). The resulting residue was 
dissolved in water : acetonitrile (1 : 1, 0.1 % acetic acid) and purified using mass 
directed purification (ZMD Method 2). Removal of the solvent by lyophilisation 
yielded a white solid (31 mg, 59 %). 
'H NMR (250 MHz, CD3OD), 8 (ppm): 1.45 - 2.04 (12H, m, 2 x —Cl 2-
cycloheptane), 2.53 (3H, s, 3 x H-14), 2.89 - 3.04 (311, m, 2 x H-i, H-7), 3.67 (2H, 
2dd, 2 x H-6), 3.81 —4.05 (411, m, H-2, H-3, H-4, H-5). 
237 
Chapter 6 	 Experimental 
' 3 C NIvIR (63 MHz, CD3OD), ö (ppm): 24.4 (2C, C9, C12), 26.6 - 26.7 (2C, ClO, 
CI 1), 27.6— 28.4 (2C, C8, C13), 36.8 (C14), 54.5 (Cl), 61.1 (Cl), 65.3 (C7), 76.4 
(C4), 79.1 (C3), 80.0 (C2), 83.9 (C5). 
ESf4 : [M + H] = 274.3. 
HRMS FAB (+ve) found mlz = 274.20177 [M + H], C 14H28N04 requires 
274.20183. 









HO 	OH 	15 	
12 
Amine 37 (50 mg, 1 eq.) was dissolved in water (0.4 ml) and placed in a microwave 
tube. Formic acid (6 p.1, 1.1 eq.) and acetaldehyde (10 p.1, 1.1 eq.) were added and the 
tube was sealed. The tube was placed in a CEM discover microwave and heated for 5 
minutes at 150 °C (120 W). The solvent was then removed under reduced pressure 
and the residue re-dissolved in water : acetonitrile (1 : 1, 0.1 % acetic acid) and 
purified using mass directed purification (ZMD Method 2). Removal of the solvent 
by lyophilisation yielded a pale brown oily solid (34 mg, 63 %). 
'H NMR (250 MHz, CD 3OD), 6 (ppm): 1.10 (3H, t, J14,15 = 7.0 Hz, 3 x H-15),2.58 - 





3.97 - 4.06 (H, m, H-3, H-5), 7.34 (1H, dd, J12,13 = 8.5 Hz, J9, 1 3 = 2.0 Hz, H-13), 7.50 
(1H, d, J1 2, 1 3 = 8.5 Hz, H-12), 7.58 (1H, d, .19, 1 3 = 2.0 Hz, H-9). 
13C NMR (63 MHz, CD30D), ö (ppm): 9.62 (C15),47.0 (C14), 54.3 (Cl), 56.1 (C7), 
61.0 (C6), 76.2 (C4), 79.1 (0), 80.4 (C2), 82.8 (C5), 128.6, 129.4, 130.5 (3C, C9, 
C12, C13), 129.8, 130.9 (2C, dO, Cli), 138.4 (C8). 
ES1: [M + H] = 350.3 [35C1 - 35C1]. 
RRMS FAB (+ve) found m/z = 350.09290 and 452.08899 [M + H], C 15H22N04C12 




R. B. Silverman, The Organic Chemistry of Drug Design and Drug Action; 
Academic Press, 1992. 
A. Fleming, Brit. J. Exp. Pathol., 1929, 10, 226. 
M. C. Wani, H. L. Taylor, M. B. Wall, P. Coggon, A. T. McPhail, J. Am. 
Chem. Soc., 1971, 93, 2325. 
C. S. Swindell, N. E. Krauss, S. B. Horwitz, I. Ringel, J. Med. Chem., 1991, 
34,1176. 
S. H. Chen, V. Farina, J. M. Wei, B. Long, C. Fairchild, S. W. Mamber, J. F. 
Kadow, D. Vyas, T. W. Doyle, Bioorg. Med. Chem. Lett., 1994, 4, 479. 
F. Gueritte-Voegelein, D. Guenard, F. Lavelle, M. T. Le Goff, L. Mangatal, 
P. Potier, I Med. Chem., 1991, 34, 992. 
B. M. Gordon, M. A. Gallop, D. V. Patel, Acc. Chem. Res., 1996, 29, 144. 
F. Balkenhohl, C. von dem Bussche-Huennefeld, A. Lansky, C. Zechel, 
Angew. Chem. mt. Edn. Engl., 1996, 35, 2288. 
G. S. Sittampalam, S. D. Kahl, W. P. Janzen, Curr. Opin. Chem. Biol., 1997, 
1,384. 
S. Wang, T. B. Sim, Y.-S. Kim, Y.-T. Chang, Curr. Opin. Chem. Biol., 2004, 
8,371. 
M. A. Gallop, R. W. Barrett, W. J. Dower, S. P. A. Fodor, B. M. Gordon, I 
Med. Chem., 1994, 37, 1233. 
L. A. Thompson, J. A. Ellman, Chem. Rev., 1996, 96, 555. 




M. P. Beavers, X. Chen, I Mol. Graph. Model., 2002, 20, 463. 
N. S. Gray, L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. 
Espinoza, D. 0. Morgan, G. Barnes, S. LeClerc, L. Meijer, S. H. Kim, D. J. 
Lockhart, P. G. Schultz, Science, 1998, 281, 533. 
R. N. Zuckermann, B. J. Martin, D. C. Spellmeyer, G. B. Stauber, K. R. 
Shoemaker, J. M. Kerr, G. M. Figliozzi, D. A. Goff, M. A. Siani, R. Simon, 
S. C. Banville, E. G. Brown, L. Wang, L. S. Richter, W. H. Moos, I. Med. 
Chem., 1994, 37, 2678. 
P. R. Andrews, D. J. Craik, J. L. Martin, J. Med. Chem., 1984, 27, 1648. 
T. J. A. Ewing, S. Makino, A. G. Skillman, I. D. Kuntz, I. Comp-Aid. Mol. 
Des., 2001, 15, 411. 
C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug 
Deliver. Rev., 1997, 23, 3. 
W. P. Walters, Ajay, M. A. Murcko, Curr. Opin. Chem. Biol., 1999, 3, 384. 
T. I. Oprea, .1. Comp-Aid. Mol. Des., 2000, 14, 251. 
M. M. Hann, T. I. Oprea, Curr. Opin. Chem. Biol., 2004, 8, 255. 
M. Vieth, M. G. Siegel, R. Higgs, I. Watson, D. Robertson, K. Savin, G. 
Durst, P. Hipskind, J. Med. Chem., 2004, 47, 224. 
W. P. Walters, M. T. Stahl, M. A. Murcko, Drug Discov. Today, 1998, 3, 
160. 
P. Kaellblad, N. P. Todorov, H. M. G. Willems, I. L. Alberts, I Med. Chem., 
2004, 47, 2761. 
T. L. Blundell, S. Patel, Curr. Opin. Pharmacol., 2004, 4, 490. 
242 
References 
T. L. Blundell, H. Jhoti, C. Abell, Nat. Rev. Drug Discov., 2002, 1, 45. 
A. Sharff, H. Jhoti, Curr. Opin. Chem. Biol., 2003, 7, 340. 
D. A. Erlanson, R. S. McDowell, T. O'Brien, J. Med. Chem., 2004, 47, 3463. 
D. J. Maly, I. C. Choong, J. A. Eliman, Proc. Nati. Acad. Sci. USA., 2000, 97, 
2419. 
M. J. Hartshorn, C. W. Murray, A. Cleasby, M. Frederickson, I. J. Tickle, H. 
Jhoti, I Med. Chem., 2005, 48, 403. 
X. Wang, Y. Choe, C. S. Craik, J. A. Eliman, Bioorg. Med. Chem. Lett., 
2002, 12, 2201. 
S. B. Shuker, P. J. Hajduk, R. P. Meadows, S. W. Fesik, Science, 1996, 274, 
1531. 
C. L. M. J. Verlinde, V. Hannaert, C. Blonski, M. Willson, J. J. Perie, L. A. 
Fothergill-Gilmore, F. R. Opperdoes, M. H. Gelb, W. G. J. Hol, P. A. M. 
Michels, Drug Res. Updates, 2001, 4, 50. 
J. Keiser, A. Stich, C. Burn, Trends Parasitol., 2001, 17, 42. 
B. M. Bakker, H. V. Westerhoff, F. R. Opperdoes, P. A. M. Michels, Mol. 
Biochem. Parasitol. 2000, 106, 1. 
J. Atouguia, J. Costa, Mem. I. Oswaldo Cruz, 1999, 94, 221. 
M. P. Barrett, J. C. Mottram, G. H. Coombs, Trends Microbiol., 1999, 7, 82. 
C. L. M. J. Verlinde, M. Callens, S. Van Calenbergh, A. Van Aerschot, P. 
Herdewijn, V. Hannaert, P. A. M. Michels, F. R. Opperdoes, W. G. J. Hol, I 
Med. Chem., 1994, 37, 3605. 
F. R. Opperdoes, Annu. Rev. Microbiol., 1987, 41, 127. 
J. J. Cazzulo,FasebJ., 1992,6,3153. 
243 
References 
C. B. Clayton, P. Michels, Parasitol. Today, 1996, 12, 465. 
A. G. M. Tielens, J. J. Van Hellemond, Parasitol. Today, 1998, 14, 265. 
A. P. Fernandes, K. Nelson, S. M. Beverley, Proc. Nat!. Acad. Sci. USA, 
1993, 90, 11608. 
F. R. Opperdoes, P. Borst, FEBS Lett. 1977, 80, 360. 
C. L. M. J. Verlinde, W. G. J. Ho!, Structure, 1994, 2, 577. 
A. Seyfang, M. Duszenko, Eur. J. Biochem., 1991, 202, 191. 
M. Duszenko, D. Mecke, Mol. Biochem. Parasitol., 1986, 19, 223. 
J. P. Barnard, B. Reynafarje, P. L. Pedersen, I Biol. Chem., 1993, 268, 3654. 
E. A. C. Wiemer, P. A. M. Michels, F. R. Opperdoes, Biochem. J., 1995, 312, 
479. 
A. H. Fairlamb, F. R. Opperdoes, P. Borst, Nature, 1977, 265, 270. 
C. Van der Meer, J. A. M. Versluijs-Broers, F. R. Opperdoes, Exp. Parasitol., 
1979, 48, 126. 
N. Minagawa, Y. Yabu, K. Kita, K. Nagai, N. Ohta, K. Meguro, S. Sakajo, A. 
Yoshimoto, Mo!. Biochem. Parasitol., 1997, 84, 271. 
A. M. Aronov, S. Suresh, F. S. Buckner, W. C. Van Voorhis, C. L. M. J. 
Verlinde, F. R. Opperdoes, W. G. J. Ho!, M. H. Gelb, Proc. Nat!. A cad. Sci. 
USA, 1999, 96, 4273. 
M. L. Cardenas, A. Cornish-Bowden, T. Ureta, Biochim. Biophys. Acta, 1998, 
1401, 242. 
F. R. Opperdoes, P. A. M. Michels, mt. J. Parasitol., 2001, 31, 482. 
M. Nwagwu, F. R. Opperdoes, Acta Trop., 1982, 39, 61. 
M. Willson, Y.-H. Sanejouand, J. Perie, V. Hannaert, F. Opperdoes, Chem. 
244 
References 
Biol., 2002, 9, 839. 
M. Willson, I. Airic, J. Perie, Y. H. Sanejouand, J. Enzyme Inhib., 1997, 12, 
101. 
P. A. M. Michels, N. Chevalier, F. R. Opperdoes, M. H. Rider, D. J. Rigden, 
Eur. J. Biochem., 1997, 250, 698. 
S. Claustre, F. Bringaud, L. Azema, R. Baron, J. Perie, M. Willson, 
Carbohydr. Res., 1999, 315, 339. 
S. Claustre, C. Denier, F. Lakhdar-Ghazal, A. Lougare, C. Lopez, N. 
Chevalier, P. A. M. Michels, J. Perie, M. Willson, Biochemistry, 2002, 41, 
10183. 
S. Claustre, PhD Thesis, Université Paul Sabatier, Toulouse, 2000. 
D. M. Chudzik, P. A. Michels, S. de Waique, W. G. J. Hol, I Mol. Biol., 
2000, 300, 697. 
W. D. Mercer, S. I. Winn, H. C. Watson, J. Mol. Biol., 1976, 104, 277. 
B. M. Bakker, P. A. M. Michels, F. R. Opperdoes, H. V. Westerhoff, I Biol. 
Chem., 1997, 272, 3207. 
L. A. Fothergill-Gilmore, P. A. M. Michels, Prog. Biophys. Mol. Biol., 1993, 
59,105. 
E. Van Schaftingen, F. R. Opperdoes, H. G. Hers, Eur. J. Biochem., 1985, 
153, 403. 
A. A.-H. Abdel-Rahman, E. S. H. El Ashry, R. R. Schmidt, Carbohydr. Res., 
1999, 315, 106. 
I. McCort, M. Saniere, Y. Le Merrer, Tetrahedron, 2003, 59, 2693. 




R. C. Reynolds, N. Bansal, J. Rose, J. Friedrich, W. J. Suling, J. A. Maddry, 
Carbohydr. Res., 1999, 317, 164. 
D. Horton, K. D. Philips, Carbohydr. Res., 1973, 30, 367. 
J. Martinez, M. Brown, Unpublished results, University of Edinburgh, 2003. 
J. Martinez, Unpublished results, University of Edinburgh, 2003. 
M. Walkinshaw, Unpublished results, University of Edinburgh, 2004. 
L. A. Fothergill-Gilmore, Unpublished results, University of Edinburgh, 
2003. 
N. Tranter, Honours report: The identification of novel inhibitors of 
Leismania mexicanapyruvate kinase, University of Edinburgh, 2004. 
N. Tranter, Unpublished results, University of Edinburgh, 2004. 
L. B. Tulloch, PhD Thesis, University of Edinburgh, Edinburgh, 2005. 
V. Hannaert, C. Yernaux, D. J. Rigden, L. A. Fothergill-Gilmore, F. R. 
Opperdoes, P. A. M. Michels, FEBSLett., 2002, 514, 255. 
M. Navaro, Unpublished results, University of Edinburgh, 2004. 
S.-Y. Han, Y.-A. Kim, Tetrahedron, 2004, 60, 2447. 
S. A. W. Gruner, E. Locardi, E. Lohof, H. Kessler, Chem. Rev., 2002, 102, 
491. 
H. Haruyama, T. Takayama, T. Kinoshita, M. Kondo, M. Nakajima, T. 
Haneishi, J. Chem. Soc., Perkin Trans. 1, 1991, 7, 1637. 
M. Nakajima, K. Itoi, Y. Takamatsu, T. Kinoshita, T. Okazaki, K. Kawakubu, 




D. Siehi, Plant Physiol., 1996, 110, 753. 
H. Umezawa, T. Aoyagi, T. Komiyama, H. Morishima, M. Hamada, T. 
Takeuchi, J. Antibiot., 1974, 27, 963. 
S. F. Oliver, C. Abel!, Curr. Opin. Chem. Biol., 1999, 3, 299. 
A. Kirschning, H. Monenschein, R. Wittenberg, Angew. Chem., mt. Edn. 
Engl., 2001, 40, 650. 
S. W. Kaldor, M. G. Siege!, J. E. Fritz, B. A. Dressman, P. J. Hahn, 
Tetrahedron Lett., 1996, 37, 7193. 
R. J. Booth, J. C. Hodges, Acc. Chem. Res., 1999, 32, 18. 
R. J. Booth, J. C. Hodges, J. Am. Chem. Soc., 1997, 119, 4882. 
P. H. J. Carisen, T. Katsuki, V. S. Martin, K. B. Sharpless, J. Org. Chem., 
1981, 46, 3936. 
S. Carrettin, P. McMom, P. Johnston, K. Griffin, G. J. Hutchings, Chem. 
Commun., 2002, 696. 
A. E. J. de Nooy, A. C. Besemer, H. van Bekkum, Tetrahedron, 1995, 51, 
E1i*J 
A. B. J. Dc Nooy, A. C. Besemer, H. Van Bekkum, Synthesis, 1996, 1153. 
R. Sied!ecka, J. Skarzewski, J. Mlochowski, Tetrahedron Lett., 1990, 31, 
2177. 
A. E. J. de Nooy, A. C. Besemer, H. van Bekkum, Carbohydr. Res., 1995, 29, 
89 
N. J. Davis, S. L. F!itsch, Tetrahedron Lett., 1993, 34, 1181. 




M. J. Sofia, R. Hunter, T. Y. Chan, A. Vaughan, R. Dulina, H. Wang, D. 
Gange,i Org. Chem., 1998, 63, 2802. 
R. M. van Well, M. E. A. Meijer, H. S. Overkleeft, J. H. van Boom, G. A. 
van der Marel, M. Overhand, Tetrahedron, 2003, 59, 2423. 
C. Boim, A. S. Magnus, J. P. Hildebrand, Org. Lett., 2000, 2, 1173. 
B. R. Travis, M. Sivakumar, G. 0. Hollist, B. Borhan, Org. Lett., 2003, 5, 
1031. 
B. Tejo, Unpublished results, University of Edinburgh, 2005. 
M. Walkinshaw, Unpublished results, University of Edinburgh, 2005. 
J. W. Perich, R. B. Johns, Synthesis, 1988, 142. 
T. Sowa, S. Ouchi, Bull. Chem. Soc. Jpn., 1975, 48, 2084. 
W. L. Dills Jr, T. R. Covey, P. Singer, S. Neal, M. S. Rappaport, Carbohydr. 
Res., 1982, 99, 23. 
W. Eschweiler, Ber. Deut. Chem. Ges., 1905, 38, 880. 
H. T. Clarke, H. B. Gillespie, S. Z. Weisshaus, J. Am. Chem. Soc., 1933, 55, 
4571. 
P. Sahakitpichan, S. Ruchirawat, Tetrahedron Lett., 2003, 44, 5239. 
G. Argouarch, G. Stones, C. L. Gibson, A. R. Kennedy, D. C. Sherrington, 
Org. Biomol. Chem., 2003, 1, 4408. 
S. Torchy, D. Barbry, J. Chem. Res., Synop., 2001, 292. 
J. R. Harding, J. R. Jones, S.-Y. Lu, R. Wood, Tetrahedron Lett., 2002, 43, 
9487. 




Lipinski Rule of 5 parameters for a selection of inhibitors. 








32, CL0gP = 2.3, 
MW = 329, HBD = 4, HBA = 5 
""'---N --0 HO 
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34, CL0gP = 1.1, 






37, CL0gP = 2.3, 
MW = 322, HBD =4, HBA = 5 
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50, CL0gP = 1.1, 
MW = 233, HBD = 4, HBA = 5 
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57, CL0gP = 2.0, 	 58, CL0gP = 0.1, 
MW = 293, HBD = 4, HDA = 5 
	









59, CL0gP = 2.3, 	 70, CL0gP = 1.8, 
MW = 261, HBD = 4, HBA = 5 
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	 110, CL0gP = 4.7, 
MW = 233, HBD = 4, HBA = 5 
	




Dose-response curves for calculating 10 50 values. 
Determination of IC 50  Values for 42, 48, 50 and 57 
ran 






Determination of IC Values for 58, 61 and 6750 
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Procedure br determinine the molaritv of reieent erade NaOC'l. 
NaOCI (10 ml) was diluted to 100 ml and 0.5 M potassium iodide solution (1 ml), 3 
M H2SO4 and 3 % ammonium molybdate (3 drops) were added. 25 ml of the solution 
was titrated against 0.025 M Na 2 S 204 . 
Amount of Na2S 204 titrated = 17 ml. 
Moles of Na2 S204 = 4.25 x 10 
ocr + 21+ 21130 	12 Cl + 31420 and 12  + 2S2032 - 21 + S4062 
So, moles of 0C1 = 2.125 x 10 
Moles in original 10 ml sample = 8.5 x 10 
Therefore, concentration of NaOC1 = 0.086 M. 
Procedure for determining the molarity of commercial NaOC1. 
Commercial NaOC1 (1 ml) was diluted to 100 ml and 0.5 M potassium iodide 
solution (1 ml), 3 M H2SO4 and 3 % ammonium molybdate (3 drops) were added. 10 
ml of the solution was titrated against 0.025 M Na 2 S204 . 
Amount of Na2 S 204 titrated = 13.5 ml. 
Moles ofNa2S2O 4 = 3.375 x 10 
ocr + 21+ 21-130 -p 12 Cl + 3H20 and 12 + 252032 -21- + S406 2 
So, moles of OCI = 1.6875 x 10 
Moles in original 1 ml sample = 1.6875 x 10 
Therefore, concentration of commercial NaOCI = 1.69 M. 
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